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Abstract 
 
Cocaine- and amphetamine- regulated transcript (CART) was originally identified as a 
mRNA transcript upregulated in rats in response to administration of cocaine and 
amphetamine. CART is widely expressed in the central nervous system (CNS) with high 
levels of expression in hypothalamic nuclei such as the arcuate nucleus (ARC). 
 
CART was initially thought to act as an anorectic peptide since it is coexpressed with the 
anorectic neuropeptide pro-opiomelanocortin (POMC) in the ARC. In addition, 
intracerebroventricular (ICV) administration of CART (55-102) peptide inhibits feeding and 
administration of anti-CART antibody results in stimulation of feeding. However, subsequent 
studies have suggested CART may also act as an orexigen since injection of CART (55-102) 
specifically into the ARC and ventromedial nucleus (VMN) of the hypothalamus results in a 
significant increase in food intake. These data suggest CART acts through both anorectic and 
orexigenic circuits. Given the importance of the hypothalamus in the regulation of energy 
homeostasis, and the role of the ARC in integrating peripheral signals, it is essential to 
elucidate the role of ARC derived CART. In order to elucidate CART’s true physiological 
role in the ARC I used a combination of genetic approaches. I generated a recombinant 
Adeno-associated virus (rAAV) expressing CART antisense (CART-AS) and a transgenic 
mouse model which utilises the POMC promoter to drive expression of CART-AS.  
 
In the transgenic CART-AS model mice exhibited a significantly higher body weight relative 
to control animals, no significant difference in food intake was observed. In addition, mice 
expressing the CART-AS transgene demonstrated a reduction in uncoupling protein-1 (UCP-
1) mRNA expression in brown adipose tissue (BAT) which is suggestive of decreased 
thermogenesis. This may explain the observed increase in body weight in the transgenic 
mice. Bilateral intra-ARC injections of rAAV-CART-AS resulted in a significant increase in 
cumulative food intake and body weight gain compared to control animals. There was no 
significant difference in activity or metabolism levels.  
 
The data presented in my thesis provides an important contribution to understanding the role 
of CART within the ARC.  The results from my genetic studies appear to suggest that ARC 
derived CART has an anorectic role. 
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1. General Introduction  
1.1 Obesity 
Obesity is a major public health issue and it is predicted that by 2010 40% of children in 
Europe will be obese. This increase in obesity is a result of people adopting a more sedentary 
life style, accompanied by an increase in availability and affordability of highly calorific 
foods. Obesity has significant effects on morbidity and mortality due to comorbid diseases 
such as type II diabetes, coronary heart disease and cancer. In turn this will lead to greater 
strains on health care. The National Audit Office which scrutinises public spending estimates 
the cost of obesity to the NHS is £50 million with further indirect costs of between £1.7 and 
£1.9 billion, accounting for around 4% of total NHS spending (Bourn, 2001). There is an 
urgent need to understand how appetite is regulated in order to identify new targets for the 
development of effective anti-obesity drugs. Energy balance is a highly regulated process 
with the hypothalamus and brainstem thought to play a central role in this regulation by 
integrating short term satiety signals and long term signals of energy store. 
 
 
1.2 The Hypothalamus (Figure 1.1) 
The hypothalamus is one of the main sites, in conjunction with the brainstem and ventral 
tegmental area (VTA), which regulate food intake and energy balance. The hypothalamus is 
situated at the base of the brain lying immediately above the pituitary, either side of the third 
ventricle and it is composed of a number of discrete nuclei (Figure 1.2) which have been 
implicated in the regulation of energy homeostasis such as; the arcuate nucleus (ARC), 
paraventricular nucleus (PVN), ventromedial nucleus (VMN), dorsomedial nucleus (DMN), 
lateral hypothalamus (LH) and perifornical area (PFA). The hypothalamus can be divided 
into three distinct regions; the lateral, medial and periventricular zones. The hypothesis that 
the hypothalamus is involved in the regulation of appetite originally came from clinical 
observations that patients with pituitary tumours, and injuries to the base of the brain, 
developed obesity. These observations led to experimental lesioning studies of specific 
hypothalamic nuclei which resulted in changes in feeding. Lesioning of the LH resulted in 
hypophagia and weight loss whereas lesioning of the ventromedial hypothalamus resulted in 
hyperphagia and weight gain in rats (Hetherington and Ranson, 1942; Nand and Brobeck, 
1951). 
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Figure 1.1 The hypothalamus. Diagram of the hypothalamus. The blue shaded area is the 
anterior region of the hypothalamus, the red area is the tuberal region and the green area is 
the lateral posterior region of the hypothalamus. Hypothalamic nuclei shown are 
paraventricular nucleus, the lateral and medial preoptic nuclei, anterior nucleus, 
suprachiasmatic nucleus, supraoptic nucleus, arcuate nucleus, ventromedial nucleus, 
mammillary body, posterior area and dorsomedial nucleus. Other areas outside the 
hypothalamus that are present are fornix, thalamus, tuber cinereum, anterior and posterior 
pituitary, infundibular stalk and optic chiasm. Adapted from (Holmes et al., 2003) 
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Figure 1.2 Organisation of the hypothalamus. Schematic representation of the organisation 
of the zones and regions of the hypothalamus (a- area, n-nucleus). Adapted from (Simerly 
and Paxinos, 1998).  
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These initial findings laid the foundation of the dual centre hypothesis which stated that 
feeding was controlled by a satiety centre, the ventromedial hypothalamic nucleus, and a 
feeding centre, the lateral hypothalamus. However, this is now accepted to be an 
oversimplification as other hypothalamic and non hypothalamic areas have been implicated 
in appetite regulation. 
 
 
1.2.1 The Arcuate Nucleus 
The arcuate nucleus is located at the base of the hypothalamus, close to the median eminence, 
and is ideally positioned to integrate peripheral signals due to the incomplete blood brain 
barrier. The ARC has a high density of orexigenic neurones that coexpresses neuropeptide Y 
(NPY) and agouti related peptide (AgRP). Immunohistochemistry has demonstrated 
approximately 95 percent of AgRP neurones coexpress NPY in the ARC (Broberger et al., 
1998). A second dense neuronal population coexpress the anorectic pro-opiomelanocortin 
(POMC) and cocaine- and amphetamine -regulated transcript (CART) neuropeptides. Double 
label in situ hybridisation studies showed that over 90% of ARC POMC neurones contain 
CART mRNA (Elias et al., 1998). Both of these major neurone populations have been 
heavily implicated in the control of food intake. Food restriction results in an increase in NPY 
and AgRP mRNA expression and a decrease in the expression of POMC and CART mRNA 
in the rodent ARC (Mizuno et al., 1999; Swart et al., 2002). The ARC is also a site of 
expression of other neurotransmitters and neuropeptides such as galanin (Skofitsch and 
Jacobowitz, 1985) and γ-amniobutyric acid (GABA) (Cowley et al., 2001; Hentges et al., 
2004) and glutamate (Boulland et al., 2004). 
 
Neuronal projections from the ARC to various hypothalamic and non hypothalamic brain 
areas involved in the control of food intake is consistent with the ARC being well positioned 
to integrate signals of energy status. For example, POMC and AgRP neuronal fibres 
originating in the ARC project to the VMN, DMN, PVN and LH (Elmquist et al., 1998; 
Elmquist et al., 1999). Beyond the hypothalamus, ARC neurones have been identified 
projecting to the brainstem, VTA and nucleus accumbens (NAc). These non-hypothalamic 
brain regions have also been linked with a role in appetite (Haskell-Luevano et al., 1999; 
Jacobowitz and O'Donohue, 1978; Joseph and Michael, 1988). The ARC also possesses 
glucose responsive neurones (Muroya et al., 2005; Parton et al., 2007; Wang et al., 2004) and 
receptors for the circulating hormones leptin and insulin (Hakansson et al., 1996; Obici et al., 
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2002) suggesting that the ARC can sense and transduce signals from peripheral hormonal and 
nutrient factors.  
 
 
1.2.2 The Paraventricular Nucleus 
The paraventricular nucleus sits adjacent to the top of the third ventricle and receives 
neuronal input from brain areas which include the ARC, LH and amygdala. The neurones in 
the PVN can be divided into two components; the magnocellular component and the 
parvocellular component. The magnocellular component contains oxytocin and arginine 
vasopressin expressing neurones which project to the neural lobe of the posterior pituitary. 
The parvocellular component contains a range of neuropeptides including corticotropin 
releasing hormone (CRH), which causes anorexia, and thyrotropin releasing hormone (TRH) 
which reduces food intake in addition to controlling the release of adrenocorticotropic 
hormone (ACTH) and thyroid stimulating hormone (TSH) from the pituitary (Vijayan and 
McCann, 1977; Vogel et al., 1979). The presence of neuropeptides in the PVN which reduce 
food intake is indicative of the PVN being involved in the regulation of energy homeostasis. 
Evidence for the importance of the PVN in appetite control comes from PVN lesioning 
studies which resulted in the development of hyperphagia and obesity whereas stimulation of 
the PVN led to a decrease in feeding in rats (Hetherington and Ranson, 1942). Later research 
involved the administration of feeding related peptides into the PVN which complemented 
the initial findings from lesioning studies. Intra-nuclear injection into the PVN of the 
orexigenic peptide NPY (Stanley et al., 1985) or ghrelin (Wren et al., 2001) resulted in 
increased food intake and the injection of the anorectic cholecystokinin (CCK) resulted in a 
decrease in food intake (Blevins et al., 2000) suggesting the PVN can mediate both 
orexigenic and anorexigenic signals. These studies highlight a physiological role for the PVN 
in food intake. 
 
 
1.2.3 The Ventromedial Nucleus  
The ventromedial nucleus lies above the ARC and can be divided into two separate regions, 
the dorsomedial and ventrolateral areas. Laser scanning photostimulation of mouse brain 
slices show that the VMN sends excitatory innervations to POMC neurones of the ARC 
(Sternson et al., 2005). The VMN also receives innervations from the brainstem and medial 
zone of the hypothalamus. Afferent and efferent connections of the VMN with other brain 
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regions associated with appetite control suggest that the VMN plays a part in this regulation. 
Evidence for the physiological involvement of the VMN in appetite regulation was initially 
suggested in VMN lesioning studies which resulted in hyperphagia and obesity in rats 
relative to sham treated animals (Hetherington and Ranson, 1942). Leptin and insulin levels 
were also raised in the VMN lesioned rats (Suga et al., 1999). In addition, injection of NPY 
peptide into the VMN results in a robust increase in feeding, and fasting has been associated 
with increased NPY peptide concentration in the rat VMN (Bouali et al., 1995). Evidence 
detailing the VMN as a site of action of NPY, coupled with results from lesioning studies 
suggests a role for the VMN in the control of appetite.  
 
 
1.2.4 The Lateral Hypothalamus 
The lateral hypothalamus is positioned laterally to the VMH and has also been implicated in 
the control of feeding, a role that was initially suggested by the ablation of the LH which 
resulted in decreased food intake and weight loss in rats (Milam et al., 1980). The 
neuropeptides melanin concentrating hormone (MCH) and orexins A and B, which have been 
shown to increase feeding, have been identified in the LH. MCH and the orexins are 
expressed in separate but spatially overlapping neuronal populations in the perifornical region 
of the LH and zona incerta. Fasted rats show an increase in hypothalamic MCH mRNA 
expression and injection of MCH into the lateral ventricle of rats leads to a stimulation of 
food intake (Qu et al., 1996). Genetic models of MCH provide evidence of a physiological 
role for the MCH peptide in energy homeostasis. Mice with targeted deletion of MCH are 
lean (Shimada et al., 1998) and MCH overexpressing mice are hyperphagic, obese and insulin 
resistant (Ludwig et al., 2001) which is consistent with MCH being an orexigenic peptide.  
The orexin peptides have also been linked with an orexigenic role since rats fasted for 48 
hours show an increase in prepro-orexin mRNA and intracerebroventricular (ICV) 
administration of orexin-A and -B increase food intake (Sakurai et al., 1998; Yamanaka et al., 
2000). However, the orexin peptides are thought to have a range of functions within the 
central nervous system (CNS) due to the LH orexin neurones projecting widely within the 
brain. For example, orexin neurones from the LH project to the VTA (Zheng et al., 2007), 
which is suggestive of communication between the hypothalamus and reward pathway via the 
VTA. In addition, it is thought that the orexin peptides mediate the sleep-wake cycle and 
locomotor activity since ICV administration of orexin-A in rats is accompanied by an 
increase in arousal during the normal rodent sleep period and increased activity levels such as 
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grooming (Hagan, 1999). The orexin mediated increase in arousal may contribute to the 
increase in food intake associated with the orexin peptides since increased periods of 
wakefulness allow more opportunities for rodent feeding. Electrophysiology studies suggest 
that the orexin peptides mediate their effects on arousal through the locus coeruleus (LC), a 
modulator of attentional state and stress, since application of orexin to brain slices of the LC 
results in increased firing of the noradrenergic neurones from this nucleus (Hagan, 1999). 
The presence of the orexigenic MCH and orexin peptides in the LH strongly links this 
nucleus with a role in regulating food intake. 
 
  
1.2.5 Brainstem 
The brainstem plays an important role in the regulation of energy homeostasis. The brainstem 
senses and integrates signals from circulating peripheral factors released from the 
gastrointestinal tract and is considered to be a primary site of regulation of gastrointestinal 
function (Jobst et al., 2004). The brainstem nuclei that have been implicated in the regulation 
of energy homeostasis are the nucleus of the solitary tract (NTS), dorsal motor nucleus of the 
vagus (DMV) and the area postrema (AP). These are collectively known as the dorsal vagal 
complex (DVC).  
 
The AP, like the ARC, possesses an incomplete blood brain barrier and is thus able to 
respond to circulating peripheral orexigenic and anorectic signals. Injection of the peripheral 
hormone ghrelin into the brainstem results in hyperphagia, implying the brainstem can 
respond to peripheral hormones (Faulconbridge et al., 2003). The NTS is thought to integrate 
viscerosensory information originating from the gastrointestinal tract via vagal nerve inputs 
which then project to other hypothalamic nuclei such as the PVN, ARC and LH (Jobst et al., 
2004). POMC neurones have been shown to project from the brainstem to the hypothalamus, 
although these POMC neurones do not coexpress CART (Ellacott et al., 2006) and NPY 
neurones have been shown to project from the NTS to the PVN. Collectively this suggests 
that the melanocortins and NPY play a role in mediating stimuli from the gastrointestinal 
tract via the brainstem. The role of the brainstem seems to be one of integrating 
gastrointestinal signals for meal initiation and termination whereas the role of the 
hypothalamus is one of regulating long term energy balance.  
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1.2.6 Ventral Tegmental Area 
The ventral tegmental area lies medial to the substantia nigra (SN), between the caudal 
hypothalamus and brainstem. The VTA is one of the main sites from which dopamine (DA) 
neurones project to other brain regions including the NAc, prefrontal cortex (PFC) and LH 
(Margolis et al., 2006). The dopaminergic neuronal projections from the VTA to the NAc and 
subsequently to the ventral pallidum form the mesolimbic dopamine pathway, which is 
implicated in mediating the effects of reward and addiction. In addition to dopaminergic 
neurones, GABAergic and glutamatergic neurones have also been identified in the VTA. 
Electrophysiological studies confirmed the presence of GABA and glutamate innervation 
from the VTA to the NAc and PFC (Carr and Sesack, 2000; Chuhma et al., 2004).  
 
Various substances associated with reward and addiction such as cocaine, amphetamine and 
opioids, have been shown to mediate their rewarding effects through the VTA since 
intravenous administration of these compounds results in increased dopamine release in the 
rat VTA. In addition, self administration of cocaine by rats is reduced upon pretreatment with 
dopamine receptor antagonists administered into the NAc and VTA (Caine and Koob, 1994; 
Wise, 2004). Peripheral administration of cocaine and amphetamine is associated with a 
decrease in feeding whereas opioid administration is linked with an increase in feeding 
(Balopole, 1979; Hsieh et al., 2005; Glass et al., 1999; Yun et al., 2004). It is hypothesised 
that the VTA may mediate these effects on appetite since injection of ghrelin into this nucleus 
increases food consumption confirming the ability of the VTA to mediate increases in food 
intake (Naleid et al., 2005). These data together suggest the VTA mediates the hedonistic 
component of food intake. 
 
 
1.3 Neuropeptide Signalling 
The ARC is one of the main sites at which peripheral signals of long term energy store, such 
as leptin and insulin, and short term signals of satiety are integrated within the CNS. These 
peripheral signals act at specific receptors in the ARC to transduce a neuronal response to 
other brain areas. The main neuropeptides involved in this signal transduction include the 
melanocortins, NPY and CART. 
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1.3.1 The Melanocortin System 
The melanocortin system consists of agouti related peptide, the endogenous melanocortin 
antagonist and several neuropeptides derived from posttranslational processing of pro-
opiomelanocortin; these include α, β, and γ- melanocortin stimulating hormone (MSH), β 
endorphin and adrenocorticotropin hormone. POMC is expressed in the ARC and 
immunoreactive fibres from POMC expressing neurones project to other hypothalamic nuclei 
involved in appetite regulation including the PVN, DMN and LH (Elias et al., 1998; Elmquist 
et al., 1998; Elmquist et al., 1999). In addition, POMC is also present in the pituitary and 
NTS. In the periphery POMC has been detected by in situ hybridisation in the testes, ovary, 
placenta and liver (Bicknell, 2008; Gizang-Ginsberg and Wolgemuth, 1985; Chen et al., 
1986). 
 
The melanocortin system has five G-protein coupled melanocortin receptors (MC1R-MC5R). 
These receptors act through adenylyl cyclase to generate the secondary messenger cyclic 
adenosine monophsophate (cAMP). The MC1R was the first receptor to be cloned and is 
expressed exclusively in melanocytes where it has a role in determining coat colour in mice. 
The MC2R is specific for ACTH and is expressed in the adrenal cortex and adipocytes. The 
MC3R and MC4R are both implicated in energy homeostasis (Chen et al., 2000; Marsh et al., 
1999) with MC3R limited to the hypothalamus and brainstem whereas MC4R is more widely 
distributed throughout the CNS (Mountjoy et al., 1994; Huszar et al., 1997)}. Mice which 
lack functional MC3R show an increase in fat mass and a decrease in lean mass without 
significant changes in food intake or body weight (Chen et al., 2000). In contrast, mice with 
targeted deletion of MC4R develop maturity onset obesity associated with hyperphagia, 
hyperinsulinemia and hyperglycemia (Huszar et al., 1997). 
 
Antagonism at the melanocortin receptors was identified from studies using the agouti mouse 
(Ay/a). The agouti gene was cloned in 1992 and encodes a 131 amino acid peptide (Bultman 
et al., 1992). The expression of agouti is normally restricted to the hair follicle where it is a 
paracrine factor secreted during the hair growth cycle. Agouti acts as an antagonist at the 
MC1R causing a switch in synthesis from eumelanin to phaeomelanin. In the Ay/a mouse a 
chromosomal rearrangement occurs that results in the promoter and the first non coding exon 
of the closely linked raly gene being spliced to the exon of the agouti gene. As a result, 
expression of the agouti gene is under the control of the raly promoter and is consequently 
ectopically expressed. The ectopic expression of the agouti gene produces a severe phenotype 
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with the Ay/a mouse having a yellow coat colour and hyperphagia leading to severe obesity. 
Hyperinsulinemia and hyperglycemia are also characteristics of the agouti mouse (Bultman et 
al., 1992). The agouti obese phenotype is thought to be a result of antagonism of the 
hypothalamic MC4R (Fan et al., 1997).  
 
An agouti like peptide was identified from studies involving the screening of cDNA 
sequences with homology to agouti (Shutter, 1997). The AgRP gene was isolated in 1997 
based on its 40 amino acid cysteine rich carboxyl terminal homology to agouti (Ollmann et 
al., 1997) and is expressed at high levels in the ARC and adrenal gland and at lower 
concentration in the testis, lung and kidney. The hyperphagic effect of AgRP was 
demonstrated by ICV administration in rodents (Rossi et al., 1998; Small et al., 2001) and 
receptor binding studies demonstrate that AgRP is a competitive antagonist of the MC4R 
(Fan et al., 1997). The current data supports the hypothesis that α-MSH and AgRP are 
involved in the control of food intake and that the relationship between the two peptides is an 
antagonistic one mediated by the melanocortin receptor. 
 
The physiological importance of the melanocortin system in the regulation of appetite has 
been further emphasised by transgenic studies. Overexpression of POMC in mice increases α-
MSH production leading to a reduction in food intake and reduced adiposity. This is in 
contrast to mice with a targeted deletion of the POMC gene which are hyperphagic and have 
reduced energy expenditure leading to obesity (Yaswen et al., 1999). Transgenic mice which 
overexpress human AgRP exhibit an obese phenotype, identical to the agouti mouse, but with 
normal pigmentation (Ollmann et al., 1997). This confirms the importance of AgRP and α-
MSH in the physiological regulation of appetite. In contrast, mice with a targeted deletion of 
the AgRP gene exhibit normal body composition and food intake. Furthermore, the 
transgenic mice also display similar levels of suppression of food intake as wildtype mice 
upon leptin administration (Qian et al., 2002). The lack of a phenotype in mice with a 
targeted deletion of the AgRP gene may be attributed to developmental compensation. 
Following from this, genetic studies have been conducted which have studied the effect of 
temporal ablation of AgRP neurones. One study deleted the mitochondrial transcription factor 
A (Tfam) in AgRP neurones with the result being progressive post natal cell death (Xu, 
2005). Another study attempted to temporally control the ablation of the AgRP neurones 
using diphtheria toxin (Gropp, 2005).  Both studies demonstrated that the loss of AgRP 
produced a robust phenotype of hypophagia and leanness. However, many neurones express 
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more than one neuropeptide, so ablation of the AgRP neurone may also ablate other 
neurotransmitters and neuropeptides that are colocalised with AgRP, consequently whether 
the resulting phenotype is due to AgRP is hard to state. Data from transgenic studies, coupled 
with the pharmacological data are indicative of the melanocortin system being important in 
energy homeostasis. 
 
The relevance of the melanocortin system in humans is highlighted in genetic studies which 
examine the phenotype resulting from mutations within this system. Congenital POMC 
deficiency in humans presents with several clinical features. There is failure of adrenal 
steroidogenesis which is due to the loss of action of ACTH at the MC2R. In addition subjects 
have pale skin and red hair due to the loss of α-MSH action at the MC1R and obesity due to 
the loss of its stimulation of MC3R and MC4R. Additionally, these subjects suffer from mild 
central hypothyroidism (Krude et al., 2003). Conversely, mutations in the human AgRP gene 
have been associated with increased susceptibility to anorexia nervosa (Vink et al., 2001). 
Interestingly, human studies have also implicated β-MSH as a potential regulator of food 
intake, rodents lack the necessary cleavage site to generate β-MSH hence research has mainly 
focused on the function of α-MSH. A heterozygous mutation disrupting a conserved pair of 
basic amino acids at the prohormone processing site Arg236Gly between β-MSH and β-
endorphin results in the fusion protein of β-MSH/β-endorphin which binds to the MC4R, but 
has a reduced ability to activate the receptor. This mutation was found in 0.9% of individuals 
with early onset obesity compared with 0.2% of normal weight individuals (Biebermann et 
al., 2006). Another heterozygous mutation in the POMC gene affecting the processing of β-
MSH has been identified. The Tyr221Cys mutation results in decreased binding of the 
peptide to the MC4R and occurs in 0.9% of obese individuals relative to 0.08% of normal 
weight individuals (Lee et al., 2006). The human data together with that from rodent models 
provides strong evidence of the melanocortin system in the regulation of appetite.  
 
 
1.3.2 Neuropeptide Y  
Neuropeptide Y was first isolated and sequenced from porcine brain and is distributed in the 
central and peripheral nervous system (Tatemoto et al., 1982). NPY is a 36 amino acid 
peptide synthesised from a 98 amino acid propeptide, proNPY. The propeptide consists of a 
29 amino acid signal sequence, a Gly-Lys-Arg processing site and a 30 amino acid carboxyl 
terminal flanking peptide. NPY is highly conserved and is identical between rat and human.  
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The site of expression and projection of NPY neurones is suggestive of a role in energy 
homeostasis since arcuate NPY neurones innervate other hypothalamic nuclei involved in 
energy homeostasis including the PVN, DMN and LH (Jobst et al., 2004). Research indicates 
an orexigenic role for NPY as ARC NPY mRNA expression was upregulated, and NPY 
peptide release from the PVN increased, in response to food deprivation (Kalra et al., 1991). 
NPY peptide concentration normalises on re-feeding following a fast (Swart et al., 2002).  An 
orexigenic role for NPY was further confirmed by chronic ICV administration of NPY which 
resulted in hyperphagia in rats (Zarjevski et al., 1993).  
 
Within the ARC fluorescent double immunolabelling studies demonstrate colocalisation of 
GABA with NPY in approximately 33% of NPY neurones (Horvath et al., 1997). The 
NPY/GABA interneurones were found to exert an inhibitory tone on the POMC neurone 
population. This was demonstrated by Cowley et al where electrophysiology was used to 
determine the effect of leptin on POMC neurones. Leptin was found to depolarise 72 out of 
77 POMC neurones and this was shown to be, in part, mediated by NPY/GABA neurones. 
GABA mediated inhibitory post synaptic currents (IPSC) were observed in POMC cells and 
leptin was found to reduce the frequency of IPSC in GABAergic neurones by 25% (Cowley 
et al., 2001). The evidence of GABAergic projections from orexigenic neurones that can 
reduce anorectic POMC/CART neuronal firing is consistent with the NPY being an 
orexigenic agent. 
 
Physiological evidence of a role for NPY in feeding comes from NPY content and release 
studies. NPY peptide content and release is significantly increased during the dark phase, the 
period of nocturnal feeding in rodents. ICV administration of NPY antibodies during the dark 
phase blocks this nocturnal feeding, emphasising the physiological orexigenic role of NPY. 
Further physiological evidence of NPY’s involvement in the regulation of appetite is 
presented in genetic studies. Administration of recombinant adeno-associated virus (rAAV) 
expressing NPY antisense mRNA into the rat ARC resulted in a decrease in food intake and 
reduced body weight gain (Gardiner et al., 2005). Attempts to establish a transgenic line with 
targeted deletion of NPY have resulted in mice with no obvious phenotype, although this is 
generally attributed to developmental compensation (Erickson et al., 1996). Experiments 
designed to ablate NPY/AgRP neurones postnatally have confirmed this neuronal population 
as being important in energy homeostasis since ablation of NPY/AgRP neurones by 
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administration of diphtheria toxin in adult rats resulted in rapid starvation (Luquet et al., 
2005).  
 
NPY acts via a family of G protein coupled receptors known as Y1R-Y5R. Mice with 
targeted deletion of these receptors have been useful as a means to investigate the role of the 
Y receptor subtype. The Y1 and Y5 receptors are thought to be the main mediators of the 
orexigenic effects of NPY. Daily food intake and NPY stimulated feeding are only slightly 
decreased in Y1R deficient mice (Pedrazzini et al., 1998) and the central administration of 
Y1R selective antagonist inhibits the feeding effects of exogenous NPY (O'Shea et al., 1997). 
The Y5 receptor has also been implicated in the control of food intake since the mice with a 
targeted deletion of the Y5R exhibit a blunted response to ICV administration of NPY and 
develop mild obesity with age (Marsh et al., 1998). Furthermore, the Y5R antagonist, 
Velneperit, has been developed and is currently in phase III clinical trials. Collectively, these 
data implicate a role for NPY in the control of feeding.  
 
 
1.4 Cocaine- and Amphetamine -Regulated Transcript  
Cocaine- and amphetamine -regulated transcript was originally identified as an mRNA 
transcript upregulated in the rat striatum in response to intraperitoneal (i.p) administration of 
cocaine or amphetamine (Douglass et al., 1995). 
 
 
1.4.1 Cocaine- and Amphetamine -Regulated Transcript Gene 
The CART gene is composed of three exons and two introns. The CART peptide is highly 
conserved across species with approximately 80% nucleotide homology between rat and 
human CART cDNA and between mouse and rat homology is 98% (Douglass and Daoud, 
1996). The conserved nature of the CART sequence suggests that it plays an important role in 
the different species. The carboxyl terminus of the CART peptide is the most conserved 
region and contains six cysteine residues which form three disulphide bonds. The formation 
of disulphide bridges maintains the tertiary structure of the protein and are essential to CART 
bioactivity (Thim et al., 1998). 
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1.4.2 Cocaine- and Amphetamine -Regulated Transcript Peptide 
In the rat and mouse CART DNA sequence two different polyadenylation sites have been 
identified which consequently leads to the transcription of two pre-mRNA transcripts, one of 
700bp and the other of 900bp in length. Due to alternate splicing of a 39bp sequence from the 
coding region of exon two the translation of the CART mRNA results in the two pre-
propeptides (pre-proCART) which contains a 27 amino acid leader sequence. The leader 
sequence is removed by posttranslational cleavage which results in two proCART peptides of 
102 (long form) and 89 (short form) amino acids. The ProCART peptides are processed 
further by posttranslational cleavage resulting in different sized CART fragments. The sites at 
which the proCART peptide is cleaved are thought to be at positions where pairs of basic 
amino acids occur (Figure 1.3). Two bioactive forms of CART have been identified, CART 
(55-102) and CART (62-102) (Thim et al., 1999) which are highly expressed in the ARC 
(Kristensen, 1998). The nomenclature of CART (55-102) and CART (62-102) is based on the 
amino acid residues number from the long form of CART peptide.  
 
CART (55-102) has been isolated from the ovine hypothalamus and is generated from  
cleavage at the pair of basic amino acid residues Lys53-Arg54 (Spiess et al., 1981). It is this 
fragment of CART that is commonly used in rodent studies. The prohormone convertase (PC) 
enzymes PC2 and PC1/3, which are expressed at high levels in the ARC, have been 
implicated in mediating the cleavage of proCART into its bioactive fragments (Schafer et al., 
1993). The role of prohormone convertase enzymes in the processing of CART was 
confirmed by cell line transfection studies. The CART fragments that resulted from the 
processing of proCART by the two PC enzymes in the cell transfection study were identified 
by high performance liquid chromatography (HPLC) (Dey et al., 2003). PC2 was shown to be 
more efficient at generating CART (55-102) and the sole generator of CART (62-102). PC1/3 
was shown to be responsible for the generation of additional intermediate CART fragments 
(Dey et al., 2003). The resulting fragments from the processing of proCART that have been 
shown to be biologically active in rats are CART (55-102) and CART (62-102).  
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Figure 1.3 Schematic representation of the primary translation product of CART. 
Fragments are labelled according to nomenclature based on both the shorter 89 amino acid 
spice variant and the longer 102 amino acid variant. Adapted from (Thim et al,. 1999) 
 
 
1.4.3 Cocaine- and Amphetamine -Regulated Transcript Localisation 
CART is expressed in several hypothalamic nuclei. In situ hybridisation and 
immunohistochemical staining has shown that CART is abundant in the periventricular 
nucleus (PeV), PVN, the supraoptic nucleus (SON), ARC, the zona incerta and the LH 
(Vrang et al., 1999).  
 
CART peptide was detected in the ARC by immunohistochemistry. Double label in situ 
hybridisation shows that over 90% of CART neurones also express POMC mRNA in the rat 
ARC (Elias et al., 1998). There was no evidence of CART colocalising with NPY (Vrang et 
al., 1999). In the human infundibular nucleus CART immunoreactivity is not found in the 
POMC neurones, but is found in approximately one third of NPY/AgRP containing neurones 
(Menyhert et al., 2007). 
 
CART neurones in the PVN, DMN and the posterior PeV coexpress TRH (Elias et al., 2001) 
but CART containing neurones were not found to colocalise with CRH within the PVN. This 
suggests that CART may play a role in the regulation of thyroid hormone release through the 
pituitary (Kristensen, 1998). 
 
The largest group of CART neurones within the hypothalamus are found in the zona incerta 
and LH where CART has been shown to colocalise extensively with MCH, but not with the 
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orexin peptides. In the zona incerta MCH and CART colocalise in almost 100% of neurones 
(Elias et al., 2001). In the medial LH a similar degree of colocalisation is present, however, in 
the lateral and ventral areas of the LH approximately 70% of MCH neurones coexpress 
CART (Elias et al., 2001).  
 
Studies investigating the sites of CART expression and identifying neuropeptides that are 
colocalised in CART neurones implicates CART as having a wide ranging role in the control 
of energy homeostasis. It may appear contradictory for CART to colocalise with orexigenic 
peptides such as MCH and anorectic peptide such as TRH and POMC. However, this may 
suggest that CART acts in competing orexigenic and anorectic circuits within the 
hypothalamus.   
 
 
1.4.4 Physiological Role of Cocaine- and Amphetamine -Regulated Transcript  
 
1.4.4.1 Cocaine- and Amphetamine -Regulated Transcript and the Reward System 
CART has been implicated in mediating the rewarding effects of pyschostimulants. The 
mechanism of reward and addiction is thought to be mediated through the mesolimbic 
dopamine pathway (see section 1.2.6). CART immunoreactivity has been identified in this 
pathway, specifically in the VTA and NAc. Furthermore, CART mRNA expression in the 
NAc has been shown to be increased in response to i.p administration of cocaine in adult 
male rats (Hunter et al., 2005). This suggests CART plays a role in mediating reward and 
addiction through the VTA and NAc. In addition, VTA immunostaining studies demonstrate 
CART containing neurones synapse with DA and GABAergic neurones (lvechia-Adams et 
al., 2002). The physical interaction between the CART and DA neurones suggests that CART 
may modulate firing of DA neurones within the reward pathway. The current data suggests a 
role for CART in the reward pathway, specifically in the VTA and NAc.  
 
 
1.4.4.2 Cocaine- and Amphetamine -Regulated Transcript and the Stress Response 
Stress causes an increase in firing of the CRH neurones in the PVN. CRH neurones 
stimulates the release of ACTH from the pituitary which subsequently acts on the adrenal 
gland to stimulate the release of glucocorticoids which are associated with an increase in 
feeding and appetite, possibly through interference of leptin action at the hypothalamus 
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(Solano and Jacobson, 1999). In addition, glucocorticoids have also been linked with an 
increase in salience for pleasurable activities such as increased sucrose consumption in rats 
(Dallman, 2003; Laugero et al., 2002). CART is thought to have a role in mediating the stress 
response since ICV administration of CART peptide results in an increase in plasma 
concentration of ACTH and corticosterone (Vrang, 2000). Furthermore, adrenalectomy in 
rats, which removes endogenous glucocorticoids, results in a decrease in CART mRNA 
expression in the PVN and ARC which is partially reversed by glucocorticoid replacement 
(Balkan et al., 2001). Collectively the data suggests a feedback loop between CART and 
corticosteroid secretion since CART has been shown to increase plasma glucocorticoid 
concentrations and the loss of glucocorticoids results in a reduction in CART mRNA 
expression. 
 
 
1.4.5 Peripheral Cocaine- and Amphetamine -Regulated Transcript   
Stanley et al found circulating CART levels follow a diurnal pattern in rats. 
Radioimmunoassay (RIA) was used to measure plasma CART (55-102) -like 
immunoreactivity, CART peptide concentration was found to be higher in the dark phase, 
which is the phase most associated with feeding in rodents (Stanley et al., 2004). This 
suggests that increased plasma CART may promote feeding in the dark phase. However, 
peripheral CART administration has been shown to have no effect on feeding indicating that 
circulating CART is not involved in the regulation of food intake (Jensen et al., 1999). 
 
 
1.4.6 Central Cocaine- and Amphetamine -Regulated Transcript and Food Intake 
Hypothalamic CART is thought to be an anorectic agent. ICV administration of CART (55-
102) peptide inhibits feeding in satiated and fasted rats. In addition, the orexigenic effect 
associated with ICV administration of NPY is inhibited by CART in a dose dependent 
manner, which is consistent with CART acting as an anorectic peptide (Kristensen, 1998). 
Physiological data further supports an anorectic role for endogenous CART peptide since 
ICV administration of anti-CART antibody, which blocks endogenous CART, resulted in 
stimulation of overnight feeding (Lambert, 1998; Kristensen, 1998). The evidence from ICV 
studies and CART antibody studies is further affirmed by injection of rAAV expressing 
CART cDNA into the third ventricle of rats. Expression of the CART transgene was 
demonstrated in cells of the third ventricle and median eminence. Throughout the seven 
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month study rAAV-CART injected rats displayed decreased food intake and body weight 
gain (Qing and Chen, 2007).  
 
Aja et al also showed that ICV administration of CART was accompanied by a reduction in 
food intake and c-fos expression, a marker of neuronal activation, in areas of the brain 
associated with energy homeostasis (Aja et al., 2001). Collectively the data is indicative of 
CART having an inhibitory physiological effect on food intake. However, Aja et al reported 
that administration of CART into the third ventricle was also associated with movement 
tremors as a result of CART peptide diffusing to the fourth ventricle, an area that is linked 
with motor control, suggesting the effect of food intake may be secondary to an effect on 
motor control. However, when CART was prevented from diffusing to the fourth ventricle by 
means of blocking the aqueduct with the use of a plug, a reduction in food intake was still 
observed without the movement tremors (Aja et al., 2001). This suggests that movement 
tremors cannot fully explain the reduction in food intake following third ventricle 
administration of CART peptide. 
 
While ICV injection of CART (55-102) has been consistently shown to reduce food intake, 
there is conflicting data regarding the effect of CART (55-102) following injection into 
specific hypothalamic nuclei. Studies suggest that CART has an orexigenic role in certain 
nuclei. Injection of 0.04nmol CART (55-102) into the rat ARC and VMN produced a delayed 
but significant increase in feeding between 1 and 4 hours post injection. Significant increases 
in feeding were seen after injection of CART at a higher dose (0.2nmol) into the ARC, VMN, 
PVN, LH, DMN and SON. In contrast, injection of CART peptide into the 3rd ventricle 
inhibited food intake (Abbott et al., 2001; Kong et al., 2003). Injection of CART into specific 
hypothalamic nuclei was not associated with any movement tremors (Abbott et al., 2001). 
Furthermore, CART stimulated the release of NPY and inhibited α-MSH release from 
hypothalamic explants (Stanley et al., 2001) which is consistent with CART acting as an 
orexigen. The data on the role of CART is controversial since CART has been linked with 
both anorectic and orexigenic roles in the regulation of energy homeostasis. Further 
investigation is needed to elucidate the physiological role of CART within the hypothalamus 
and its constituent nuclei. 
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1.4.7 Energy Expenditure 
In addition to its role in food intake, CART has also been implicated in the control of energy 
expenditure. Triple-labelling fluorescent in situ hybridisation and immunofluorescence 
studies demonstrated that CART containing neurones which coexpress α-MSH synapse with 
TRH neurones, suggesting CART plays a role in the regulation of TRH release (Fekete et al., 
2000). TRH is linked with a role in energy expenditure through mediating release of TSH 
from the pituitary which in turn stimulates the release of thyroxine (T4) and tri-iodothyronine 
(T3) from the thyroid gland (Mittler et al., 1969). In agreement with this anatomical data 
administration of CART peptide has been demonstrated to result in an increase in TRH 
release from hypothalamic explants (Rondeel et al., 1992). A role for CART in energy 
expenditure was further confirmed in studies by Kong et al which investigated the effect of 
chronic overexpression of CART cDNA in the arcuate nucleus of rats by gene delivery (Kong 
et al., 2003). Twenty five days post injection of CART cDNA expressing plasmid into the 
ARC, brown adipose tissue (BAT) uncoupling protein (UCP-1) mRNA was 80% higher in 
treated rats relative to the control animals (Kong et al., 2003). Chronic administration of 
CART peptide into the ARC has been demonstrated to cause hyperphagia and to increase 
thermogenesis. Hyperphagia is suggestive of CART acting as an orexigen whereas the 
increase thermogenesis is consistent with CART acting as an anorectic peptide, hence CART 
seems to be acting as both an anorectic and an orexigenic peptide. However, this may be 
explained by the observation by Kong et al that rats exposed to a temperature of 4oC over 20 
days demonstrated a 124% increase in ARC CART mRNA (Kong et al., 2003). Therefore 
CART mediated hyperphagia and increased thermogenesis suggests that CART is involved in 
cold adaptation.  
 
 
1.4.8 Transgenic Models 
Transgenic models have been used in an attempt to investigate the physiological role of 
CART in energy homeostasis. Mice with targeted deletion of the CART gene were generated 
by Asnicar et al and exhibited no body weight difference relative to wildtype mice when fed a 
standard chow diet. However, these mice did display an increase in body weight and food 
intake relative to wildtype mice when maintained on a high fat diet which suggests that 
CART may protect against diet induced obesity (Asnicar et al., 2001). 
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A second strain of mice with a targeted deletion of the CART gene was generated by Wierup 
et al and they exhibited an increase in body weight relative to control animals with transgenic 
mice being 14% heavier than wildtype mice at 40 weeks of age when fed standard chow 
(Wierup et al., 2005). Insulin secretion was also measured in these mice since CART mRNA 
expression has been identified by immunocytochemistry and in situ hybridisation in the 
pancreatic nerve fibres in the normal mouse pancreas (Wierup et al., 2004). Mice with a 
targeted deletion of CART displayed impaired insulin secretion and it was hypothesised that 
this was a result of β cell dysfunction. This was confirmed by immunocytochemistry which 
showed mice with a targeted deletion of CART displayed age dependent reduction in 
immunoreactivity of pancreatic duodenal homeobox 1 (PDX-1) transcription factor, which is 
important in β cell development and insulin gene expression, and glucose transporter 2 
(GLUT2), which is a major determinant of cellular glucose uptake. The absence of GLUT2 
and PDX-1 is associated with defective insulin secretion and glucose tolerance (Wierup et al., 
2005; Wierup, 2006). The impairment in insulin secretion was observed before an increase in 
body weight presented suggesting CART directly affects islets cells. 
 
The data from mice with targeted deletion of CART suggests an anorectic physiological role 
for CART. However, CART peptide is widely expressed in the brain and the periphery and 
the phenotype of mice with body wide deletion of CART is an amalgamation of the effect of 
the loss of CART peptide throughout the organism. Therefore it is difficult to conclude a 
precise role for CART in a specific brain region.   
 
 
1.4.9 Differential Regulation of Cocaine- and Amphetamine -Regulated Transcript  
Studies have suggested that CART acts both as an anorectic and an orexigenic agent in the 
control of energy homeostasis. CART mRNA expression is reduced in rats fasted for 48 
hours implicating it with an anorectic role, although, intra-ARC injection of CART peptide 
causes an increase in feeding which is suggestive of CART acting as an orexigenic factor. To 
reconcile the data which demonstrates the two competing functions of CART it has been 
hypothesised that CART is differentially regulated within the hypothalamus. Abbot et al has 
suggested that CART may be involved in two appetite circuits, one orexigenic and one 
anorectic (Abbott et al., 2001). Interestingly, POMC neurones in the ARC have been shown 
to mainly coexpress glutamate but a proportion of POMC neurones coexpress the GABA 
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neurotransmitter, suggesting that POMC neurones within the ARC may have stimulatory and 
inhibitory functions (Hentges et al., 2004).  
 
 
1.4.10 Cocaine- and Amphetamine -Regulated Transcript in Humans 
The need to understand the role of CART is underlined by human genetic studies. In humans, 
a heterozygous CART missense mutation has been identified which cosegregates with 
obesity through three generations of an Italian family. The missense mutation results in an 
amino acid substitution of leucine to phenylalanine at codon 34 (Leu34Phe) within the amino 
terminal CART region.  Obese individuals with this mutation have low resting metabolic 
rates. The leucine residue at codon 34 precedes two lysine residues which may be a site for 
proteolysis by the PC enzymes. The Leu34Phe mutation may alter the susceptibility of CART 
to proteolysis and effect energy expenditure (del Giudice et al., 2001). The mutation may 
reduce the ability of the prohormone convertase enzymes to catalyse proteolysis at this site, 
alternatively, the mutation may alter the structure of the proCART peptide making it more 
susceptible to proteolysis. Depending on the effect of the mutation of posttranslational 
processing the concentration of CART peptide fragments will be either increased or 
decreased. The exact effect of the Leu34Phe mutation on CART peptide processing is unclear 
as CART peptide concentration was not measured in the affected individuals (del Giudice et 
al., 2001). A second study by Yamada et al studied polymorphisms in the CART gene to 
investigate whether there was a link to obesity. The 5’ flanking region of the CART gene was 
screened for associations between polymorphisms and obesity. The 5’ flanking region of the 
CART gene was sequenced. Six polymorphic sites were identified A-->G at -156, T-->C at -
390, T-->G at -484, G-->T at -915, G-->C at -929 and C-->T at -962. The nucleotide 
substitution at -156 was significantly associated with greater body mass index (BMI) and the 
allele frequency of the -156 variant was significantly higher in obese subjects. The 
polymorphism at -156 site may be linked with a genetic predisposition to obesity (Yamada et 
al., 2002). 
 
 
1.5 Neurotransmitters  
Several chemical neurotransmitters have been implicated in the control of food intake. In 
some circumstances the neurotransmitters have been demonstrated to colocalise with the 
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neuropeptides described previously which may allow multiple responses through the same 
neuronal population.  
 
 
1.5.1 Glutamate and γ-aminobutyric acid 
L-Glutamate is the main excitatory and γ-aminobutyric acid is the main inhibitory 
neurotransmitter in the CNS and both have been implicated in the control of food intake. 
Injection of glutamate into the LH results in feeding in satiated rats and this feeding is 
inhibited by the administration of glutamate receptor antagonists (Stanley et al., 1993; 
Stanley et al., 1996). GABA is also involved in the control of feeding. GABA expressed in 
ARC NPY neurones exerts an inhibitory tone on ARC POMC neurones (Cowley et al., 
2001). Furthermore, ICV administration of GABA agonists cause an increase in feeding in 
rodents which is reversed by ICV administration of GABA receptor antagonists (Stratford 
and Kelley, 1997; Ebenezer, 1990). Collectively the evidence suggests that both GABA and 
glutamate are involved in appetite regulation and for this reason a GABA receptor antagonist 
named Zonisamide has been developed by Pharma as an anti-obesity drug and is currently in 
phase III clinical trials. 
 
 
1.5.2 Monoamine Neurotransmitters 
The main monoamine neurotransmitters that have been linked with a role in potentiating food 
intake are dopamine, norepinephrine (NE) and 5-Hydroxytryptamine (5-HT). Dopamine is 
thought to increase food intake since administration of dopamine receptor antagonists results 
in a reduction in feeding (Clifton et al., 1991). DA plays a prominent role in mediating an 
increase in food intake through the mesolimbic pathway since restoration of DA to the NAc 
in dopamine deficient mice restores feeding (Szczypka et al., 2001). 5-HT has been 
implicated as having a suppressive effect on food intake since injection of exogenous 5-HT 
into the PVN, VMH and DMN leads to a reduction in food intake (Leibowitz and Alexander, 
1998). As a result 5-HT has been targeted as a treatment for obesity. Sibutramine is a 
serotonin and norepinephrine reuptake inhibitor which reduces food intake by inducing the 
sense of satiety and preventing the decline in metabolic rate that is associated with a low 
calorie diet by increasing the concentration of 5-HT in the synapse. Sibutramine has been 
shown to cause dose dependent weight loss in humans in addition to improved lipid and 
glucose profiles (Blackburn and Smith, 1997; Kim et al., 2003) although the drug has now 
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been withdrawn for use in the UK by the Medicines and Healthcare Products Regulatory 
Agency after the drug was linked with an increase in heart attacks and strokes. NE has been 
shown to both stimulate and inhibit food intake. There are 5 types of adrenergic receptor, α1, 
α2, β1, β2 and β3. Activation of hypothalamic α1, β2 and β3 adrenergic receptors results in a 
decrease in food intake, whereas stimulation of α2 leads to an increase in food intake 
(Goldman et al., 1985). In fact, Eli Lilly have developed a β3 receptor agonist, LY362884, 
which is currently in phase III clinical trials. Evidence suggests that the monoamine 
neurotransmitters can mediate effects on food intake through actions at the hypothalamus and 
the reward pathway. Interestingly, a drug named tesofensine, which acts by blocking the 
reuptake of the DA, 5-HT and NE is in phase III clinical trials as an anti-obesity therapy. 
 
 
1.5.3 Endocannabinoids and Opioids 
Endocannabinoids and opioids have both been shown to effect food intake. Intra-nuclear 
administration of the endocannabinoids anandamide (AEA) and 2-arachidonyl glycerol (2-
AG), and the opioids β-endorphin and dynorphin, promote feeding in rodents confirming a 
stimulatory effect on food intake by the opioids and endocannabinoids (Kirkham et al., 2002; 
Hao et al., 2000; Baile et al., 1986; Glass et al., 1999). In addition, ICV administration of  β-
endorphin in rats has been shown to reduce sympathetic nerve activity to intrascapular BAT 
in a dose dependent fashion (Egawa et al., 1993). Collectively the evidence suggests that the 
endocannabinoids and opioids have a stimulatory effect on food intake. The ability of the 
cannabinoid receptor 1 (CB1) to mediate the feeding effect of endocannabinoids has made it 
an attractive target for anti-obesity therapy. Rimonobant is a drug that acts as a CB1 receptor 
antagonist which prevents endogenous endocannabinoid action at the CB1 receptor with the 
result being a reduction in food intake. However, the approval for rimonobant was withdrawn 
early in 2009 by the European Medicine Agency’s due to evidence linking an increase in the 
prevalence of psychiatric conditions in patients taking the drug (Christensen et al., 2007). 
 
 
1.6 Peripheral Signals of Adiposity (Figure 1.4) 
The brain integrates a number of peripheral signals as part of its role in regulating energy 
homeostasis. These peripheral hormones include signals of long term energy store, such as 
leptin and insulin, and short term signals of satiety from the gastrointestinal tract.  
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1.6.1 Leptin 
Leptin is synthesised in the white adipocytes and released into the circulation at a level 
proportional to body fat and as such is an indicator of peripheral energy stores (Considine et 
al., 1996). Chronic administration of leptin results in a decrease in food intake, fat mass, and 
body weight (Halaas et al., 1995). Leptin is a product of the ob gene, but prior to the 
discovery of the ob gene, the existence of leptin was first suggested by parabiosis studies in 
obese, hyperphagic ob/ob mice (Coleman, 1973). Ob/ob mice carry a mutation in the ob gene 
resulting in a truncated inactive version of leptin which results in an obese phenotype (Zhang 
et al., 1994). Further to this, Animal models with mutations in the leptin receptor (Ob-R), 
namely db/db mouse and the fa/fa rat, showed compromised leptin signalling, diabetes and 
obesity, which is consistent with the phenotype observed in the ob/ob mice which are 
deficient in the leptin protein (Chua, Jr. et al., 1996; Lee et al., 1996). The leptin receptor is 
widely expressed in the hypothalamus including the ARC, PVN and VMN (Mercer et al., 
1996). Within the ARC the Ob-R is expressed on both NPY/AgRP and POMC/CART 
neurones (Hakansson et al., 1996) and c-fos activation has been demonstrated in these 
neurones following intraperitoneal and intravenous administration of leptin which suggests 
that leptin acts on both populations of neurones (Elmquist et al., 1997). Leptin action on ARC 
neuropeptides was confirmed in subsequent studies. Electrophysiology demonstrated that 
action potential frequency in the NPY/AgRP neurones decreased upon administration of 
leptin, confirming leptin inhibition of neuronal firing (Takahashi and Cone, 2005). 
Additionally, in the ob/ob mouse CART mRNA expression was found to be significantly 
decreased in the ARC and to a lesser extent in the DMN and LH, suggesting that leptin 
activates POMC/CART neurones (Kristensen, 1998). This was confirmed in studies which 
showed that chronic peripheral leptin administration over 10 days increased CART mRNA 
expression in the ARC and LH of ob/ob mice, a reduction in food intake was also observed in 
the leptin treated group (Kristensen, 1998). Many of the CART expressing neurones in the 
ARC project to the thoracic spinal cord and Elias et al demonstrated leptin activation of these 
neurones which provides a possible mechanism by which leptin stimulates the sympathetic 
nervous system (Elias et al., 1998). Collectively, the evidence detailing the action of leptin on 
hypothalamic neuropeptides confirms a functional role for leptin at the ARC. The importance 
of leptin in humans has been highlighted by a few cases of congenital leptin deficiency with 
the result being hyperphagia and obesity that can be corrected by treatment with recombinant 
leptin (Farooqi et al., 1999). However, in the majority of obese patients there is a high 
46 
 
circulating level of leptin suggesting the development of leptin resistance (Heymsfield et al., 
1999). 
 
 
1.6.2 Insulin 
Insulin is produced in the Islets of Langerhans within the pancreas and was the first peptide to 
be identified as an adiposity signal (Porte, Jr. and Woods, 1981) since levels circulate relative 
to body fat. Insulin exerts its effects centrally in a similar way to leptin. Chronic ICV infusion 
of insulin into streptozotocin induced diabetic rats over six days, at levels that did not affect 
plasma glucose levels, decreased adiposity and body weight, which is suggestive of insulin 
acting as an anorectic peptide in the CNS (Sipols et al., 1995). The insulin receptor is widely 
expressed throughout the brain with particularly high levels of expression in the ARC NPY 
and POMC neurones (Baskin et al., 1987) suggesting that insulin acts centrally by 
modulating ARC neuropeptides. ICV administration of insulin has been found to reduce food 
intake and was also associated with the activation of the POMC/CART neurones and the 
inhibition of NPY neuronal firing within the ARC (Sipols et al., 1995). It is thought that the 
main action of insulin on the POMC/CART neurones is through the melanocortin system 
since ICV administration of insulin induces an increase in POMC mRNA expression but not 
in CART mRNA (Fekete, 2006). However, in states of fasting which are characterised by 
reduced leptin and insulin concentrations, rodents demonstrate a decrease in CART mRNA 
expression. Furthermore, chronic ICV administration of CART is accompanied by a decrease 
in plasma insulin concentration (Rohner-Jeanrenaud, 2002) which is suggestive of CART 
exerting an inhibitory effect on plasma insulin release. The physiological importance of 
central insulin signalling in energy homeostasis is highlighted by mice with brain specific 
deletion of the insulin receptor in which the mice develop an obese phenotype (Bruning et al., 
2000). A second study using antisense oligonucleotides specific for the insulin receptor 
confirmed these observations. A reduction in insulin receptor expression resulted in an obese 
phenotype which is consistent with results from mice with targeted deletion of the insulin 
receptor. In addition, there was an increase in expression of NPY and AgRP and adiposity 
(Obici et al., 2002).  The current evidence confirms a role for insulin acting on the CNS as a 
signal of long term energy store. 
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Figure 1.4  Integration of peripheral signals by the arcuate nucleus. Diagram showing 
two populations of arcuate nucleus neurones, AGRP/NPY and POMC/CART neurones. The 
AGRP/NPY neurones increase food intake and decrease energy expenditure. The 
POMC/CART neurones inhibit feeding and increase energy expenditure. These neurones are 
regulated by circulating peripheral factors. Leptin and insulin circulate at levels proportional 
to body fat and inhibit AGRP/NPY neurones and activate POMC/CART neurones. Ghrelin is 
released from the stomach and activates AGRP/NPY neurones leading to an increase in food 
intake. Ghrs, Growth hormone secretagogue receptor; Y1r/Y2r, neuropeptide Y receptor; 
Lepr, leptin receptor;Mc3r/Mc4r, melanocortin 3/4  receptor;  
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1.6.3 Integration of Insulin and Leptin Signalling 
Leptin and insulin have been shown to mediate similar actions within the CNS, for example 
both insulin and leptin have been shown to reduce food intake when administered ICV 
(Fekete, 2006). Therefore, it has been hypothesised that due to leptin and insulin mediating 
similar actions they may act through a common signalling pathway. Activation of the insulin 
receptor results in its autophosphorylation. The phosphorylated sites on the insulin receptor 
act as a binding domain for the insulin receptor subunit (IRS) protein. Once the IRS protein is 
bound to the intracellular domain of the insulin receptor it is also phosphorylated. Following 
the activation of the IRS proteins downstream targets are activated, one of which is 
phosphatidylinositol-3-kinase (PI3K). Conversely, leptin acts through the Janus Kinase 
(JAK) signal transducers and activator of transcription (STAT) signalling pathway, 
specifically the JAK2 and STAT3 proteins. STAT proteins act as transcription factors and are 
thought to mediate the decrease in POMC and CART gene expression that accompany leptin 
administration (Banks et al., 2000; Vaisse et al., 1996). However, studies using hypothalamic 
explants demonstrate that leptin causes hyperpolarisation of hypothalamic neurones through 
activation of potassium ion channels in the neuronal membrane. The effect on ion 
permeability cannot be accounted for by STAT3 induced alterations in gene expression due 
to the short time frame between leptin administration and activation of ion channels, this 
suggests that leptin may act through additional signalling pathways to that of the JAK-STAT 
pathway (Spanswick et al., 1997). Confirmation came from studies involving a targeted 
substitution of specific tyrosine amino acids with the amino acid serine on the leptin receptor. 
The amino acid Tyr 1138 is essential for the recruitment of the STAT 3 protein; hence, by 
introducing a mutation at this site the STAT3 leptin signalling pathway is blocked. If the 
JAK-STAT pathway was the only pathway through which leptin signalled then mice with a 
mutation at Tyr1138 should display a similar phenotype to the db/db mouse which has a 
targeted deletion of the leptin receptor. Instead mice with a mutation at Tyr1138 show normal 
NPY mRNA expression levels and improved glucose tolerance. In addition, other leptin 
receptor mediated signalling pathways such as the mitogen activated protein kinase (MAPK) 
signal cascade were still active in mice with a mutation at the Tyr1138 position, suggesting 
that leptin can signal through an alternate pathway independent of the STAT protein (Bates, 
2003; Banks et al., 2000). The leptin receptor is also thought to activate the IRS-PI3K 
component of the insulin signalling pathway via JAK mediated phosphorylation which is 
independent of the STAT3 protein since immunoprecipitation has demonstrated that the 
JAK2 protein can phosphorylate and activate IRS and PI3K proteins (Carvalheira et al., 2005; 
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Kellerer et al., 1997; Bjorbaek et al., 1997). This was confirmed using rat hypothalamic slices 
in which leptin and insulin were shown to reduce the firing on the same potassium-ATP (K-
ATP) channels in the ARC (Spanswick et al., 2000). The ability of either leptin or insulin to 
reduce the firing of neurones from hypothalamic slices was blocked by the administration of 
the PI3K inhibitor wortmannin (Spanswick et al., 1997; Spanswick et al., 2000). Studies on 
hypothalamic explants confirm that the action of both leptin and insulin to reduce neuronal 
firing is through PI3K since PI3K appears to be necessary for regulating the permeability of 
K-ATP ion channels in the neuronal membrane. Failure to properly activate PI3K may form 
the basis of leptin resistance. 
 
Evidence of crossover in the signalling pathway of leptin and insulin allows for integration of 
signals of long term energy status and may also serve as a control point for the anorectic 
effects of these peptides. 
 
 
1.6.4 Gastrointestinal Hormones 
The orexigenic peptide ghrelin, and short term signals of satiety originating from the 
gastrointestinal tract (GIT) signal through the hypothalamus and brainstem.  
 
Ghrelin is a 28 amino acid acylated peptide which is released from the oxyntic cells of the 
stomach and increases food intake through binding to the growth hormone secretagogue 
receptor (GHSR) (Kojima et al., 1999) which is expressed in the hypothalamus and brainstem 
(Guan et al., 1997; Date et al., 2002)}. ICV and peripheral administration of ghrelin results in 
increased food intake and body weight in rodents, confirming an orexigenic role for ghrelin 
(Tschop et al., 2000). It is thought that NPY mediates the observed increase in food intake 
associated with ghrelin since 90% of activated ARC neurones resulting from peripheral 
administration of ghrelin were found to express NPY (Wang et al., 2002).  The orexigenic 
effect of ghrelin may be mediated by the vagal nerve projection to the brainstem (Jobst et al., 
2004). The GHSR has been identified on the vagus nerve and peripheral administration of 
ghrelin increases neuronal activation in the NTS and AP. In addition, vagotomised rats do not 
respond to peripheral administration of ghrelin which highlights the importance of the vagus 
nerve in mediating the effect of peripheral ghrelin (Date et al., 2002). Physiological evidence 
of ghrelin’s orexigenic role is provided by transgenic models. Transgenic overexpression of 
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ghrelin leads to the development of hyperphagia and reduced glucose and leptin sensitivity 
which is consistent with ghrelin being an orexigenic peptide (Bewick et al., 2009).  
 
Peptide tyrosine tyrosine (PYY) is a 36 amino acid peptide (PYY1-36) which is cleaved by 
the enzyme dipeptidyl peptidase IV into its more active form PYY3-36. PYY is released from 
the enteroendocrine L cells lining the distal gastrointestinal tract which is released post 
prandially. The largest increases in PYY are observed following ingestion of high fat meals 
(Adrian et al., 1985) which is consistent with PYY being an anorectic peptide. Peripheral 
administration of PYY3-36 in rodents, and intravenous administration of PYY3-36 in humans 
result in decreased food intake and body weight (Batterham et al., 2002; Batterham et al., 
2003; Degen et al., 2005). The food reducing effect of PYY is thought to be mediated 
through the Y2R which is an auto-inhibitory receptor expressed on the ARC NPY neurones. 
This hypothesis is supported by a lack of response to PYY3-36 administration in the Y2R 
knockout mouse (Batterham et al., 2002).  Collectively the evidence demonstrates that PYY 
plays a critical role in meal termination by acting through the Y2R at the ARC to decrease 
food intake. 
 
Pancreatic polypeptide (PP) is a 36 amino acid peptide which is synthesised in the PP cell of 
the pancreas and released postprandially. In the gut cholecystokinin (CCK) is primarily 
produced in the I cells and, like PP, is also released post prandially. Peripheral administration 
of PP and CCK have both been shown to decrease food intake in rodents implicating both 
peptides with an anorexigenic function (Asakawa et al., 2003; Gallmann et al., 2006). The 
actions of both PP and CCK are thought to be mediated through actions at the brainstem by 
inhibiting gastric emptying which is consistent with the brainstem being a primary site for 
integration of gastrointestinal signals (Schmidt et al., 2005; Wu et al., 2002). CCK receptors 
have been identified in the vagal afferents, a main site of projection to the gastrointestinal 
tract (Moran et al., 1986; Moran and Kinzig, 2004)} and PP binds with high affinity to the Y4 
receptor which is found in the brainstem (Whitcomb et al., 1990). In further support of 
integration of PP signal at the brainstem, vagotomised rats result in elimination of meal 
related secretion of PP (Rogers et al., 1996). 
 
Glucagon like peptide 1 (GLP-1) is released from the L cell of the gastrointestinal tract and 
exists in two bioactive forms, GLP-1 (7-37) and GLP-1 (7-36). GLP-1 acts as an incretin, 
stimulating insulin release in a glucose dependent manner, in addition to inhibiting the 
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secretion of glucagon (MacDonald et al., 2002; Willms et al., 1996)}. Intravenous infusion of 
GLP-1 to normal and obese subjects reduced food intake in a dose dependent fashion 
(Verdich et al., 2001) and ICV administration in rodents of the potent GLP-1 antagonist 
exendin 9-39 increased food intake (Turton et al., 1996). Collectively suggesting a 
physiological role for GLP-1 in energy homeostasis. 
 
The data collectively suggests that peptides from the gastrointestinal tract can relay 
information on the current status of fuel availability and these signals are integrated at the 
ARC and brainstem. 
 
 
1.7 Summary 
As has been discussed the ARC is a major site within the hypothalamus for integrating 
peripheral signals of energy stores and satiety. The transduction of peripheral signals into 
neuronal responses is mediated through the orexigenic neuropeptides NPY and AgRP as well 
as the anorectic peptide POMC. Additionally, evidence suggests that CART plays an 
important role in appetite regulation. However, the exact physiological role of CART is 
difficult to define since in different experimental paradigms CART has been shown to 
increase and decrease food intake. Given that antibody blockade of CART peptide results in 
an increase in food intake, and the importance of mutations in the CART gene in human 
familial obesity, it is important to understand the true physiological role of CART. In order to 
elucidate the physiological role of CART more complex genetic paradigms need to be used to 
pick apart the role of CART in particular hypothalamic nuclei. 
 
 
1.8 Aim of Thesis 
I aim to investigate the role of ARC CART by characterising the phenotype that results from 
a physiological reduction in CART peptide concentration specifically in this nucleus. To 
achieve a reduction in CART peptide concentration I will use CART antisense expression 
which will be targeted to the ARC by rAAV and BAC transgenesis. 
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Chapter 2 
 
General Materials and 
Methods 
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2 Materials and Methods 
 
2.1 Materials 
Unless otherwise stated all chemicals were purchased from VWR, Poole, Dorset, UK and all 
enzymes from New England Biolabs, Hitchin, Herts, UK. 
 
 
2.2 Methods 
 
2.2.1 Total RNA extraction – Tri-reagent method 
 
Materials 
Tri-Reagent (Helena Biosciences, Tyne and Wear, UK) 
1-Bromo-Chloro-Propane (Sigma-Aldrich, Poole, Dorset, UK) 
Isopropanol  
Absolute Ethanol  
Sterile distilled water (GDW) 
 
Method 
Total RNA was extracted using Tri-Reagent according to the manufacturer’s protocol. Tissue 
(up to 100mg) was homogenised in 1ml Tri-Reagent, transferred to sterile 1.5ml eppendorf 
tubes and incubated for five minutes at room temperature. When extracting RNA from cells, 
cell media was removed and 5ml tri reagent added per 75cm3 flask (Nunc, Thermo Fisher 
Scientific, Denmark). The flask was shaken gently to detach the cells from the flask wall. 
Cells were then removed and divided into 1.5ml eppendorfs and incubated for five minutes at 
room temperature. 
 
One hundred microlitres of bromo-chloro-propane was added per millilitre of tri reagent and 
mixed vigorously. The mixture was incubated at room temperature for ten minutes, then 
centrifuged at 12000g for fifteen minutes at 4oC (centrifuge 5417 C/R, Eppendorf, Hamburg, 
Germany).  The upper aqueous phase was transferred to a clean eppendorf tube, precipitated 
with 0.5ml isopropanol for ten minutes at room temperature then centrifuged at 12000g for 
ten minutes at 4oC (centrifuge 5417 C/R, Eppendorf, Hamburg, Germany). The supernatant 
was removed and the pellet washed with 75% (v/v) ethanol in GDW, air dried and 
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resuspended in 400µl of GDW.  RNA concentration was determined by spectrophotometry.  
The RNA was diluted 1:100 in GDW and 1ml placed into a quartz cuvette (VWR). The 
absorbance was read at 260 and 280nm, and the concentration calculated using the following 
formula:  
concentration (µg/ml) = (A260 x dilution factor) x 40. 
 
 
2.2.2 RNA Denaturing Gel 
 
Materials  
Agarose, type II-A (Sigma-Aldrich, Poole, Dorset, UK) 
40% (v/v) Formaldehyde (VWR) 
20x MOPS pH 7.0 (appendix I) 
 0.4M 3-(N-Morpholin) propanesulphonic acid (MOPS) 
 0.1M sodium acetate 
 0.02M EDTA 
 0.04% (v/v) formaldehyde  
10mg/ml Ethidium bromide (VWR) 
DENAT (appendix I)  
 70% (v/v) formamide (appendix I) 
 3.5% (v/v) formaldehyde 
 1.5x MOPS 
Gel loading buffer (appendix I) 
 25% (v/v) glycerol 
 0.1% (w/v) orange G 
 25mM EDTA  
100x TE pH 7.5 (appendix I)  
 1M Tris Base 
 0.1M EDTA 
2M Sodium acetate pH 5.2 (appendix I) 
Sterile distilled water (GDW) 
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Method 
A 1% (w/v) agarose denaturing gel was prepared in 1x MOPS buffer with 7.5% (v/v) 
formaldehyde.  Following quantification by spectrophotometry, the RNA samples were 
ethanol precipitated with 0.1 volumes sodium acetate pH 5.2 and 2.5 volumes of ice cold 
absolute ethanol.  The samples were precipitated at -20°C for a minimum of one hour then 
centrifuged at 12000g for ten minutes at room temperature (F45-12-11 microfuge, Eppendorf, 
Hamburg, Germany).  The supernatant was removed and the pellet air dried under vacuum 
for five minutes.  RNA pellets were resuspended in the appropriate volume of GDW to a final 
concentration of 5mg/ml.  One micro litre of this solution was added to 12µl of DENAT.  The 
samples were denatured at 65°C for five minutes and 3µl gel loading buffer added.  The 
samples were loaded onto the gel and run in 1x MOPS buffer with 7.5% (v/v) formaldehyde 
at 150V for approximately forty minutes until the samples had ran 10cm.  The gel was then 
stained in 1x TE with 0.01% (v/v) ethidium bromide on a shaking platform for thirty minutes, 
then de-stained overnight in 1x TE to allow visualisation of the 18S and 28S ribosomal bands 
under UV light. The presence of these bands indicated that the RNA had not degraded. 
 
 
2.2.3 Northern Blot Hybridisation 
Northern blotting is a technique to identify and quantity RNA in tissues. The method is 
adapted from Southern Blotting, a technique developed in the 1970s to quantify DNA 
(Southern, 1975). A denaturing formaldehyde gel is used to size fractionate RNA fragments. 
The RNA is then transferred to a nylon membrane by capillary action and the membrane 
baked to increase the membrane to RNA binding strength 
 
 
2.2.3.1 Electrophoresis and Immobilisation of Nucleic Acids (Lehrach et al., 1977) 
 
Materials 
20x SSC (appendix I) 
3M sodium chloride (appendix I) 
 0.3M tri-sodium citrate pH 7.0 
Hybond-N (Amersham Biosciences) 
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Method 
A denaturing formaldehyde gel was prepared and 50µg of total RNA was denatured and 
loaded onto the gel as described in section 2.2.2.  Following electrophoresis, the RNA was 
transferred from the gel to Hybond-N membrane by capillary action overnight.  The gel was 
inverted and placed into a stack constructed as illustrated in Figure 2.1. After transfer, the 
filter was baked at 80°C for 1-2 hours to covalently link the RNA to the filter.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Northern blotting. Apparatus used for the transfer of RNA by capillary action 
from a gel to Hybond-N membrane prior to northern blot analysis. 
 
 
2.2.3.2 Hybridisation of 32P Labelled Probe to the Filter 
Probes for northern blot analysis were prepared from pBluescript containing the appropriate 
insert, prepared as described in section 2.2.7. To prepare fragments for labelling, pBluescript 
was cut with BamHI and EcoRI and the fragment excised from the gel and electroeluted 
(section 2.2.7.1 and 2.2.7.2). Fragments were labelled using random primer labelling. Pre-
hybridisation is carried out before the membrane is bound to radiolabelled probe; this blocks 
20x SSC 
Support 
3MM filter paper 
Saran wrap 
Inverted gel 
Hybond-N 
Paper towels 
Glass plate 
Weight (approx 200g) 
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irreversible non-specific binding of the probe to the membrane. Following hybridisation, a 
number of increasingly stringent washes are performed to remove non-specifically bound 
probe. 
 
 
2.2.3.3 Random Primer Labelling of DNA Fragments (Feinberg and Vogelstein, 1983) 
 
Materials 
DNA probe fragment 
5x ABC Buffer: (appendix I) 
12.5mM magnesium chloride 
125mM Tris-HCl, pH8.0 
        23µM 2-mercaptoethanol 
        50µM dATP (Pharmacia) 
        50µM dGTP (Pharmacia) 
        50µM dTTP (Pharmacia) 
        1M N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES), pH 6.6 
(Sigma-Aldrich, Poole, Dorset, UK) 
        34µg/ml random deoxynucleotide hexamers (Amersham Bioscience) 
10mg/ml BSA, fraction V (Sigma-Aldrich, Poole, Dorset, UK) 
[α-32P]-dCTP: 10Ci/ml, 3000Ci/mmol (Amersham Bioscience) 
DNA polymerase I, Klenow fragment 9U/µl (Amersham Bioscience) 
Sephadex G50 (appendix I) 
1x TE (appendix I) 
  
Method 
Twenty nanograms of DNA in a total volume of 15µl of GDW was boiled for five minutes.  
After boiling, the solution was made up to a total volume of 25µl containing 1XABC buffer, 
2mg/ml BSA, 10µCi dCTP and 1U Klenow.  The reaction was incubated at 37oC for at least 
one hour.  Incorporation of radiolabelled nucleotide into the DNA probe was measured using 
a mini Sephadex G50 column.  The column was prepared by plugging a glass Pasteur pipette 
with glass wool, and adding Sephadex G50.  The labelling reaction volume was made up to 
200µl with 1x TE and loaded onto the column.  The column was then eluted with 1x TE and 
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200µl fractions collected.  The fractions were counted and the percentage incorporation 
calculated.  The two fractions with the greatest radiolabel incorporation were pooled. 
 
 
2.2.3.4 Hybridisation of Northern Filters 
 
Materials 
32P labelled probe (section 2.2.3.2) 
Hybridisation buffer (appendix I) 
 0.25M sodium phosphate buffer 
 5% (w/v) SDS 
 0.5% (w/v) dried milk 
 2.5mM EDTA 
 25µM ATA (appendix I) 
Amasino wash buffer (appendix I) 
 0.25M sodium phosphate pH 7.2 
 1mM EDTA 
 2% (w/v) SDS  
Universal wash buffer (appendix I) 
 0.2x SSPE 
 0.2% (w/v) SDS 
  
Method 
The baked filter was placed in a heat sealed polythene bag and pre-hybridised in 20ml 
hybridisation buffer at 60°C for a minimum of two hours. Half the labelled probe (section 
2.2.3.2) was boiled for 5 minutes and added to 20ml fresh hybridisation buffer.  The pre-
hybridisation solution was removed, the hybridisation mix added and the filter incubated 
overnight at 60°C.  Non-specifically bound probe was removed from the filter by washing in 
decreasing concentrations of sodium chloride.  Three twenty minute washes at 60°C were 
carried out in Amasino wash buffer followed by a further three twenty minute washes at 60°C 
in Universal wash buffer.  The filter was then sealed in a clean plastic bag and exposed to a 
storage phosphor screen (Molecular Dynamics, Amersham, UK). Radiolabelled RNA was 
visualised using a Storm imaging system and ImageQuant software (Molecular Dynamics, 
Amersham, UK).  
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2.2.3.5 Filter Stripping 
Following hybridisation with a radiolabelled probe, northern filters can be stripped of 
radioactivity and re-used with minimal loss of RNA. Most northern filters can be stripped and 
re-probed five or six times depending on the abundance of the transcript of interest. 
 
Materials 
100 x TE (appendix I) 
20% (w/v) SDS (appendix I) 
 
Method 
The filter was stripped by incubation in 200 ml of 1xTE/0.5%SDS for 30 minutes in a water 
bath at 80oC. The filter was then exposed overnight to a phosphoimager plate to ensure that 
all radioactive probe had been removed. 
 
 
2.2.3.6 Oligo dT Labelling 
A radiolabelled oligo dT probe was prepared which hybridises to the polyA tail of mRNA. 
This allows mRNA to be quantified.  
 
Materials 
20ng oligo dT template 
20U/µl Terminal deoxytransferase (Promega) 
5x reaction buffer (as supplied) 
GDW 
[α-32P] dATP 10Ci.ml, 3000Ci/mmol (GE healthcare) 
Sephadex G50 (appendix I) 
1x TE 
Hybridisation  buffer (appendix I) 
20x SSPE (appendix I) 
20% (w/v) SDS (appendix I) 
Milk power 
Nonidet 
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Method 
Twenty nanograms of oligo dT template were added to 1x reaction buffer with 20U of 
terminal transferase in a final volume of 20µl with GDW. The reaction was incubated at 37°C 
for one hour. A mini sephadex G50 column was used to measure incorporation of the labelled 
nucleotide, as described in section 2.2.3.3. 
 
The baked filter was prehybridised in hybridisation buffer (5xSSPE, 0.2% milk powder, 0.2% 
nonidet) for at least 2 hours at room temperature on a shaking platform. Hybridisation 
solution was prepared by adding one tenth of the labelled probe to 10ml hybridisation buffer. 
Hybridisation buffer was removed and replaced with hybridisation solution containing 
labelled probe. This was incubated overnight at room temperature. A series of washes were 
carried out to remove non-specifically bound probe. Filter was washed twice in 5x SSPE with 
0.2% SDS for 5 minutes, then twice in 2x SSPE with 0.2% SDS for 30 minutes at room 
temperature. Filter was then exposed to a phosphorimager screen and bands were quantified 
using ImageQuant software (Molecular Dynamics, Amersham, UK) . 
  
 
2.2.4 Reverse Transcription 
 
Materials 
5mg/ml RNA 
10mM dNTPs (Amersham Biosciences) (appendix I) 
5x Reverse transcriptase buffer (Promega) 
 250mM Tris-HCl, pH 8.3 
 2560mM KCl 
 50mM Magnesium Chloride 
 2.5mM Spermidine 
 50mM Dithiothreitol (DTT) 
Avian myoblastoma virus reverse transcriptase (RT) 10U/µl (Promega) 
200ng/µl Oligo dT (12-18) (Amersham Biosciences) 
 
Method 
The reaction was set up in a final volume of 20µl containing the following: 1mg/ml RNA, 1x 
RT buffer, 1mM dNTPs and 10mg/ml oligo dT.  The solution was heated to 65oC for five 
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minutes and allowed to cool to room temperature for thirty minutes.  Ten units of RT were 
added and the reaction incubated at 42oC for one hour.  The reaction was then used in a 
polymerase chain reaction (PCR). 
 
 
2.2.5 Polymerase Chain Reaction 
 
Materials 
10x Taq Buffer (Sigma-Aldrich, Poole, Dorset, UK) 
500mM Potassium Chloride 
 100mM Tris-HCl, pH 9.0 
 15mM Magnesium chloride 
 1% (v/v) Triton x100 
20µM oligonucleotide primers (Oswel DNA services) 
Taq DNA polymerase (Sigma-Aldrich, Poole, Dorset, UK) 
 
Method 
cDNA fragments were amplified by PCR using primers corresponding to nucleotides specific 
to the target of interest. Ten microlitres of the reverse transcription reaction was added to a 
tube containing 1x Taq buffer, 0.2mM dNTPs, and 200nM oligonucleotide primers.  The 
reaction was heated to 95oC for five minutes after which time 5U of Taq DNA polymerase 
were added.  The reaction was cycled thirty times through the following temperatures: 95oC 
for forty seconds, 55oC for forty seconds, 72 oC for one minute.  After completion of the 
reaction, 10µl of the PCR product was analysed by gel electrophoresis on a 1% (w/v) 
TAE/agarose gel.   
 
 
2.2.6 Agarose Gel Electrophoresis 
  
Materials 
Agarose, type II-A medium (Sigma-Aldrich, Poole, Dorset, UK) 
50x TAE (appendix I) 
2M Tris-Acetate pH 8.5 
 0.05M EDTA pH 8.0   
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10mg/ml Ethidium bromide  
DNA marker (BRL 1Kb ladder, Invitrogen Life Technologies) 
Gel loading buffer (appendix I) 
 
Method 
A 1% (w/v) agarose gel was prepared by dissolving the agarose in 1x TAE using a 
microwave oven.  The gel was cooled to 45°C and ethidium bromide added to a final 
concentration of 0.5µg/ml.  Once set, the gel was placed into an electrophoresis tank 
containing 0.5x TAE with 0.5µg/ml ethidium bromide.  Three microlitres of loading buffer 
were added to 10µl of PCR product, 1µl of DNA marker was added to 9µl GDW and treated 
in the same way.  Samples were loaded onto the gel and electrophoresed at 10V/cm.  The 
DNA was visualised by illumination with UV light (300nm). 
 
 
2.2.7 Cloning of DNA (Sambrook, 2000) 
Among the most important advances in the field of molecular biology was the ability to cut 
DNA at specific sites and to ligate the cut ends.  DNA is cut using restriction endonucleases, 
isolated from bacteria, which recognise specific target sites within double stranded DNA and 
cleave it.  Equally important is the ability to ligate these fragments.  This relies on the use of 
a virus-derived enzyme that catalyse the formation of phosphodiester bonds between a free 5' 
phosphate and a free 3' hydroxyl group. 
 
 
2.2.7.1 Restriction Endonuclease Digestion of DNA  
 
Materials 
Restriction endonuclease: various enzymes were used and will be covered in the relevant 
sections. All restriction enzymes were purchased from New England Biosciences with the 
exception of restriction enzyme Bsp119I which was purchased from Fermentas. 
 
10x restriction buffer (as supplied) 
Phenol /chloroform/Iso-amyl alcohol (IAA) (appendix I) 
2M sodium acetate, pH 5.2 (appendix I) 
Absolute Ethanol 
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4U/µl Shrimp alkaline phosphatase (SAP) (Amersham Biosciences) 
 
Method 
DNA was dissolved in GDW and restriction buffer added to give a final concentration of 1x.  
Restriction endonuclease was added to five times excess; the volume of enzyme added was 
kept below 10% of the final volume.  The reaction was incubated for at least one hour at 
37oC.  If the digested DNA was a plasmid, 8U of SAP were added which removes 5' 
phosphates and prevents self-ligation of the plasmid.  The reaction was extracted with an 
equal volume of phenol/chloroform/IAA and the phases separated by centrifugation for three 
minutes at 12,300g at room temperature (F45-12-11 microfuge, Eppendorf, Hamburg, 
Germany). The DNA was precipitated by addition of 0.1 volumes of sodium acetate pH5.2, 
and 2.5 volumes of cold absolute ethanol and incubated at -20oC for at least one hour.  DNA 
was recovered by centrifugation for seven minutes at 12,300g at room temperature (F45-12-
11 microfuge, Eppendorf, Hamburg, Germany). 
 
 
2.2.7.2 Electroelution of DNA fragments 
After restriction digestion, purification of the DNA fragment of interest from other 
contaminating fragments is often advantageous.  This is particularly true for plasmids, since 
restriction digests are not 100% efficient and a small amount of closed circular DNA can 
produce a high background during transformations.  The DNA was therefore size fractionated 
by electrophoresis on an agarose gel and the DNA of interest electroeluted. 
 
Materials 
50x TAE (appendix I) 
Dialysis tubing (appendix I)  
Gel loading buffer (appendix I) 
DNA marker 
 
Method 
A 1% (w/v) agarose gel was prepared as described in 2.2.6.  The DNA was dissolved in 
GDW and 0.25 volumes of loading buffer added. 1µl of DNA marker was added to 9µl of 
GDW and treated in the same way.  The samples were loaded on to the gel and 
electrophoresed at 10 V/cm.  The DNA was visualised by illumination with UV light 
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(300nm). The band of interest was excised from the gel and placed into a piece of dialysis 
tubing sealed at one end with a clip.  Four hundred microlitres of 0.5x TAE was added to the 
gel slice, air was excluded from the tubing and the end sealed with a clip. The DNA was 
eluted from the gel slice by electrophoresis at 20V/cm for 20 minutes. The TAE was removed 
from the bag, phenol/chloroform extracted and the DNA recovered by ethanol precipitation 
(section 2.2.7.1). The DNA was dissolved in GDW and quantified, either by 
spectrophotometry or using an agarose gel.  To quantify DNA spectrophotometrically it was 
diluted 1:100 in GDW and 1ml placed into a quartz cuvette (VWR).  The absorbance was 
read at 260 and 280nm (UV-160 spectrophotometer, Shimadzu, Kyoto, Japan).  The reading 
at 280nm gives an indication of the purity of the DNA sample as phenol absorbs more 
strongly at 280nm than DNA.  The concentration of DNA was calculated using the following 
formula:  
 
concentration (µg/ml) = (A260 x dilution factor) x 50. 
 
For small quantities of DNA, using an agarose gel is more convenient, although not as 
accurate. This involves electrophoresing an aliquot of the DNA alongside standards of known 
concentration and estimating the concentration of the sample from its relative luminescence 
under UV illumination (300nm). 
 
 
2.2.7.3 Ligation of DNA fragments  
 
Materials 
T4 DNA ligase (6 units/µl)  
10x ligase buffer: 
  500mM Tris-HCl 
  100mM magnesium chloride 
   100mM dithiothreitol (DTT) 
10mM ATP 
  250µg/ml acetylated bovine serum albumin (acetylated BSA) 
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Method 
DNA ligation was used to insert the DNA fragments of interest (inserts) into plasmids.  All 
the fragments ligated had overhanging ends, which increases the efficiency of ligation as the 
ends are held juxtaposed by hydrogen bonding between the complementary bases. The 
method was identical for all combinations of plasmids and inserts.  Twenty nanograms of 
plasmid were dissolved in GDW and a fourfold molar excess of the insert added.  Reaction 
buffer was added to a final concentration of 1x and 1µl of T4 DNA ligase added to give a 
final volume of 10 µl.  The reaction was incubated at 16 ºC overnight.  The ligation reaction 
was then used to transform bacteria. 
 
 
2.2.8 Production of Competent Bacteria (Hanahan, 1983) 
Gram negative bacteria such as E. coli have a cell wall that prevents entry of exogenous 
DNA. To allow entry of plasmids into the bacteria, they have to be rendered competent to 
take up DNA. There are several ways of achieving this, including electroporation and 
treatment with cations. The method of choice for Xl1-Blue cells is treatment with cations, 
which is reliable and relatively easy. The method of choice for JC8111 bacteria is 
electroporation.  
 
 
2.2.8.1 Production of Competent Bacteria using Cations 
 
Materials 
XL1-Blue cells (Stratagene Ltd, La Jolla, CA, U.S.A.)  
LB (appendix I) 
10mg/ml Tetracycline (Sigma-Aldrich, Poole, Dorset, UK) in absolute ethanol (appendix I) 
TFB I: (appendix I) 
30mM potassium acetate  
    100mM rubidium chloride  
    10mM calcium chloride (appendix I)  
   50 mM manganese chloride  
    15% (v/v) glycerol  
TFB II: (appendix I) 
    10mM MOPS (Sigma-Aldrich, Poole, Dorset, UK) 
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    75mM calcium chloride (appendix I)  
    10mM rubidium chloride  
    15% (v/v) glycerol 
 
Method 
One hundred millilitres of LB supplemented with 5µg/ml of tetracycline (LBtet) was 
inoculated with a colony of XL1-Blue and incubated overnight, with vigorous shaking, at 
37oC.  One millilitre of this overnight culture was inoculated into 100ml of fresh LBtet  
(prewarmed to 37oC) and incubated at 37oC, with vigorous shaking, until the bacteria were in 
log phase growth (OD580 = 0.4-0.5).  The bacteria were recovered by centrifugation at 800g 
for fifteen minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, Du Pont).  The 
bacteria were resuspended in 40ml of ice cold TFB I and incubated on ice for ten minutes.  
The bacteria were recovered as above and resuspended in 4ml of TFB II, then incubated on 
ice for a further fifteen minutes.  They were then aliquoted into 50µl volumes and stored at -
70oC. 
 
 
2.2.8.2 Production of Competent Bacteria using Electroporation 
 
Materials 
E.coli JC8111 (LGC Standards, Middlesex, UK) c 
LB (appendix I) 
H2O (ice cold) 
10% (v/v) glycerol in GDW (ice cold) 
SOC medium (appendix I) 
 
Method. 
Five millilitres of LB was inoculated with a single colony of the JC8111 strain of E.coli and 
grown overnight at 37oC with moderate shaking. From this overnight culture, 2.5ml was used 
to inoculate 500ml of fresh LB (prewarmed to 37oC) and incubated at 37oC with vigorous 
shaking until the bacteria were in the log phase of growth (OD 600 = 0.5-0.6). The cells were 
then chilled in an ice water bath for fifteen minutes before being centrifuged at 2000g for 
twenty minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, Du Pont). The 
supernatant was removed and the pellet resuspended in 5ml ice-cold water. Following 
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resuspension of the cells a further 5ml of ice-cold water was added and mixed well before a 
further centrifugation cycle at 2000g for twenty minutes at 4oC (HB-4 rotor in RC-5B super 
speed centrifuge, Du Pont). This step was repeated once more and the resulting cell pellet 
resuspended in 40mls of ice-cold 10% (v/v) glycerol and mixed well. The cells were then 
centrifuged at 2000g for 10 minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, Du 
Pont). The volume of the resulting pellet was estimated and an equal volume of ice-cold 10% 
(v/v) glycerol was added and the pellet resuspended. The cells were then aliquoted into 50µl 
volumes and stored at -80oC until ready for use in transformation by electroporation (see 
section 4.4.2). 
 
 
2.2.8.3 Transformation of Competent XL1-Blue Bacteria 
Although treating bacteria with cations renders them competent to take up DNA, to obtain 
efficient transformation requires several additional steps.  The initial step, incubation on ice, 
is believed to allow attachment of the plasmid to the bacterial cell membrane.  The heat shock 
step is believed to allow efficient transport of the plasmid into the bacteria.  The incubation 
following the heat shock allows expression of the resistance genes before exposure to the 
antibiotic. 
 
Materials 
LB (appendix I) 
LB(antibiotic) plates (section 2.2.9) 
Plasmid DNA 
Competent bacteria (section 2.2.8.1) 
 
Method 
An aliquot of frozen competent bacteria was thawed on ice, 10ng of plasmid (5µl ligation 
reaction) added and the mixture incubated on ice for twenty minutes.  The reaction was then 
incubated at 42oC for forty seconds followed by incubation on ice for two minutes.  Two 
hundred microlitres of LB were added and the reaction incubated at 37oC for thirty minutes.  
Simultaneously, agar plates supplemented with the appropriate antibiotic were dried at 37oC 
for 10 minutes.  The volume of transformed bacteria added to the plate varied depending on 
the source of the DNA (up to 200µl per 90mm Petri dish).  The bacteria were spread on the 
surface of the agar, the plate inverted and incubated at 37oC overnight. 
68 
 
2.2.9 Production of Agar Plates 
After transformation of bacteria with plasmid DNA, the bacterial culture was grown on an 
agar plate containing an antibiotic. The antibiotic allows selection of bacteria which carry the 
plasmid of interest.  
 
Materials 
LB (appendix I) 
Bacto-Agar (Difco Laboratories, MI, USA) 
Ampicillin 100mg/ml in GDW (appendix I) 
Chloramphenicol 25mg/ml in ethanol (appendix I) 
Spectinomycin 50mg/ml in GDW (appendix I) 
Petri dishes 90mm (Plastiques Gosslin, Hazebrouck, France) 
 
Method 
7.5g of Bacto-Agar was added to 500ml of LB and autoclaved at 120oC for twenty minutes to 
melt and sterilise the agar.  The agar was then cooled to below 50oC before addition of 250µl 
of the required antibiotic.  The agar was then poured into Petri dishes to just cover the bottom 
surface.  The agar was then flamed before the lids were placed on the Petri dishes.  Once the 
agar had set the plates were wrapped in parafilm and stored upside down at 4oC. 
 
 
2.2.10 Small Scale Preparation of Plasmids (Sambrook, 2000) 
Initially, plasmids were normally isolated on a small scale culture to allow several clones to 
be analysed simultaneously.  To isolate plasmids from bacteria it is necessary to disrupt the 
cell wall to release the plasmid, and at the same time to remove contaminating proteins, 
genomic DNA and RNA.  The method used involved disruption of the cell wall by treatment 
with alkali and SDS followed by precipitation of bacterial debris with sodium acetate.  This 
step also removes most of the genomic DNA, since in bacteria this is anchored to the cell 
wall.  The RNA is removed at a later stage by treatment with RNAse A. 
 
Materials 
LB (appendix I) 
0.2 M sodium hydroxide /1% (w/v) SDS  (appendix I) 
2M sodium acetate, pH 5.2 (appendix I) 
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5M potassium acetate (appendix I) 
Phenol/chloroform/IAA (appendix I) 
GTE: (appendix I) 
25 mM Tris-HCl, pH 8.0 
10 mM EDTA  
50mM glucose  
 
Method 
Two millilitres of LB(antibiotic) were inoculated with a single bacterial colony and incubated 
overnight at 37oC with vigorous shaking.  Five hundred microlitres of this culture was added 
to an equal volume of 80% (w/v) glycerol and stored at -70oC. The rest of the culture was 
centrifuged for three minutes at 12,300g at room temperature (F45-12-11 microfuge, 
Eppendorf, Hamburg, Germany) to pellet the bacteria. The supernatant was discarded and the 
pellet resuspended in 100µl of GTE.  Two hundred microlitres of alkaline SDS was added 
and the sample incubated on ice for five minutes, followed by the addition of 150µl of 5M 
potassium acetate and a further five minute incubation on ice.  The precipitated bacterial 
debris was removed by centrifugation for five minutes at 12,300g at room temperature (F45-
12-11 microfuge, Eppendorf, Hamburg, Germany). 350µl of supernatant was then transferred 
to a clean tube. An equal volume of phenol/chloroform/IAA was added and the sample 
mixed.  The phases were separated by centrifugation for five minutes at 12,300g at room 
temperature (F45-12-11 microfuge, Eppendorf, Hamburg, Germany) and the supernatant 
transferred to a new clean tube.  The DNA was precipitated by the addition of 0.6 volumes of 
propan-2-ol and incubation at room temperature for ten minutes.  The DNA was recovered by 
centrifugation for seven minutes at 12,300g at room temperature (F45-12-11 microfuge, 
Eppendorf, Hamburg, Germany) and then dissolved in 100µl of GDW. 0.2 M sodium acetate 
and 250µl of absolute ethanol (-20oC) were added and the solution incubated at -20oC for at 
least one hour.  After precipitation the DNA was recovered by centrifugation at 12,300g at 
room temperature (F45-12-11 microfuge, Eppendorf, Hamburg, Germany) and then dissolved 
in 10-20µl GDW. 
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2.2.11 Large Scale Plasmid Purification 
 
Materials 
LB (appendix I) 
50,000 U/mg Lysozyme (Sigma-Aldrich, Poole, Dorset, UK) 
GTE (appendix I) 
10mg/ml DNAse free RNAse A in GDW (Sigma-Aldrich, Poole, Dorset, UK) 
0.2 M sodium hydroxide /1% (w/v) SDS (appendix I) 
2M sodium acetate, pH 5.2 (appendix I) 
5M potassium acetate, (appendix I) 
Phenol/chloroform/IAA (appendix I) 
 
Method 
Following small scale preparation of the plasmid the size of the insert was confirmed by 
restriction digest (section 2.2.7.1) and agarose gel electrophoresis (section 2.2.6).  A large 
scale preparation of the plasmid was carried out prior to purification using a caesium chloride 
gradient.  A small quantity of bacteria containing the plasmid with the correct size insert was 
inoculated into 500ml LB(ampicillin), and incubated at 37°C overnight with vigorous shaking.  
The bacteria were recovered by centrifugation for eight minutes at 3000g (4000rpm in HS-4 
rotor in RC-5B super speed centrifuge, Du Pont) at 4°C.  The pellet was resuspended in 25ml 
GTE supplemented with 2mg/ml lysozyme and incubated at room temperature for five 
minutes.  Fifty millilitres of 0.2 M sodium hydroxide /1% (w/v) SDS solution was added, the 
sample mixed and incubated on ice for five minutes.  Then, 38ml of 5M potassium acetate 
was added, the sample mixed and incubated on ice for a further ten minutes. The bacterial 
debris was removed by centrifugation for 15 minutes at 9000g (7000rpm in HS-4 rotor in 
RC-5B super speed centrifuge, Du Pont) at 4°C.  The supernatant was transferred to a clean 
tube and 0.6 volumes propan-2-ol added.  The sample was incubated on ice for 15 minutes, 
and the DNA recovered by centrifugation for 15 minutes at 9000g at 4°C (7000rpm in HS-4 
rotor in RC-5B super speed centrifuge, Du Pont).  The pellet was dissolved in 10ml 1x TE.  
RNAse A was added at a concentration of 0.1mg/ml and the reaction incubated at 37°C for 
30 minutes.  The reaction was extracted with an equal volume of phenol/chloroform and the 
phases separated by centrifugation for 20 minutes at 10000g at 4°C.  The DNA was 
recovered by addition of 0.1 volumes 2M sodium acetate pH 5.2, one volume propan-2-ol, 
and incubation at -20°C for at least one hour.  
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2.2.11.1 Caesium Chloride Gradient Purification 
Large scale plasmid purification was carried out using a caesium chloride gradient 
(Sambrook, 2000).  This method depends on the decrease in density of nucleic acids when 
they bind ethidium bromide.  Because ethidium bromide binds by intercalation into the DNA, 
it causes unwinding of the helix.  In closed circular DNA the increased super coiling of the 
plasmid limits binding of ethidium bromide, and the plasmid has a higher buoyant density 
than linear (genomic) or nicked plasmids. This difference allows separation of the plasmid on 
a caesium chloride density gradient.   
 
Materials 
TES (appendix I) 
Caesium chloride  
10mg/ml ethidium bromide  
Propan-2-ol, caesium chloride saturated (appendix I) 
1x TE (appendix I) 
 
Method 
The DNA obtained from section 2.2.11 was recovered by centrifugation for 20 minutes at 
24,000g (12,000 rpm in a HB4 rotor of a RC5B super speed centrifuge, Du Pont) at 4°C, and 
then dissolved in 8.25ml of TES containing 8.4 grams of caesium chloride. 150µl of ethidium 
bromide was added and the solution mixed.  The sample was loaded into a polyalumina tube 
(Ultracrimp, Du Pont), overlaid with paraffin oil, the tube sealed and centrifuged for 16 hours 
at 20°C and 216,518g (60,000rpm in a T-8100 rotor in a Sorvall SE100 centrifuge).  After 
centrifugation, the DNA bands were visualised by UV illumination and the band containing 
the closed circular DNA removed using an 18-gauge needle and a 2ml syringe.  The ethidium 
bromide was removed from the plasmid by repeated extraction with an equal volume of 
caesium chloride saturated propan-2-ol, until both phases were colourless.  The DNA was 
precipitated by addition of two volumes of GDW and six volumes of room temperature 
absolute ethanol.  The DNA was recovered by centrifugation for 15 minutes at room 
temperature and 24,000g (12,000 rpm in a HB4 rotor of a RC5B super speed centrifuge, Du 
Pont), the supernatant removed and the pellet dissolved in 0.4 ml GDW.  The DNA was 
ethanol precipitated, recovered by centrifugation for 10 minutes at 12,300g (12,000 rpm in a 
HB4 rotor of a RC5B super speed centrifuge, Du Pont), dissolved in 1ml GDW and 
quantified by spectrophotometry (see section 2.2.7.2) 
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2.2.12 Radioimmunoassay 
Radioimmunoassay (RIA) was used to measure the amount of CART (55-102) and α-MSH 
immunoreactivity. The technique relies upon competition between a radiolabelled antigen 
and an unlabelled antigen for antibody binding sites.  A fixed amount of antibody is added to 
samples along with a fixed amount of 125I labelled antigen. The ratio of bound to unbound 
radiolabelled antigen gives a measure of how much unlabelled antigen is present in the 
sample.  The unbound antigens are separated from the antigen-antibody complex and the 
amount of label in both is measured using a gamma counter.  Separation of bound and 
unbound antigen can be carried out using the charcoal adsorption method.  The unbound 
antigen is small enough to become trapped in the charcoal whereas the antibody-bound 
antigen is larger and remains in solution. Separation of bound and unbound antigen can also 
be achieved using a secondary antibody. A standard curve is constructed using known 
amounts of unlabelled peptide.  
 
 
2.2.12.1 Assay Protocol 
125Iodine labelled peptides were prepared by Professor M. Ghatei and purified by high 
pressure liquid chromatography (HPLC). The details of the antisera used for each assay are 
described below. Assays were performed in a total volume of 350µl in 0.06M phosphate 
buffer (0.05M Na2HPO4.2H20, 0.006M KH2PO4, 0.01M disodium-EDTA.2H2O, 0.008M 
NaN3), at pH 7.4 with 0.3% BSA, unless otherwise stated.  
 
All samples were assayed in duplicate.  To prevent inter assay variation all test samples for a 
particular peptide were assayed within the same radioimmunoassay. The general structure of 
the RIA is outlined in Table 2.1. 
 
Non specific binding tubes enable the assessment of label integrity. The half and two times 
tubes indicate whether greater sensitivity could be achieved by using half or twice the volume 
of label. Zero tubes are placed at regular intervals throughout the assay and enable 
assessment of assay drift. Standard curves were prepared using synthetic peptide in assay 
buffer, and added in duplicate at concentrations of 1, 2, 3, 5, 10, 15, 20, 30, 50 and 100 
fmol/tube.  A second standard curve towards the end of the assay included 20µl of 0.5M 
acetic acid per standard. The peptide concentration of tissue extract samples was determined 
from this standard curve. Tissue extracts were assayed neat, diluted 1 in 10, and 1 in 100, at a 
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volume of 20µl. Radiolabel was diluted to 180-200 counts/ 10 seconds/ 50µl in assay buffer. 
The assays were incubated for 72 hours at 4°C.  Free and bound peptides were separated 
using charcoal absorption.  Immediately prior to centrifugation, 500µl of 0.01% Triton-X-100 
solution was added to each tube, and the samples centrifuged at 1500g, 4°C, for 20 minutes.  
For charcoal absorption, the free fraction was separated using 4 mg of charcoal per tube 
suspended in 250µl of 0.06M phosphate buffer with gelatine, added immediately prior to 
centrifugation. The samples were then centrifuged at 1500g, 4oC, for 20 minutes (RHK4B 
rotor, Jouan KR-4, DJB labcare, UK).  Bound and free label were separated and both the 
pellet and supernatant counted for 180 seconds using a β counter (model NE1600, Thermo 
Electron Corporation).  Peptide concentrations in the test samples were calculated using a 
non-linear plot (RIA Software, NE Technology) with reference to the standard. 
 
 
Tube Buffer 
(µl) 
Ab  
(µl) 
Label 
(µl) 
Standard/sample 
(µl) 
Acetic acid 
(0.5%) (µl) 
NSB 300 - 50 - - 
½ x label 275 50 25 - - 
2 x label 200 50 100 - - 
Zero 250 50 50 - - 
Standard 1-15µl 250/230 50 50 1-15 0/20 
Standard 20µl 230/210 50 50 20 0/20 
Standard 30µl 220/200 50 50 30 0/20 
Standard 50µl 200/180 50 50 50 0/20 
Standard 100µl 150/130 50 50 100 0/20 
Zero 250 50 50 - - 
Tissue extracts 230 50 50 20 - 
Excess Antibody - 300 50 - - 
 
Table 2.1 General Structure of a Radioimmunoassay. A Table outlining the general structure 
of a RIA. NSB, non-specific binding tube; Zero, tube which lacks any sample; The values 
highlighted in red detail the volume of buffer adjusted for acetic acid. 
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CART antiserum showed 100% cross reactivity with rat and mouse CART (55-102) and 20% 
cross reactivity with CART (62-102) and less than 0.1% cross reactivity with CART 91-39). 
The sensitivity of the CART assay was 1.25 fmol/ml. The intra- and inter assay variation was 
8 and 9% respectively. The α-MSH antiserum showed 100% specific for α-MSH. The 
antibody was less than 0.0018% cross reactive with ACTH, γ-MSH, β-MSH and β-
lipoprotein. The sensivity of the assay was 1 fmol/ml. The intra- and inter assay variation was 
7 and 8% respectively. 
 
2.2.13 Confirmation of Gene Transfer by In situ Hybridisation 
In situ hybridisation is a technique which allows detection of mRNA within a tissue whilst 
maintaining structural integrity. A complimentary probe is hybridised to sectioned tissue 
mounted on poly-lysine coated slides. Probes can be radiolabelled or labelled with 
compounds such as digoxygenin (DIG). In situ hybridisation was carried out using a 35S 
labelled riboprobe. The primer sets used to generate specific riboprobes are detailed in the 
relevant sections. All riboprobes were prepared in pBluescript plasmid.    
 
 
2.2.13.1 Production of Radiolabelled RNA Probe for In situ Hybridisation  
 
Materials 
200µg/µl Template plasmid linearised by digestion with BamHI for antisense or EcoRI for 
sense  
100mM dithiothreitol (DTT) (Promega, UK) 
30U/µl RNase inhibitor  
10x nucleotide mix: 10mM of each ATP, UTP, GTP (GE Healthcare) 
20U/µl T7 RNA polymerase (Promega, UK) 
20U/µl T3 RNA polymerase (Promega, UK) 
5x RNA polymerase buffer (Promega, UK) 
7.5U/l DNase I (Amersham Biosciences) 
10x DNase buffer 
 800mM tris/HCl, pH7.4 
 120mM MgCl2 
 40mM CsCls2 
CTPαS[35S] 46TBq/mmol,0.46GBq/ml (Perkin Elmer, Massachusetts, USA) 
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5M Ammonium acetate (NH4Ac) 
Absolute Ethanol 
GDW 
  
Methods 
Radiolabelled template probe was produced using an in vitro transcription reaction. Two 
hundred nanograms of template was added to a reaction containing 10mM DTT, 1x 
nucleotide mix, 1x polymerase buffer, 30U RNase inhibitor and 0.69MBq in a total volume 
of 18µl. Finally, 20U RNA polymerase was added (T3 to the anti-sense reaction and T7 to 
the sense reaction) and this was incubated at 37ºC for 2 hours. After incubation, 1µl DNase 
buffer and 7.5U DNaseI were added and the reaction incubated for a further 15 minutes at 
37ºC. The reaction was precipitated by adding 12µl ammonium acetate and 80µl ice cold 
ethanol. After one hour at -20ºC the reaction was centrifuged at 8000g for seven minutes at 
room temperature (12084 rotor, Sigma 1-14 microfuge, Sigma, UK), the supernatant removed 
and the pellet resuspended in 200µl GDW. The activity of 1µl radiolabelled probe was 
measured on a microbeta counter (Perkin Elmer).  
 
 
2.2.13.2 In situ hybridisation 
 
Materials 
Optimum Cutting Temperature (OCT) embedding compound (Bright Instruments, 
Huntingdon, UK) 
Poly-lysine coated slides (VWR) 
0.8% (v/v) Formaldehyde (VWR) solution in 0.01M PBS 
0.01M PBS (appendix I) 
100% acetic anhydride (VWR) 
0.1M triethanolamine pH8.0 (TEA) (appendix I) 
20x Saline sodium citrate (SSC) (appendix I) 
3M NaCl 
70% (v/v) Ethanol in GDW 
Absolute Ethanol 
Chloroform 
Hybridisation buffer (appendix I) 
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50% (v/v) formaldehyde 
60mM NaCl 
80mM Tris/HCl pH7.5 
4mM EDTA 
100mM DTT (Promega, UK) 
0.1mg/ml yeast tRNA (Sigma-Aldrich, Poole, Dorset, UK) 
2% (w/v) dextran sulphate (Sigma-Aldrich, Poole, Dorset, UK) 
1x RNase buffer 
10mM Tris pH8.0 
1mM EDTA 
0.5M NaCl 
RNaseA (appendix I) 
 
Methods 
Animals were killed by CO2 asphyxiation. Brains were removed immediately, mounted onto 
cork discs with Optimum Cutting Temperature embedding compound (Bright Instruments, 148 
Huntingdon, Cambridgeshire, U.K.) and rapidly frozen in isopentane chilled to -80°C. The brains 
were stored at -80ºC until being sectioned. Thirteen micrometer sections were cut using a cryostat 
at -25°C (Bright Instrument Company, Huntingdon, Cambridgeshire, U.K.). The sections were 
mounted onto poly-L-lysine coated slides and stored at -80°C until hybridisation. In situ 
hybridisation was performed on every third slide. Sections were fixed in 0.8% (v/v) 
formaldehyde solution in 0.01M PBS on ice for 20 minutes. Slides were washed twice in 
0.01M PBS for 5 minutes. The sections were acetylated in 0.25% (v/v) acetic anhydride in 
0.1M TEA for 10 minutes, rinsed briefly in 0.01M PBS and dehydrated by immersion for 
three minutes in 70% (v/v) ethanol in GDW. Finally, slides were delipidated in chloroform 
for 5 minutes and allowed to air dry for several hours. Hybridisation buffer was 
supplemented with 1x106MBq 35S labelled probe and 70µl added to each slide. A coverslip 
was placed over each slide and slides were hybridised overnight at 60ºC in a humid 
environment. The following day, the slides were washed in a series of washes with 
decreasing salt content to remove non-specifically bound probe. Slides were washed in 4x 
SSC and gently agitated to remove cover slips, slides were then washed four times in 4x SSC 
for 5 minutes. Slides were RNase treated by incubation in 1x RNase buffer containing 
100µg/ml RNaseA for 30 minutes at 37ºC. Slides were washed twice in 10mM DTT/2x SSC 
for 5 minutes. Slides were then washed for 10 minutes in 10mM DTT/1x SSC, then 10mM 
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DTT/0.5x SSC. Finally, slides were washed for 30 minutes in 10mM DTT/0.1M SSC at 
60ºC, rinsed in 10mM DTT/0.1x SSC and dehydrated in 70% ethanol then 100% ethanol for 
3 minutes. Slides were exposed to Bio-Max film (Kodak, Hemel Hempstead, Herts, UK). 
After 4 days film was developed and transgene expression determined by observation of 
hybridisation within specific regions. 
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3. Modification of POMC Containing Bacterial Artificial Chromosome to drive 
Cocaine- and Amphetamine -Regulated Transcript Antisense Expression Specifically in 
POMC Expressing Neurones in vivo 
 
3.1 Introduction 
Analysis of the complete human genome suggests the presence of approximately 20,000 
genes. The functions of only several hundred of these genes are actually known. Sequence 
homologies and extrapolation from invertebrate studies can suggest the functions of unknown 
genes but their in vivo functions are difficult to predict.  
 
Prior to the development of genomic technologies the analysis of mammalian gene function 
was limited to the rare spontaneous genetic mutations that produced inactivation or 
modification of a gene leading to identifiable phenotypes. Transgenic technologies and 
reverse genetics have developed as invaluable tools for investigating gene function in vivo. 
The mouse is an ideal organism for use in transgenic studies of complex genetic traits. A 
number of factors have contributed to the popularity of the mouse; there is extensive 
homology between the human and mouse genome and the relative short life span of the 
mouse, coupled with the availability of mouse embryonic stem (ES) cells and the ease of 
controlled breeding make the mouse an attractive model organism.  
 
Genomic technologies can generally be placed in two categories; those which alter the 
endogenous gene by homologous recombination in ES cells (targeted transgenesis), and those 
which insert exogenous genes into the genome (additive transgenesis). Gene targeting in ES 
cells has allowed either the inactivation of genes in vivo to produce ‘knockouts’ or the 
insertion of functional mutations to produce ‘knock-ins’. Insertion of exogenous genes into 
the genome is often termed transgenesis and has allowed the insertion of extra copies of a 
gene to produce animal models which overexpress a particular protein. Advances in 
transgenic technologies allow genetic manipulations to study gene function which are 
otherwise impossible in other organisms. Null mutations, as well as subtle missense or gain 
of function mutations, can be introduced into any gene in the mouse germ line using 
homologous recombination based gene targeting technology. The use of Cre-Lox technology 
also makes it possible to conditionally activate or inactivate gene expression in vivo (Sauer, 
1998). This can be achieved both spatially in a subset of cells and temporally with the use of 
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promoters known to switch on at a specific point or with the use of drugs to activate gene 
expression such as the case of the tet-on and tet-off system (St-Onge et al., 1996). 
 
 
3.1.1 The Transgene 
The generation of transgenic animals is an established technique with the first step being the 
selection of the transgene. The transgene consists of a promoter and a specific cDNA 
transcript, often the cDNA encodes all or part of a particular protein of interest, but it can also 
be a genomic fragment which contains all or part of a gene, or an antisense fragment (Shuto 
et al., 2002). The cDNA is sub-cloned downstream of a suitable promoter which will 
determine the level, specificity and temporal pattern of expression. Promoters such as 
cytomegalovirus (CMV) promoter can be used for ubiquitous expression whereas other 
promoters like neurone specific enolase (NSE) are tissue specific. When a transgene 
expression pattern is required to mirror that of the endogenous gene, the genes own promoter 
can be used. 
 
The transgene is introduced into fertilised mouse eggs by pronuclear injection (Figure 3.1). 
Once inside the pronucleus, the transgene either integrates into the genome in a random 
fashion or is degraded by exonucleases. Transgenes typically integrate into the genome as 
tandem repeats (head to tail concatamers) at a single locus. The exact mechanism of 
integration remains unknown but is thought to coincide with the occurrence of double strand 
breaks within the nuclear DNA during the injection procedure. The ova is then transplanted 
into a pseudo-pregnant foster mother and a normal pregnancy follows (Ittner and Gotz, 
2007). The transgene replicates with the endogenous chromosome becoming part of the 
forming embryo. Embryos which contain integrated transgenes usually acquire several copies 
of the transgene. Integration of the transgene usually occurs early in development, at the 
single cell stage, so most or all of the cells in the adult mouse contain the transgene. If 
integration occurs after a few rounds of cell division, the transgene will only be present in a 
subset of cells thus creating a mosaic transgenic adult mouse.  If the transgene is present in 
cells comprising the germ line, it will be transmitted to subsequent generations of mice.  Mice 
which successfully transmit the transgene are known as founder mice (Ittner and Gotz, 2007).  
 
 
 
                     
 
 
Figure 3.1 Generation of a transgenic m
cloned into a plasmid containing a promoter which will drive its expression 
Schematic diagram of the steps required to create a transgenic mouse colony. The transgene 
is introduced into the fertilised mouse egg by 
mouse genome in a random fashion.  The ova is then transplanted into a foster mother and 
normal pregnancy follows. Transgenic mice are mated with wildtype mice to generate 
separate transgenic lines.  
 
ouse colony. (A) Typical cDNA transgene sub
pronuclear injection where it integrates into the 
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-
in vivo. (B), 
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3.1.2 Transgene Copy Number and Position Effects 
Whilst the design of the transgene can be optimised there are other factors which can affect 
expression that cannot be controlled for in the design of the transgene construct. One such 
factor is the number of copies of the transgene that integrate into the host genome. 
 
Each founder mouse derived from one pronuclear injection is unique. One key difference 
between founder mice is the number of copies of the transgene that integrate into the genome 
which can range from 1 to greater than 50. The expression of the transgene is normally 
correlated to the number of copies integrated, although not necessarily in a linear 
relationship. The copy number, while being uncontrolled, can be useful in terms of gene 
dosage studies (Koike et al., 1994).  
 
Another important factor affecting transgene expression is known as the ‘chromosome 
position effect’. Genes can span several hundred kilobases (kb) of DNA although only a 
small part of this actually codes for the protein. Even genes that have small coding regions 
can have important regulatory sequences located a great distance from the coding region, the 
tyrosinase gene being one example. In the mouse tyrosinase gene a melanoma cell specific 
enhancer was identified approximately 12kb upstream of the tyrosinase gene by DNaseI 
hypersensitive site mapping (Ruth Ganss et al., 2007). In addition, spatiotemporal expression 
of human agouti related peptide (AgRP) has been found to be part regulated by the intron 
sequence of the neighbouring ATPase gene (ATP6V0D1) (Ilnytska et al., 2009). 
  
Because the transgene integrates randomly into the mouse genome following pronuclear 
injection, the genomic sequences flanking the site of integration can have a marked effect 
upon transgene expression; enhancing, reducing or abolishing it completely. For example 
integration of the transgene near the break point between heterochromatin and euchromatin 
could result in position effect variegation, the extent of variegation would depend on the 
distance of the gene from the breakpoint (Weiler and Wakimoto, 1995). Transgene 
integration can also disrupt endogenous promoter elements and protein coding regions 
resulting in spurious phenotypes (Cases et al., 1995). 
 
A number of strategies have been developed to overcome these position effects and increase 
the probability of optimal transgene expression following random integration. Genes are 
organised on chromosomes as contiguous but independent units called expression domains 
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(Elgin, 1990; Laemmli et al., 1992). Expression domains include regulatory elements which 
are necessary to control gene expression both spatially and temporally. The inclusion of all 
regulatory elements relevant for a given expression domain would ensure optimal transgene 
expression. The manipulation and analysis of large genes has been limited by the insert 
capacity of standard cloning vectors. Vectors such as Yeast Artificial Chromosomes (YAC), 
Bacterial Artificial Chromosomes (BAC) and P1 Artificial Chromosomes (PAC) however are 
able to incorporate large genomic segments of DNA, and would therefore be expected to 
contain whole expression domains. Other strategies that have been developed to optimise 
transgene expression after random integration into the genome include the incorporation of 
intron sequences in the transgene construct to improve transcription efficiency (Choi et al., 
1991; Brinster et al., 1988). The inclusion of a polyadenylation (pA) signal in the 
modification cassette also increases the efficiency of expression of the transgene (Azzoni et 
al., 2007). The polyadenylation signal was identified as a 3’ flanking sequence downstream 
of the AAUAAA poly A consensus sequence (Ribeiro et al., 2004). The most commonly used 
polyadenylation signal is from the bovine growth hormone (BGH) gene which has been 
shown to be as effective as the SV40 polyadenylation signal (Azzoni et al., 2007). The 
inclusion of specific sequences such as locus control regions and insulators have also been 
shown to improve transcription (Lisowski and Sadelain, 2007). 
 
 
3.1.3 Yeast, P1 and Bacterial Artificial Chromosomes 
YACs posses the largest insert cloning capacity being able to maintain genomic fragments of 
up to 1Mb (Burke et al., 1987). Due to their large size and linear nature they are difficult to 
handle in the laboratory using conventional techniques. However the main problem with 
using YACs is that they suffer from insert instability and rearrangements leading to the 
possibility of contamination of the transgene with endogenous yeast chromosome, a 
phenomenon which complicates purification. 
 
PACs do not suffer from insert instability and are easy to handle in the laboratory setting. 
PACs are capable of maintaining inserts between 70-100kb (Ioannou et al., 1994). BACs can 
accommodate larger inserts in the region of 300kb (Shizuya et al., 1992). Being circular in 
nature they are more resistant to mechanical shearing and can be isolated using conventional 
plasmid purification protocols. Due to the large size of BACs they should contain all the 
necessary upstream and downstream regulatory elements to drive accurate in vivo expression 
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if the gene of interest is positioned near the centre of the genomic insert. This should reduce 
the likelihood of transgene expression being affected by position effects. To date BACs and 
PACs have been used to create genomic libraries of many species.   
 
 
3.1.4 Bacterial Artificial Chromosome Modification 
Methods for modifying BACs rely on three basic features. The first step is the restoration of 
competence for homologous recombination to the BAC host strain which is achieved by the 
reintroduction of the E.coli recombination genes. This is necessary since homologous 
recombination is required for the targeted modification of the selected BAC by the transgene 
containing modification cassette. BACs are commonly maintained in DH10B E.coli strains 
that have a targeted deletion of the recombination gene RecA, to reduce the chance of 
sequence rearrangements in the BAC as a result of recombination. The next stage is the 
introduction of a shuttle vector or linear DNA fragment that carries the desired reporter or 
modification cassette flanked by sequences homologous to the genomic DNA carried in the 
BAC (Burke et al., 1987).  The flanking sequences are used to target the modification cassette 
into a precise site on the genomic DNA insert in the BAC.  Recombinants are selected and 
screened for precise integration.  Thirdly, unwanted sequences such as antibiotic resistance 
cassettes used for screening successful recombinants are removed through a second 
recombination event, or excised by using an appropriate site specific recombinase such as 
Cre. The modification cassette can then be expressed in transgenic animals. Modification 
protocols have enabled the insertion of marker genes such as enhanced green fluorescent 
protein (eGFP) (Liu et al., 2003), recombination enzymes such as Cre recombinase (DeFalco 
et al., 2001) and toxins into the BAC. 
 
 
3.1.5 RecE and RecT (ET) Cloning (Figure 3.2) 
In 1998 Stewart et al showed that PCR-amplified linear double stranded (ds) DNA, flanked 
by short sequences of homology >42bp could be efficiently targeted to a plasmid by 
electroporating the dsDNA into recBC sbcA strains (Zhang et al., 1998). The sbcA mutation 
activates expression of recE and recT genes (Hall et al., 1993). The recE gene encodes for 
exonuclease VIII whilst the recT encodes for the recT protein, these proteins promote 
homologous pairing and strand exchange in reactions containing linear duplex DNA and 
homologous, circular DNA as substrates.  These recombination functions enable genomic 
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DNA to be modified directly with PCR-generated linear dsDNA targeting cassettes, rather 
than using targeting cassettes that carry long homologies generated by multi-step sub cloning 
(Zhang et al., 1998). To allow for ET cloning, the pGETrec plasmid was developed which 
contains the recE and recT and gam genes coordinated under the control of an arabinose 
inducible promoter (PBAD) promoter (Narayanan et al., 1996). This allows temporal control 
over the expression of the rec genes, and consequently over homologous recombination, 
since the PBAD promoter can be induced by addition of arabinose. Activation of the recE, recT 
and gam genes makes the host cell competent for homologous recombination. The recE and 
recT genes induce a recombination event between the modification cassette and its target on a 
BAC.  The gam gene encodes the gam protein which inhibits the recBCD enzyme complex. 
This enzyme functions as a DNA exonuclease by binding to double strand breaks in DNA 
and degrades both strands simultaneously (Amundsen et al., 1986). Inhibition of recBCD 
prevents the recBCD dependent destruction of the targeting cassette. Efficiency of the 
recombination event has been shown to be increased by using longer homology arms. The 
efficiency of recombination is also dependent on the distance between homology arms on the 
host genome, optimal distances range between 7bp and 1200bp (Zhang et al., 1998). 
Successfully modified BACs are selected by the antibiotic resistance gene conferred by the 
modification cassette. Removal of the antibiotic resistance gene from the modified BAC is 
desirable since antibiotic genes have been shown to produce phenotypes in transgenic and 
knockout mice. Removal of the antibiotic resistance gene is achieved by a site specific 
recombinase such as Cre recombinase (Mejia and Larin, 2000). Cre is a 38 kDa protein 
product of the cre gene from bacteriophage P1 which is necessary and sufficient to catalyse 
recombination between two loxP sites in the P1 genome. LoxP is a 34bp site that consists of 
13bp inverted repeats flanked by an 8bp non palindromic core which gives directionality. Cre 
recognises loxP and recombination is catalysed between pairs of loxP sites. Cre has been 
shown to be functional in yeast and mammals. It is by using site specific Cre recombinase 
that the antibiotic resistance gene is excised. Cre activity is introduced to the BAC containing 
cell by introduction of a plasmid that can controllably and transiently express Cre 
recombinase e.g. by a temperature sensitive promoter. Removal of the antibiotic gene is then 
screened for by positive and negative selection and confirmed by PCR. The BAC DNA can 
then be purified for pronuclear injection. 
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Figure 3.2 ET Cloning. Diagram outlining the steps in ET cloning used to modify BACs. 
The modification cassette with homology arms is constructed in a typical cloning vector by 
PCR, restriction digests and ligation. The modification cassette is then isolated from the 
cloning vector by restriction digest and electroporated into the BAC host cell with the 
pGTErec plasmid. Incubation of the host cells with arabinose activates rec E and rec T and 
gam genes on pGETrec. recE and recT catalyse recombination between homology arms and 
the BAC. The modified BAC can then be isolated  purified and injected into the pronucleus 
to create a transgenic line.  
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3.1.6 Antisense RNA 
Antisense has enormous potential as a technology in the study of gene function. The general 
basis of antisense is the inhibition of gene expression through binding of a complementary 
ribonucleotide transcript to a specific mRNA sequence. Natural antisense was first described 
in prokaryotes where it was found to down regulate gene expression. Natural antisense has 
also been described in eukaryotes for example the αI collagen in the chicken chondrocyte 
(Neckers and Whitesell, 1993). 
 
Antisense technology provides a methodology for reducing gene expression in targeted tissue 
through the use of specific promoters. One example of this is expression of Glucocorticoid II 
receptor antisense, under the control of a neurofilament L promoter, which has been shown to 
reduce expression of the glucocorticoid II receptor by 50-70% in specific brain areas and by 
30-50% in the liver (Pepin, 1992). The antisense sequence is an inversion of the sense strand 
of the target gene. When choosing the antisense sequence the general trend is that the longer 
the antisense constructs the more effective it is as an inhibitor. The inhibition of β 
glucuronidase was shown to be more effective when a 1.4kb antisense was used relative to a 
350bp antisense transcript. In both cases the MT-1 promoter, which is a weak constitutive 
promoter, was used to drive the expression of the antisense (Ao et al., 1991). Small antisense 
transcripts are useful when they are directed against a target which has a number of closely 
related units. There are a number of promoters that are available to drive antisense 
expression. The choice of promoter very much depends on the required transgene expression 
pattern for example the CMV is a ubiquitous promoter, whereas the Cyp1a-1 promoter is 
induced fourfold by dioxin.  
 
The mechanism by which antisense RNA blocks the expression of the target gene is not 
entirely clear.  It is thought that the antisense binds to the target sense strand and forms an 
RNA duplex within the cell nucleus. The RNA duplex becomes a target of the enzyme 
adenosine deaminase. The adenosine deaminase converts adenosine residues in the RNA 
duplex to inosine residues and causes the RNA duplex molecule to unwind (Kumar and 
Carmichael, 1997). The inosine residues are recognised by nuclear proteins, for example 
p54nrb, which bind inosine containing RNA and results in nuclear retention of the RNA 
transcripts through attachment to the nuclear matrix (Zhang and Carmichael, 2001).   
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The use of such technology allows for the long term knock down of a gene of interest in order 
to determine the physiological consequences. Therefore this methodology can be applied to 
study the physiological role of cocaine- and amphetamine -regulated transcript (CART) 
within the arcuate nucleus. CART antisense (CART-AS) expression under the control of the 
pro-opiomelanocortin (POMC) expression domain will result in reduced CART mRNA 
expression specifically in POMC expressing neurones. 
 
 
 
 
 
3.1.7 Hypothesis 
Hypothesis: A BAC containing the POMC expression domain will drive accurate and 
specific expression of cocaine- and amphetamine -regulated transcript antisense in 
POMC neurones. 
 
3.1.8 AIM 
1. To identify a BAC likely to contain the POMC expression domain. 
 
2. To modify the BAC using ET cloning so that the POMC expression domain drives the 
expression of the CART-AS in a transgenic animal. 
 
3. To create transgenic lines by pronuclear injection of the modified POMC BAC and to 
characterise the resulting transgenic lines.  
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3.2 Materials and Methods 
 
3.2.1 Bacterial Artificial Chromosome DNA Purification 
The large size of BAC DNA makes them more vulnerable to shearing by mechanical forces 
than small cloning vectors.  Extra care and slightly modified techniques are therefore required 
when isolating BAC DNA from their host E.coli cells. 
 
 
3.2.1.1 Small Scale Purification of Bacterial Artificial Chromosome DNA 
BACs were initially isolated by small scale culture to allow several clones to be analysed 
simultaneously.  To isolate plasmids from bacteria it is necessary to disrupt the cell wall to 
release the plasmid, and at the same time to remove contaminating proteins, genomic DNA 
and RNA. 
 
Materials 
Lysogeny Broth (LB)  (appendix I) 
25mg/ml Chloramphenicol (Cm) (appendix I) 
0.2 M sodium hydroxide / 1% (v/v) SDS solution in GDW (appendix I) 
5M potassium acetate, pH 4.6 (appendix I) 
Absolute Ethanol 
GTE (appendix I):  
25 mM Tris-HCl, pH 8.0 
10 mM EDTA  
50mM glucose 
 
 
Method 
Five millilitres of LB with 12.5µg/ml chloramphenicol were inoculated with a single bacterial 
colony and incubated overnight at 37oC with vigorous shaking.  Five hundred microlitres of 
this culture were added to an equal volume of 80% (v/v) glycerol and stored at -70oC.  The 
rest of the culture was centrifuged for three minutes at 12300g at room temperature (F45-12-
11 microfuge, Eppendorf, Hamburg, Germany) to pellet the bacteria.  The supernatant was 
discarded and the pellet resuspended in 100µl of GTE.  Two hundred microlitres of 0.2M 
NaOH/ 1% (v/v) SDS solution were added and the sample incubated on ice for five minutes, 
followed by the addition of 150µl of 5M potassium acetate and a further five minute 
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incubation on ice.  The precipitated bacterial debris was removed by centrifugation for five 
minutes at 12300g at room temperature (F45-12-11 microfuge, Eppendorf, Hamburg, 
Germany) and 350µl of supernatant were transferred to a clean tube.  An equal volume of 
phenol/chloroform/IAA was added and the sample mixed.  The phases were separated by 
centrifugation for three minutes at 12300g at room temperature (F45-12-11 microfuge, 
Eppendorf, Hamburg, Germany) and the upper phase transferred to a fresh tube.  The DNA 
was precipitated by the addition of 0.6 volumes of propan-2-ol and incubation at room 
temperature for ten minutes.  The DNA was recovered by centrifugation for seven minutes at 
12300g at room temperature (F45-12-11 microfuge, Eppendorf, Hamburg, Germany) and 
dissolved in 100µl of GDW. Ten microlitres of 2M sodium acetate and 250µl of absolute 
ethanol (-20oC) were added and the solution incubated at -20oC for at least one hour. The 
DNA was recovered by centrifugation for seven minutes at 12300g at room temperature 
(F45-12-11 microfuge, Eppendorf, Hamburg, Germany), then washed three times with 500µl 
of 70% (v/v) ethanol in GDW before air drying and resuspending in 20µl GDW.  The DNA 
can then be used in follow on protocols such as restriction digests (see section 2.2.7.1). 
 
 
3.2.1.2 Large Scale Purification of Bacterial Artificial Chromosome DNA 
 
Materials 
Qiagen Large Construct Kit 
Sterile GDW 
 
Method 
The manufactures protocol was modified slightly to give optimal results.  A small quantity of 
bacteria containing the plasmid of interest (see section 3.2.1.1) was inoculated into 500 ml of 
LB(Cm) and incubated at 37oC overnight with vigorous shaking. The bacteria were recovered 
by centrifugation for fifteen minutes at 6000g (HS-4 rotor in RC-5B super speed centrifuge, 
Du Pont) at 4oC. The pellet was resuspended in 40ml of ice cold solution P1 before addition 
of 40ml of solution P2, the sample was mixed by gently inverting six to eight times and 
incubated for five minutes at room temperature. Forty millilitres of solution P3 was then 
added. The sample mixed by inversion and the lysate incubated on ice for thirty minutes. The 
neutralised lysate was then centrifuged at 20,000g for thirty minutes at 4oC (JA-18 rotor, 
Beckman J2-21 centrifuge). The supernatant containing the BAC DNA was removed and re-
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centrifuged at 20,000g for fifteen minutes (JA-18 rotor, Beckman J2-21 centrifuge). The 
DNA supernatant was filtered through the folded filter paper provided in the kit. The 
resulting solution was precipitated using 0.6 volumes of room-temperature isopropanol 
(approx 36mls) and immediately centrifuged at 15,000g (Beckman JA-18 rotor, Beckman J2-
21 centrifuge) for thirty minutes at 4oC. The pellet was then washed in 5ml 70% (v/v) ethanol 
in GDW and centrifuged at 15,000g (Beckman JA-18 rotor, Beckman J2-21 centrifuge).  
After air drying the pellet for two to three minutes the pellet was re-dissolved in 9.5ml of 
buffer EX, and 200µl of ATP-dependent exonuclease plus 300µl of ATP solution added. This 
solution was incubated for one hour at 37oC before addition of 10mls of buffer QS and run 
through an equilibrated Qiagen-tip 500. The tip was washed with two x 30mls of QC buffer 
and the DNA eluted with 15mls of buffer QF warmed to 65oC. The eluted DNA was 
precipitated with 10.5ml room-temperature isopropanol and centrifuged at 15,000g (Beckman 
JA-18 rotor, Beckman J2-21 centrifuge). The DNA pellet was then washed with 5ml of room-
temperature 70% (v/v) ethanol, centrifuged at 15,000g (Beckman JA-18 rotor, Beckman J2-
21 centrifuge), and resuspended in 100µl of GDW.   
 
 
3.2.2 Construction of Cocaine- and Amphetamine -Regulated Transcript Antisense 
Modification Cassette (Figure 3.4) 
When constructing the CART-AS modification cassette for insertion into the POMC BAC by 
homologous recombination there were several considerations to be taken into account such as 
the position of the homology arms, ensuring that the antisense fragment is not compromised 
by endogenous BAC sequence and the inclusion of elements thought to increase transgene 
transcription, such as intron sequences. Homology arm 1 was designed so that it was 
homologous to the noncoding sequence at the 5’ end of exon 1 of the POMC gene. This 
positioning of homology arm 1 ensured that there would be minimal endogenous POMC 
sequence transcribed with the antisense sequence whilst at the same time not disrupting 
possible transcription control elements. The presence of additional sequences to that of the 
CART-AS may affect the specificity with which the antisense will bind to its target sense 
strand. The distance between the homology arms should be kept to a minimum in order to 
reduce possible disruption to the endogenous BAC sequence, for this reason homology arm 2 
was designed so it was homologous to the end of POMC exon 2 and a small section of the 
non coding sequence following exon 2. The design of homology arm 2 also maintained the 
intron sequence between exon 2 and 3 of the POMC gene (Figure 3.3). It has been 
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demonstrated that the presence of intronic sequences can increase expression of the transgene 
(Brinster et al., 1988; Choi et al., 1991). The cloning of a polyadenylation signal 3’ of the 
CART-AS sequence enhances transcription and nuclease protection of the transcript (Azzoni 
et al., 2007). Additionally, the positioning of the polyadenylation signal adjacent to the 
CART-AS directs termination of transcription to this point and ensures that the remaining 
POMC sequence is not present in the antisense transcript. The result being that the specificity 
of the antisense is not compromised by additional endogenous POMC sequence. A floxed 
antibiotic gene must be included to screen for successful recombinants and then allow for its 
subsequent removal. 
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Figure 3.3 Strategy used to modify the POMC BAC. Homologous recombination between the modification cassette and the POMC BAC was 
catalysed by the pGETrec plasmid so that the POMC expression domain could drive the expression of the CART-AS. The POMC BAC 
regulatory elements and exon 1-3 (E1-E3) are shown. Homology arm 1 from the modification cassette undergoes recombination with exon 1 in 
the POMC domain. Homology arm 2 of the modification cassette undergoes recombination with exon 2 in the POMC domain. 
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A BAC containing the POMC gene near the centre of its insert was chosen for modification 
with CART-AS (RP24-034C3 BAC). A flow diagram for the construction of the modification 
cassette is shown in Figure 3.5. The homology arms were generated by PCR (see section 
2.2.5) using the POMC BAC as the template. Homology arm 1 (414bp) was amplified using 
primers corresponding to nucleotides 89353-89372 (5’primer) and 89749-89771 (3’primer) in 
the RP24-034C3 BAC (http://www.ensembl.org/index.html). Homology arm 2 (282bp) was 
amplified using primers that correspond to nucleotides 93333-93352 (5’ primer) and 93067-
93089 (3’primer) in the RP24-034C3 BAC (http://www.ensembl.org/index.html). The 
CART-AS fragment was amplified by RT-PCR firstly a reverse transcriptase reaction (see 
section 2.2.4) was carried out using RNA extracted from mouse hypothalamus, followed by a 
PCR reaction (see section 2.2.5) from the resulting RT mixture using primers corresponding 
to nucleotides 32-62 (5’Primer) and 421-441 (3’primer) in the mouse CART mRNA 
sequence (accession number NM_013732). The PCR reaction yielded products of 369bp and 
408bp. The two PCR products are due to alternate splicing in exon 2 on the CART gene. The 
primer set amplifies this region so both transcripts were produced. The BGH polyadenylation 
signal (230bp) was isolated from the pTRCGW plasmid (kind gift from Dr J. Gardiner) 
(Figure 4.1) using the restriction enzymes SacI and NotI (see section 2.2.7.1.). The products 
from the restriction digest were run on a 1% agarose gel (see section 2.2.6) and the 230bp 
BGH polyadenylation signal was excised from the gel and purified by electroelution (see 
section 2.2.7.2.). 
 
 
Table 3.1 Primers for PCR amplification of homology arm 1 and homology arm 2 using the 
BAC containing POMC as a template. Primers are shown for CART-AS using mouse 
hypothalamus RNA as template. The restriction sites are shown in bold with the 
corresponding restriction enzyme. 
Primer   Oligonucleotide sequence 
Restriction 
Site 
Arm1 5' AGC TGC TAG CCA TTG GGG AAA TCT GCG ACA NheI 
  3' AGC TGG ATC CCT GTC GCT CTT CTC TCT TCT BamHI 
Arm2 5' AGC TTT CGA AAG TGC TGA GGA GTC CTC ACA Bsp119I 
  3' AGC TGC GGC CGC AGA GCA ACC TGC TGG TAT GT NotI 
CART AS 5' AGC TCG GTC CGC AGA ACC ATG GAG AGC TCC C SacI 
  3' AGC TGG ATC CCC TTC ACA AGC ACT TCA AGA GG BamHI 
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The PCR product for homology arm 1 and the cloning vector pFastBAC Dual (Figure 3.6) 
were cut with NheI and BamHI restriction enzymes (see section 2.2.7.1). The products from 
the restriction digest were run on a 1% agarose gel (see section 2.2.6.) and the linearised 
plasmid and homology arm were excised from the gel and purified by electroelution (see 
section 2.2.7.2). Homology arm 1 was sub-cloned by ligation (see section 2.2.7.3) into the 
linearised pFastBAC Dual cloning vector to form pFASTBAC/ARM1. The 
pFASTBAC/ARM1 plasmid and the amplified CART-AS were then cut in a restriction digest 
with BamHI and SacI, run on a 1% agarose gel and electroeluted. The 369bp CART-AS cut 
PCR product was sub-cloned into the pFASTBAC/ARM1 plasmid to produce 
pFASTBAC/ARM1/CARTAS. The pFASTBAC/ARM1/CARTAS vector was then cut with 
SacI and NotI restriction enzymes. The linearised plasmid was then electroeluted and the 
BGH polyadenylation signal, which was isolated from the pTRCGW plasmid, was sub-
cloned into pFASTBAC/ARM1/CARTAS to form pFASTBAC/ARM1/CARTAS/pA. 
Homology arm 2 and pFASTBAC/ARM1/-CARTAS/pA were then cut by the restriction 
enzymes NotI and Bsp119I. After the linearised pFASTBAC/ARM1/-CARTAS/pA and 
homology arm 2 were electroeluted, homology arm 2 was sub-cloned into the plasmid to 
form pFASTBAC/ARM1/CARTAS/pA/ARM2. A 2.15kb NotI fragment containing a floxed 
spectinomycin resistance gene was isolated from plasmid pDLOX5 (a kind gift from Dr C 
Huxley) (Figure 3.6). The spectinomycin gene and pFASTBAC/ARM1/CARTAS/pA/ARM2 
were cut with NotI. The spectinomycin gene was then sub-cloned between homology arm 2 
and polyadenylation signal to form pFASTBAC/ARM1/CARTAS/pA/Spec/ARM2. The final 
plasmid was purified by large scale purification (see section 3.2.1.2) and the integrity of the 
modified cassette checked by DNA sequencing (Advanced Biotechnology Centre, Imperial 
College, Faculty of Medicine, Charing Cross Campus, London). 
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Figure 3.4 Schematic of the CART-AS modification cassette. The homology arms were amplified by PCR using the POMC BAC as a 
template. The antisense (CART-AS) gene was amplified from mouse hypothalamus RNA. The bovine growth hormone polyadenylation signal 
(pA) was cut from the pTRCGW plasmid (kind gift from Dr J. Gardiner). The spectinomycin gene was cut from the pDLOX5 plasmid.
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Figure 3.5 Flow diagram of the construction of the CART-AS modification cassette. 
Homology arm 1 was subcloned into the NheI and BamHI restriction sites in the cloning 
vector pFASTBac Dual. This was then followed by the CART-AS gene into the BamHI and 
SacI sites on the same vector. The pA signal was cloned into the same vector at the SacI and 
NotI sites. Homology arm 2 was then subcloned into the NotI and Bsp119I sites. Finally the 
spectinomycin gene was isolated in a NotI fragment from pDLOX5 and subcloned into the 
NotI site of the vector containing the homology arms, antisense gene and pA signal. 
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Figure 3.6 pFASTBAC Dual. A map of the vector pFASTBAC Dual and its multiple cloning 
sites. Pcmv, cytomegalovirus promoter; BGH pA, bovine growth hormone polyadenylation 
signal; f1 ori, origin of replication for F1 filamentous phage; SV40 ori, origin of replication 
for SV40; Sv40 pA, SV40 polyadenylation signal; pUC ori, pUC origin of replication; HSV 
tk pA, herpes simplex virus thymidine kinase polyadenylation signal; Tn7L, left element of 
transposon 7; Tn7R right element of transposon 7; Pp10, P10 promoter, Pph, polyhedrin 
promoter. 
  
 
Figure 3.7 pDLOX5 Plasmid. Map of plasmid pDLOX5 showing Spectinomycin resistance cassette (Sp), restriction sites, T7 T3 
promoters, chloramphenicol resistance gene (Cm) and LoxP sites.  
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transcription 
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3.2.3 Modification of the POMC Bacterial Artificial Chromosome by ET Cloning 
 
Materials 
Agarose (Sigma-Aldrich) 
LB (appendix I) 
Ampicillin 100mg/ml in GDW (Sigma) (appendix I) 
Chloramphenicol 25mg/ml in ethanol (Sigma) (appendix I) 
Spectinomycin 50mg/ml in GDW (Sigma) (appendix I) 
10% (v/v) Glycerol in GDW (appendix I) 
10% (w/v) L-arabinose (Sigma) in GDW (appendix I) 
10X Taq buffer (Sigma) 
20µM oligonucleotide primers (Oswel DNA service, University of Southampton, 
Southampton, U.K.) 
Taq DNA polymerase (Sigma) 
0.1cm electrode gap cuvette (BTX, San Diego, CA) 
 
Methods  
A strategy for modifying the POMC BAC is shown in Figure 3.8. The CART-AS 
modification cassette was isolated from pFASTBacDual/ARM1/CARTAS/-pA/SPEC/HOM2 
by digesting the plasmid with NheI and Bsp119I restriction enzymes (see section 2.2.7.1).  
The DNA was excised and run on a 1% agarose gel (see section 2.2.6) and the modification 
cassette was electroeluted (see section 2.2.7.2). 
 
Initially the pGETrec plasmid (Figure 3.9) was electroporated into DH10B E.coli containing 
the POMC BAC.  To prepare electrocompetent cells 1ml of culture grown overnight in LB 
with 12.5µg/ml chloramphenicol (Cm) was seeded into fresh LB with Cm at a ratio of 1:100 
and grown for four to five hours at 37oC with shaking.  When the optical density (OD) of the 
cells reached 0.5-0.6, measured at 580nm using a spectrophotometer, the cells were 
centrifuged at 800g for ten minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, Du 
Pont).  The cell pellet was washed twice by resuspending in ice cold 10% (v/v) glycerol and 
centrifuging at 4,000g for 10 minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, 
Du Pont) and then repeating. After the final wash, the pellet was resuspended in 100µl of ice 
cold 10% (v/v) glycerol. 40µl of the cell suspension and 10ng of pGETrec was used per 
electroporation.  Electroporation conditions were: 1.8kV, 186Ω, 25F in 0.1cm electrode gap 
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cuvette using an Electro Cell Manipulator 600 (BTX).  Following electroporation the cells 
were immediately removed into 960µl of prewarmed (37oC) LB and incubated for two hours 
at 37oC with shaking before being plated on LB + Chloramphenicol 12.5µg/ml + Ampicillin 
100µg/ml plates (see section 2.2.9) which selects for E.coli cells which contain the POMC 
BAC and pGETrec plasmid.  
 
The isolated and eluted CART-AS modification cassette was then electroporated into the 
DH10B E.coli strain containing the POMC BAC and pGETrec plasmid.  Electrocompetent 
cells were prepared as described above except that after seeding the overnight culture in 
LB+Cm+Amp and culturing for three hours, 10% (w/v) L-arabinose was added to the cells to 
a final concentration of 0.2% (v/v) to induce the arabinose inducible PBAD promoter on 
pGETrec plasmid. Induction of the PBAD promoter on pGETrec drives production of recE and 
recT which catalyse homologous recombination between the modification cassette and the 
POMC BAC. Cells were cultured for 40 minutes in the presence of L-arabinose, then 
centrifuged at 4,000g for ten minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, 
Du Pont) and washed twice in ice cold 10% (v/v) glycerol. 40µl of cell suspension and 400ng 
of the isolated CART-AS modification cassette was used for each electroporation as 
described above.  Electroporated cells were incubated in prewarmed (37oC) LB for three 
hours at 37oC with shaking then plated onto LB agar plates with chloramphenicol and 
spectinomycin 50µg/ml. 
 
Three colonies were screened for successful recombination by PCR (see section 2.2.5) after 
small scale POMC BAC DNA isolation. Three PCR primer sets were used to check correct 
integration of the CART-AS modification cassette; the 5’ end was checked using a forward 
primer outside the region of homology arm 1 and the forward primer for CART-AS. 
Screening for correct 3’ integration was confirmed using forward primer for homology arm 2 
and the reverse primer outside the region of homology arm 2. Integration of the complete 
construct was checked using the forward primer outside the region of homology arm 1 which 
corresponds to nucleotides 89171-89191 of the RP24-034C3 BAC and the reverse primer 
outside the region of homology arm 2 which corresponds to nucleotides 93411-93431 of the 
RP24-034C3 BAC (Table 3.2).  PCR was carried out in 1x taq buffer, 0.2mM dNTPs, 200nM 
oligonucleotides and with 5U of taq per reaction. The PCR reaction was heated to 95oC for 
fifteen minutes before being cycled thirty times through the following temperatures: 95oC for 
forty seconds, 55oC for forty seconds, 72oC for two minutes. 
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To remove the spectinomycin gene a Cre-reaction was performed using plasmid pJM2545 (a 
kind gift from Dr. C. Huxley) in the DH10B E.coli strain containing the CART-AS modified 
BAC.  Electrocompetent cells were prepared from cells with the modified BAC as above, and 
20ng of plasmid pJM2545 electroporated into the cells. After electroporation cells were 
incubated in LB + 0.5mM IPTG to induce Cre expression. Following a 60 minute incubation 
at 37oC shaking, the cells were plated onto LB + 12.5µg/ml chloramphenicol and incubated 
for 75 minutes at 30oC and then finally overnight at 42oC. The colonies were cultured into 96 
well plates containing LB agar + chloramphenicol or spectinomycin. Clones which exhibited 
chloramphenicol resistance and sensitivity to spectinomycin were checked by PCR after 
small scale BAC DNA isolation (see section 3.2.1.1). The same primer sets were used to 
check correct integration of the modification cassette and to show successful removal of the 
spectinomycin resistance gene. Successful integration was followed by large scale BAC DNA 
isolation (see section 3.2.1.2)  
 
Primer Primer Sequence 
OUTARM1 TAG AGT TTG GGC ACA GAA GG 
OUTARM2 GTT GAT TTG GGA GCC AAA GG 
 
Table 3.2 Primers used to check correct integration of the CART-AS modification cassette 
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Figure 3.8 Strategy used to modify the POMC BAC. Homologous recombination between the modification cassette and the POMC BAC was 
catalysed by the pGETrec plasmid so that the POMC expression domain could drive the expression of the CART-AS. The POMC BAC 
regulatory elements and exon 1-3 (E1-E3) are shown. Homology arm 1 from the modification cassette undergoes recombination with exon 1 in 
the POMC domain. Homology arm 2 of the modification cassette undergoes recombination with exon 2 in the POMC domain.  
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Figure 3.9 Map of pGETrec plasmid. The recE, recT and gam genes are under the control of the PBAD promoter. PBAD, PBAD promoter; 
ampR, ampicillin resistance gene, Pc prom, PC promoter; P3 prom, P3 promoter,; M13 ori, origin of replication for M13; pBR322, origin of 
replication for pBR322; araC, arabinose promoter. 
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3.2.4 Generation of Transgenic Mice and Genotyping PCR 
 
Materials 
Tail digestion buffer: 
 6.7mM Tris-HCL 
 1.66mM (NH4)2SO4 
 0.67mM MgCl2 
 0.5% (v/v) Triton X-100 
 1%  (v/v) β-mercaptoethanol (added just before use) 
20mg/ml Proteinase K in GDW (appendix I)   
10X Taq buffer (sigma) 
20µM oligonucleotide primers (Oswel DNA service, University of Southampton, 
Southampton, U.K.) 
Genomic Red Taq DNA polymerase (Sigma) 
 
Method 
DNA of the modified POMC BAC was isolated using a Qiagen large construct kit and 
microinjected at low concentration (0.5-1 ng/µl) into pronuclei of fertile mouse (c57BL/6J x 
CBA/Ca) oocytes. Oocytes were cultured from and then implanted into foster females using 
standard techniques. All DNA injections and mouse manipulations were carried out by the 
MRC Transgenic unit at Hammersmith Hospital, London, UK. Offspring resulting from these 
injections were weaned and genotyped by PCR (see section 3.3) at three weeks of age.  DNA 
was isolated from a 1mm tail biopsy by digestion in 100µl of tail digestion buffer.  The 
reaction was incubated at 95oC for 10 minutes then 1mg/ml proteinase K was added and the 
reaction incubated for 2 hours at 55oC. Proteinase K was inactivated with a final ten minutes 
at 95oC. Digested tails were centrifuged in a microfuge to settle the debris and 1µl of 
supernatant added to a 25µl PCR reaction. Primers designed to amplify a cDNA fragment 
from the vector portion of the POMC BAC, pBeloBAC11, were used (Table 3.3). PCR was 
carried out in 1x Red Taq buffer, 0.2mM dNTPs, 200nM oligonucleotides with 3U of 
Genomic Red Taq per reaction, the PCR reaction was heated to 95oC for fifteen minutes 
before being cycled thirty times through the following temperatures: 95oC for thirty seconds, 
55oC for thirty seconds, 72oC for thirty seconds.  20µl of PCR reactions were analysed on a 
1% agarose gel (see section 2.2.6).   
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Primer  Oligonucleotide sequence 
BeloBAC  
5’ TCATTCTGCAATCGGCTTGC 
3’ GTGCCTGGAGAAATGCTCTT 
 
      Table 3.3 Primer set used for genotyping PCR to identify transgenic offspring. 
 
 
3.2.5 Animals 
As a result of pronuclear injection several founder mice were identified by genotyping PCR 
which contained the transgene (CART-AS 3A, CART-AS 4A, CART-AS 5A, CART-AS 6A, 
CART-AS 13A and CART-AS 18A). These were maintained as separate transgenic lines. 
Mice were maintained in cages under controlled temperature (21-23°C) and light (eleven 
hours light/thirteen hours dark) with ad libitum access to food (RM3 diet, SDS UK Ltd.) and 
water.  Animal procedures were approved under the British Home Office Animals Scientific 
Procedures Act 1986 (Project licence numbers 70/6270 and 70/6402). From the identified 
founder mice, line CART-AS 13A was selected for further characterisation. Although line 
CART-AS 5A was the only other line to produce transgenic offspring they failed to exhibit a 
body weight or food intake phenotype (data not shown).   
 
 
3.2.6 Food Intake and Body Weight 
Food intake and body weight were measured two times per week at 0900h (Adam 
Equipment, Milton Keynes, UK).  
 
 
3.2.7 Measurement of Uncoupling Protein-1 mRNA Expression in Brown Adipose 
Tissue 
One hundred milligrams of brown adipose tissue (BAT) was homogenised per 1ml tri reagent 
and total RNA extracted as described in section 2.2.1. RNA viability was checked using RNA 
denaturing gel (section 2.2.2). BAT uncoupling protein (UCP-1) mRNA expression was 
determined by northern blot analysis (section 2.2.3) of 30µg of BAT RNA. A 32P labelled 
UCP-1 DNA probe was generated using a primer set specific for the mouse UCP-1 gene and 
these are detailed in Table 3.4 (accession number BC012701).   
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Primer  Sequence Restriction Site 
UCP1  5’ AGCTGGATCCAAGGCCAGGCTTCCAGTACT BamHI 
UCP1  3’ AGCTGAATTCGGTTTGATCCCATGCAGATG EcoRI 
 
Table 3.4 Primer sequence for UCP-1 DNA probe. The highlighted sequence details the 
restriction site associated with the particular primer. UCP1 5’ primer corresponds to 
nucleotides 368-396 and UCP1 3’ primer corresponds to nucleotides 661-687 of the mouse 
UCP1 gene (accession number BC012701). 
 
 
 
3.2.8 Measurement of Cocaine- and Amphetamine -Regulated Transcript peptide from 
punch biopsy 
Mice were killed via CO2 inhalation, and death confirmed by dislocation of the cervical 
vertebrae. Following confirmation of death animals were decapitated and brains removed. 
Brains were then placed on filter paper with the ventral surface facing upwards so that the 
hypothalamus was visible, and sections lateral to the hypothalamus on either side were cut 
away using a razorblade. The remaining block of brain was then frozen using isopentane 
cooled on dry ice. Frozen brains were mounted upon a freezing sled microtome (Shandon 
Southern Products Ltd, Runcorn, UK) so that a sagittal section of brain was facing upwards. 
Sections were then removed from the brain until a section approximately 0.675mm from the 
midline was exposed (as identified using a mouse brain atlas (Figure 3.10)). The brain was 
then removed from the sled and flipped over so that the opposite sagittal section was exposed 
and the process repeated. The remaining section of brain was then mounted onto a slide. 
Slides containing brain sections were kept on dry ice to re-freeze sections and nuclei were 
identified using the Allen mouse brain atlas. Paraventricular nucleus (PVN) biopsies were 
removed using a 0.5mm diameter neuropunch (Harvard apparatus, Edenbridge, UK), arcuate 
nucleus (ARC)/ventromedial nucleus (VMN) biopsies were removed using a 1.0mm diameter 
neuropunch (Harvard).  
 
Peptide extraction was carried out immediately on all punch biopsies using acetic acid 
extraction. Localisation and tissue content of punch biopsies are summarised in Figure 3.10. 
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3.2.9 Acetic Acid Extraction of Peptide 
 
Materials: 
0.5M Acetic Acid 
Water bath (100oC) 
 
Method 
0.5M acetic acid was warmed in a boiling water bath. 500µl of warmed acid was added to 
each eppendorf containing biopsy tissue which was subsequently placed in the boiling water 
bath for 20 minutes, ensuring that holes are pierced in the top of the eppendorf to release any 
pressure. After incubation in the water bath the sample is stored at -20oC until required.  
CART Activity was then assayed for using radioimmunoassay (RIA) (see section 2.2.12) 
 
 Figure 3.10 Location of punch biopsies in the mouse brain.
Mouse brains were placed on a sledge microtome in the saggital orientation, sections were removed from the brain until a sect
approximately 0.68mm from the midline was exposed (as identified using the Allan mouse brain atlas 2008). This process 
the opposite side of the brain. Punch biopsies were then collected from the remaining slice of brain and homogenised for use 
Punch biopsies were collected from:  
A) VMH punch biopsy, containing VMN and ARC areas. 
B) PVN punch biopsy, containing PVN only. Diameter 0.5mm.
Abbreviations: AHA: Anterior hypothalamic area. ARC: Arcuate nucleus. DMN: Dorsomedial hypothalamic nuclei. PVN: Paraventricular 
nucleus. VMN: Ventromedial hypothalamic nuclei. Adapted from  the Allen Brain Atlas: Mouse Brain, 2008.
  
Diameter 1mm. 
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ion located 
was then repeated on 
in the CART assay. 
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3.3 Results 
 
3.3.1 Identification of POMC Containing Bacterial Artificial Chromosome 
Using the UCSC genome browser (http://genome.ucsc.edu) a BAC clone was identified 
which contained the POMC gene at the centre of its insert. The insert was therefore likely to 
contain all the necessary regulatory sequences required to replicate POMC like expression in 
vivo (Figure 3.11). 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 In Silico identification of POMC containing BAC. Screen shot from the 
UCSC genome browser highlighting the BAC RP24-340C3 which was selected for 
modification. The position of the POMC gene within the BAC is shown in the box. The 
RP24-340C3 BAC was selected because of the central position of the POMC gene thus 
maximising the possibility that all of the necessary regulatory elements are present. 
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3.3.2 Production of the Cocaine- and Amphetamine -Regulated Transcript Antisense 
Modification Cassette 
The components of the modification cassette were generated separately before being cloned 
into the pFASTBAC Dual vector. Homology arm 1 (~414bp) and homology arm 2 (~282bp) 
were successfully generated by PCR using primer sets Arm1 and Arm2 (see Table 3.1) and 
the POMC BAC as a template. The primer set for homology arm 1 contained NheI and 
BamHI restriction sites. The primer set for homology arm 2 contained NotI and Bsp119I 
restriction sites. The inclusion of these restriction sites in the primer sequence allowed for 
cloning into the pFASTBAC Dual vector. Mouse hypothalami total RNA was used as the 
template for production of the CART-AS insert. An RT reaction was first performed followed 
by a PCR reaction using the CART-AS primer set (see Table 3.1). The CART-AS primer set 
included the sequence for the BamHI and SacI restriction enzyme cut sites to facilitate 
cloning. The resulting products from the PCR reactions can be seen in Figure 3.12. The BGH 
polyadenylation signal was isolated from the pTRCGW plasmid (Figure 4.1) (a kind gift from 
Dr J. Gardiner) using the SacI and NotI restriction enzymes. A 2.15kb fragment containing 
the spectinomycin gene was digested from the pDLOX plasmid (a kind gift from Dr C 
Huxley) using NotI restriction enzymes. 
 
The components of the modification cassette were sub-cloned into the pFASTBAC Dual 
vector. To confirm successful incorporation of the inserts into the completed modification 
cassette restriction digest analysis was performed. The correct integration of homology arm 1 
was demonstrated using restriction enzymes Nhe1 and BamHI (Figure 3.13). The resulting 
digest yielded a product of 414bp indicating successful integration of homology arm 1. There 
were additional products resulting from the restriction digest; digestion of the spectinomycin 
gene, due to a BamHI restriction site, yielded products of either 680bp or 2630bp which 
subsequently yielded a plasmid backbone of 7589bp or 5639bp respectively. The different 
product sizes resulting from the restriction digest are due to the presence of a BamHI 
restriction site within the spectinomycin gene and the orientation in which the spectinomycin 
gene was cloned into the modification cassette. Correct integration of the CART-AS insert 
was confirmed by the presence of a 369bp product resulting from a restriction digest using 
the enzymes BamHI and SacI (Figure 3.13). The resulting restriction digests yielded 
additional products of 300bp or 2261bp due to the presence of the BamHI restriction site 
within the spectinomycin gene. 
 
  
 
                                                    
 
Figure 3.12 PCR productio
ladder; Lane 2- Homology Arm1
CART-AS (369bp and 408bp)
 
 
This consequently means that the plasmid backbone was either 8003bp or 6053bp. 
Restriction digest using SacI and NotI showing correct integration of the BGH 
polyadenylation signal yielded a product of 230bp (Fi
product corresponding to the spectinomycin gene resulted from NotI restriction digest. This 
was due to NotI restriction sites flanking the spectinomycin gene. A product of 6303bp 
corresponding to the plasmid backbone was a
homology arm 2 was confirmed by restriction digest using NotI and Bsp119I (Figure 3.14). 
The resulting restriction digest yielded a product of 282bp which corresponded to homology 
arm 2. In addition, a 2.15kb pro
6355bp product which corresponded to the plasmid backbone were also produced. The results 
from the restriction digest show that 3 colonies (colonies A, B and E) had correct insert 
incorporation. Colony B was selected and sequenced confirming that no mutations were 
present. 
 
 
3.3.3 Recombination between the 
Antisense Modification Cassette and the POMC B
The CART-AS modification cassette was introduced into the POMC BAC by homologous 
recombination. Three clones were found to have resistance to chloramphenicol and 
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spectinomycin.  To check for correct integration of the modification cassette a PCR strategy 
was employed which used three primer sets (1-3) (see Table 3.1 and Table 3.2); primer set (1) 
POMC out1/POMC out2, (2) POMC out 1/ CART AS F  (3) POMC out 2/ Arm 2 F. Two of 
the clones exhibited the correct 5’ and 3’ prime integration of homology arms 1 and 2 which 
was confirmed by PCR using primer set (1) POMC out1/POMC out2 where a PCR product of 
approximately 3.69kb indicated correct integration of the homology arms and the presence of 
the spectinomycin resistance gene in the modified BAC. The same primer set using the 
wildtype unmodified BAC as a template gave a PCR product of approximately 4.26kb equal 
to both homology arms and the POMC gene. The difference in size of products resulting from 
the PCR reaction for the modified and unmodified BAC is due to the modification cassette 
being 561bp shorter than the endogenous POMC sequence it replaced via homologous 
recombination. Primer set (2) POMC out 1/ CART AS F yielded a product of ~957bp in the 
modified BAC, no product was produced for the wildtype BAC and (3) POMC out 2/ Arm 2 
F  yielded a product of ~362bp for the modified and unmodified BAC (Figure 3.15).  
 
A successfully modified clone, clone 3, was chosen for the removal of the spectinomycin 
gene. Following exposure to Cre recombinase 96 clones were picked for positive and 
negative selection. One was found to be sensitive to spectinomycin and resistant to 
chloramphenicol. The clone was analysed for the removal of the spectinomycin gene by PCR 
using primer set 1-3. The PCR product from primer set 1 was approximately 1549bp, 
compared to a clone containing the spectinomycin gene which would be 3.69kb in length. 
Using primer sets 2 and 3 produced PCR products of 957bp and 362bp respectively 
indicating that the spectinomycin gene (~2.15kb) had been successfully removed from the 
clone and the construct remained intact with no rearrangements occurring (Figure 3.16). This 
clone was isolated, grown on a large scale and purified for pronuclear injection. Before 
pronuclear injection the large scale purified BAC was examined for rearrangements by PCR 
using the strategy employed above (Figure3.17).  
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Figure 3.13 Restriction digest from completed construct from small scale preparations. (A) The expected results from restriction digest for 
homology arm 1 (shown in green) and CART-AS (shown in black) are shown. Due to the presence of a BamHI restriction site in the 
spectinomycin gene alternate products can arise when performing restriction digests which depend on the orientation that the spectinomycin 
gene was subcloned into the modification cassette, both variations are shown. Correct integration of homology arm 1 yields a product of 414bp. 
In addition to this a product of either 680bp or 2630bp is produced which is due to a BamHI restriction site in the spectinomycin gene. This in 
turn resulted in a product of either 7589bp or 5639bp which corresponds to the plasmid backbone. Correct integration of CART-AS yields 
products of 369bp. In addition to this products of either 300bp or 2261bp are produced due to a BamHI restriction site in the spectinomycin 
gene. A product of 8003bp or 6053bp is produced which corresponds to the plasmid backbone. (B) Isolated mini prep DNA from six colonies 
was checked for the correct integration of each component of the modification cassette by restriction digest. Colonies A, B and E showed correct 
integration. Colony B was selected for sequencing prior to BAC modification. L = 1kb ladder; A-F- mini prep A-F.  
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Figure 3.14 Restriction digest of completed construct from small scale preparations. (A) The expected results from restriction digest for 
polyadenylation signal and spectinomycin (shown in yellow) and homology arm 2 and spectinomycin (shown in pink) are shown. Correct 
integration of the pA tail will yield a product of 230bp. In addition to this a product of 2.15kb spectinomycin is produced as a result of using the 
NotI enzyme in the digest and a product of 6303bp corresponding to the plasmid backbone. Confirmation of the homology arm 2 by restriction 
digest using NotI and Bsp119I will produce digest products of 282bp for arm 2 additionally products of 2.15kb corresponding to the 
spectinomycin gene and 6355bp for the backbone. (B) Isolated mini prep DNA from six colonies was checked for the correct integration of each 
component of the modification cassette by restriction digest. Colonies A, B and E showed correct integration. Colony B was selected for 
sequencing prior to BAC modification. L = 1kb ladder; A-F- mini prep A-F. 
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Figure 3.15 Analysis of 5’ and 3’ integration in the modified POMC BAC. Primer set 1-3 were used to analyse integration in the modified 
BAC. The expected PCR products are shown for a successfully modified BAC (shown in red) and wildtype BAC (shown in orange) (A). Primer 
set 1 yields a product of 3.69Kb in the modified BAC and 4.26kb in the unmodified BAC. This is due to the modification cassette being 561bp 
shorter than the sequence it replaces via homologous recombination.  Primer set 2 yields a product of 957bp in the modified BAC. Primer set 3 
yields a product of 362bp in the modified and unmodified BAC. Three clones were  found to be resistant to chloramphenicol and spectinomycin 
and were analysed using primer sets 1-3 (B). Clone 1 showed correct 3’ integration but lacked correct 5’ integration. Clone 2 and 3 showed 
correct 5’ and 3’ integration. Clone 3 was selected to remove spectinomycin. 
L=  1kb ladder; 1 = PCR product from primer set 1; 2 = PCR products from primer set 2; 3 = PCR products from primer set 3; N.C= negative 
water control; WT=wild type POMC BAC; C1-3= clone 1-3.  
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Figure  3.16 Removal of spectinomycin from Clone 3. Primer set 1-3 was used to confirm the removal of the spectinomycin gene. The 
expected PCR products are shown for a modified BAC with spectinomycin gene successfully removed (shown in red) and a wildtype BAC 
(shown in orange) (A). Primer set 1 yields a PCR product of 1549bp in the modified clone and 4260bp for the wildtype POMC BAC. The 
change in size from 3699bp to 1549bp is due to the removal of 2.15kb spectinomycin gene. Primer set 2 yields a PCR product of 957bp for the 
modified clone. No product is present for the unmodified POMC BAC as the primer cannot bind to the CART-AS sequence. Primer set 3 PCR 
product is 362bp for both the wildtype and the modified BAC indicating no rearrangements had occurred. The removal of spectinomycin gene 
from clone three was confirmed by PCR using primer sets 1-3 (B). The clone was isolated, grown on a large scale and purified for pronuclear 
injection.  
L=  1kb ladder; 1 = PCR product from primer set 1; 2 = PCR products from primer set 2; 3 = PCR products from primer set 3; N.C= negative 
water control; WT=wild type POMC BAC; C3= clone 3.  
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Figure  3.17 Checking correct arrangement in CART-AS modification cassette prior to pronuclear injection. Primer set 1-3 was used to 
confirm the removal of the spectinomycin gene from clone 3 prior to pronuclear injection. The expected PCR products are shown for a modified 
BAC with spectinomycin gene successfully removed (shown in red) and a wildtype BAC (shown in orange) (A). Primer set 1 yields a PCR 
product of 1549bp in the modified clone and 4260bp for the wildtype POMC BAC. The change in size from 3699bp to 1549bp is due to the 
removal of 2.15kb spectinomycin gene. Primer set 2 yields a PCR product of 957bp for the modified clone. No product is present for the 
unmodified POMC BAC as the primer cannot bind to the CART-AS sequence. Primer set 3 PCR product is 362bp for both the wildtype and the 
modified BAC indicating no rearrangements had occurred.. The removal of spectinomycin gene from clone three was confirmed by PCR using 
primer sets 1-3 (B). The clone was isolated, grown on a large scale and purified for pronuclear injection.  
L= 1kb ladder; 1-3 = PCR product from primer set 1-3; N.C= negative water control; WT=wild type POMC BAC; C3= clone 3.
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3.3.4 Creation of Cocaine- and Amphetamine -Regulated Transcript Antisense  
Transgenic Mice 
The modified CART-AS containing BAC was microinjected into the pronuclei of 
c57BL/6JxCBA/Ca oocytes by the MRC core transgenic facility at a concentration of 1ng/µl. 
The injected ova were then implanted into foster females using standard techniques. Tail 
biopsies were obtained from offspring of the foster mother at 3 weeks of age and their 
genotype analysed by PCR (see section 3.2.4). Founder mice were identified by a PCR 
product of 600bp using the BeloBAC primers (Table 3.3). No PCR product will be produced 
from the reaction using the BeloBAC primers if the mice are wildtype. Four male (CART-AS 
3A, CART-AS 4A, CART-AS 5A, CART-AS 6A) and two female transgenic founder mice 
(CART-AS 13A, CART-AS 18A) were produced as a result of pronuclear injection from a 
total of 20 mice (Figure 3.18). This represents a transgene integration rate of approximately 
30%. The founders were mated with wildtype c57BL/6J mice and each line maintained 
separately. Subsequent offspring from CART-AS 3A line produced 1 transgenic mouse from 
a total litter of 4 mice but failed to produce any subsequent litters containing transgenic 
offspring which suggests the transgene did not incorporate into the germline. CART-AS 5A 
line produced 19 transgenic mice from a total of 39 mice over five litters. CART-AS 13A 
produced 44 transgenic mice from a total of 90 mice over fourteen litters. Lines CART-AS 
18A, CART-AS 4A and CART-AS 6A did not produce any transgenic offspring. The CART-
AS 13A line was used in subsequent characterisation studies. The remaining CART-AS lines 
were terminated.  
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Figure 3.18 Identification of transgenic mice by PCR.  Tail biopsies obtained at weaning were subjected to a genotyping PCR protocol. 6 
transgenic mice, 3-6 and 13 and 18, were identified by a PCR product of 600bp using the BeloBAC primer set. Non transgenic mice produced no 
PCR product. L= ladder, N.C=water control, WT=positive control, 1-20= mouse tail genotyping DNA (1-12 male and 13-20 female).  
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3.3.5 Effect on Food Intake and Body Weight 
Food intake and body weight were measured from weaning to 32 weeks of age in transgenic 
mice expressing CART-AS (n= 4) and compared with wildtype litter mates (n= 3). At the 
start of the study the average body weight of wildtype mice in this study was fractionally 
higher than the average body weight of the male transgenic mice being 21.64 ± 0.35g and 
21.06 ± 0.3g respectively, although this was not significant (P = 0.25, unpaired two tail 
Students t-test). From week six onwards the transgenic mice exhibited a higher body weight 
than control animals. Male CART-AS mice were found to have a significantly increased body 
weight and body weight gain over the 27 week period when analysed using the generalised 
estimation equation (GEE) (P = <0.001). At the conclusion of the study CART-AS 
expressing mice exhibited a mean body weight that was 15% higher than that of the control 
group (Figure 3.19). However, there was no significant difference in cumulative food intake 
during the study (Figure 3.20).  
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Figure 3.19 Effect on (A) body weight and (B) body weight gain in mice expressing 
CART-AS. Body weight of male mice expressing CART-AS (n=4) (shown in blue) and male 
wildtype (WT) litter mates (n=3) (shown in red) were measured over a 27 week period after 
weaning. Values shown as mean ± SEM ***P<0.001 as analysed by GEE and compared to 
control animals over whole time period analysed. 
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Figure 3.20 Effect on cumulative food intake of CART-AS expression in male mice 
relative to wildtype litter mate controls. Food intake was measured in CART-AS mice 
(n=4) (shown in blue) and wildtype (WT) mice (n=3) (shown in red) up to 32 weeks of age. 
There was no significant difference between the transgenic mice and wildtype mice over the 
whole time period when analysed using the GEE. 
 
 
 
 
 
 
 
 
 
124 
 
3.3.6 Measurement of Cocaine- and Amphetamine -Regulated Transcript  Peptide from 
Punch Biopsies 
CART peptide concentration was measured in ARC/VMN and PVN tissue biopsies by RIA 
from CART-AS (n= 10) and wildtype mice (n= 13) at eight weeks of age. No significant 
difference in CART peptide concentration in the ARC/VMN tissue biopsies (P = 0.22 using 
an unpaired Students t-test) were identified with mean peptide concentration measuring 890.3 
± 67.5 fmol/punch biopsy from transgenic mice and 995.6 ± 104.4 fmol/punch biopsy from 
the wildtype mice (Figure 3.21). There was a trend towards decreased CART peptide 
expression in tissue from the PVN in the CART-AS mice when compared with wildtype litter 
mates (P = 0.07 using an unpaired Students t-test) with average CART peptide concentration 
being 106.1 ± 21.3 fmol/punch and 158 ± 24.7 fmol/punch respectively which represents a 
reduction in CART peptide concentration in the order of 30% in the transgenic mice, 
however this did not reach significance (Figure 3.21).  
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Figure 3.21 CART peptide concentrations in (A) ARC/VMN punch biopsy and (B) PVN 
punch biopsy. Concentration of CART peptide was measured by RIA from punch biopsies 
taken from the ARC/VMN and the PVN taken from CART-AS expressing male mice (n=10) 
(shown in blue) and wildtype (WT) litter mates (n=13) (shown in red) at 8 weeks of age. 
Values shown as mean ± SEM 
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3.3.7 Measurement of Uncoupling Protein-1 mRNA Expression in Brown Adipose 
Tissue 
UCP-1 mRNA expression was measured in BAT from wildtype (n=2) male mice and male 
mice expressing CART-AS (n=4) at 32 weeks of age. Expression of CART-AS in the ARC 
appears to have resulted in a significant decrease in UCP-1 mRNA expression in BAT 
relative to control animals (P = 0.016) as measured by an unpaired Students t-test (Figure 
3.22.). 
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Figure 3.22 Effect of ARC CART-AS on UCP-1 mRNA expression in mice. BAT UCP-1 
mRNA expression was measured in male mice expressing CART-AS (n=4, shown in blue) 
and from their wildtype (WT) litter mates (n=2, shown in red) at 32 weeks of age. There was 
a significant reduction in UCP-1 mRNA expression as measured by unpaired Students t-test. 
Values shown as mean ± SEM *P<0.05. 
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3.4 Discussion 
 
3.4.1 Choosing an Artificial Chromosome 
The RP24_340C3 BAC was chosen for modification with the CART-AS construct as it 
contains the POMC gene at the centre of its insert to maximise the chance of all regulatory 
elements that are necessary for accurate POMC like expression being present. Barsh et al 
recently used a POMC BAC clone to drive expression of green fluorescent protein (GFP) 
specifically in POMC neurones. The BAC used by Barsh et al contained approximately 60kb 
of 5’ flanking sequence and 30kb of 3’ flanking sequence (Xu et al., 2005) which suggests all 
the necessary regulatory elements to recapitulate POMC like expression in vivo are contained 
within this fragment. Since the RP24_340C3 BAC contained approximately 84kb of 5’ 
flanking sequence and approximately 70kb of 3’ flanking sequence it can be concluded that it 
too contains all the POMC regulatory elements needed to drive accurate POMC like 
expression in vivo.  
 
 
3.4.2 Antisense 
I chose to use antisense technology to reduce CART peptide concentration in the ARC as it is 
a technique which has been successfully used previously in the central nervous system 
(CNS). In addition, antisense offers a high level of control over the expression of endogenous 
genes relative to other techniques such as RNA interference (RNAi). The use of RNAi to 
study gene function has many advantages since gene silencing is directed using a 21-23 
nucleotide fragment that is homologous to the target gene. This allows for almost any gene to 
be targeted. In addition, the generation of the desired nucleotide fragment is less time 
consuming than other transgenic methods such as BAC transgenesis. However, the main 
disadvantage with using RNAi is that it requires the ubiquitous RNA polymerase 3 promoter 
which restricts the level of tissue specificity that can be obtained using this method. 
Furthermore, the use of RNAi has been associated with stimulation of the immune response 
in cells via the interferon pathway which could potentially complicate the interpretation of 
any resulting phenotype as the activation of cytokine pathways have been demonstrated to 
alter food intake (Buchanan, 2007). Cre/Lox technology is another method that can be used to 
target the knockdown of a specific gene, it can also be used to target a specific tissue, but 
there is greater complexity involved in such undertaking, for example two transgenic mouse 
lines need to be maintained and interbred. One transgenic line must be generated that 
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contains the target gene flanked by loxP sequences; this is achieved by modifying ES cells 
which is technically difficult and expensive due to the requirement of growth factors such as 
fibroblast growth factor to maintain the cells in pluripotency (Johnson et al., 2008). A second 
line must contain Cre recombinase under the control of a tissue specific promoter; this line is 
generated by pronuclear injection. Tissue specific deletion of the gene of interest only occurs 
when these lines are crossed. Cre can be expressed in most cell types making it a broadly 
applicable technique. In addition, if cre/lox is used to produce a mouse with the targeted 
deletion of a gene then the gene function will be lost in 70-80% of cells whereas antisense 
will reduce gene expression by a maximum of 50% in all cells. Therefore overall there is 
probably a greater reduction in gene function using cre/lox compared with antisense. 
However, this method is both time consuming and expensive due to the generation and 
maintenance of several transgenic lines.  
 
 
3.4.3 Designing the Modification Cassette 
The CART-AS modification cassette was designed to incorporate features that have been 
shown to be advantageous for homologous recombination efficiency. Homology regions of 
42bp have been shown to be effective for recombination, however homology arms of a larger 
size have been shown to improve recombination efficiency (Zhang et al., 1998). The 
homology arms used in the modification of the POMC gene were designed to be 300-400bp 
since this length of homology arm has been successfully used in previous BAC transgenesis 
studies conducted within the Department of Investigative Medicine (Bewick, 2005). An 
additional consideration when designing the modification cassette is the distance between the 
two homology arms, this distance should be kept to a minimum to avoid the potential loss of 
endogenous regulatory sequences which may result in inaccurate POMC like transgene 
expression. Importantly, a distance of less than 7bp separating the homology arms has been 
shown to reduce recombination efficiency. The distance between the two homology arms in 
the POMC gene was 3.3kb. 
 
The POMC gene is composed of three exons and the homology arms were designed so that 
homology arm 1 was homologous to the untranslated sequence at the 5’ end of exon one and 
homology arm 2 was designed so that it was homologous to the 3’ end of exon two. This will 
result in a recombination event that removes the POMC sequence between the homology 
arms and inserts the modification cassette. As a result of insertion of the modification cassette 
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at this site the remaining POMC sequence was maintained, this included the intron sequence 
following exon two and also exon three. The inclusion of the intron sequence is important as 
this has been shown to improve transcription efficiency, although the mechanism by which 
this is achieved is unclear (Brinster et al., 1988; Choi et al., 1991).  
 
The BGH polyadenylation signal was cloned downstream of the CART-AS fragment using 
SacI and NotI restriction enzymes. The inclusion of a polyadenylation signal has been shown 
to increase transcription efficiency and ensures that mature transcription will terminate after 
the antisense sequence (Zhang et al., 1998; Ribeiro et al., 2004). Termination of transcription 
after the antisense fragment prevents the endogenous POMC sequence being included in the 
CART-AS mRNA transcript. The presence of additional sequences other than that required 
for antisense action may have the result of reducing the binding efficiency of the antisense to 
its target sense strand.  
 
 
3.4.4 Production of Transgenic Mice 
The number of transgenic mice arising from each set of pronuclear injection can vary 
significantly as the insertion of the transgene is a random integration event. The DNA was 
purified and diluted to a concentration of 1ng/µl in order to reduce toxicity and it is also the 
optimum concentration for transgene integration.  
 
Typically between 5-30 % of the founder (F0) generation arising from pronuclear injection 
are transgenic, although it is not unexpected to observe integration rates outside of this range. 
Pronuclear injection of the CART-AS construct resulted in six out of twenty mice possessing 
the transgene; CART-AS 3A, CART-AS 4A, CART-AS 5A, CART-AS 6A, CART-AS 13A, 
CART-AS 18A, representing an integration rate of 30%. These founder mice were then 
mated with wildtype c57BL/6J mice to initiate separate transgenic colonies. The F1 
generation resulting from mating of the founder mice resulted in offspring in the following 
ratios; Line CART-AS 13A produced male and female transgenic offspring with an overall 
transgene integration ratio of 48% calculated over 14 litters. This consisted of 41% transgenic 
male mice and 30% transgenic female mice. The proportion of offspring possessing the 
transgene would be expected to fall in the range dictated by Mendelian inheritance which is 
25%. However, rates much higher than this were observed in the CART-AS 13A line which 
may be a result of the transgene conferring a selective advantage over wildtype litter mates, 
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alternatively the modified BAC may have incorporated at more than one site in the genome 
of the founder mouse. Importantly, the numbers of litters used to calculate transgene 
transmission are low and if the same calculation was performed including many more 
generations the rate of transgene transmission would be expected to be closer to that dictated 
by Mendelian inheritance. 
 
The founder line CART-AS 5A produced transgenic offspring but these did not exhibit any 
significant phenotype differences relative to their wildtype litter mates which may be caused 
by position effects leading to the silencing of transgene expression, although any position 
effect should be reduced by using BAC transgenesis. Alternatively the lack of an observable 
phenotype may be a result of a low copy number of the BAC integrating into the genome of 
the founder mouse, as a consequence the level of CART-AS expression may not have been 
high enough to produce a phenotype. The founder line CART-AS 3A produced transgenic 
offspring in the ratio of 25% in the first litter, but failed to produce subsequent transgene 
containing offspring, this is most likely to be the result of mosaic transgene integration where 
the transgene integrates late in embryonic development and consequently is only present in a 
subset of cells. Lines CART-AS 18A, CART-AS 6A and CART-AS 4A did not produce 
transgene containing litters suggesting the transgene failed to integrate into the germline. This 
is not uncommon and is a result of transgene integration into the host genome after several 
cycles of cell division meaning the transgene is expressed in a subset of cells of the founder 
mouse, but not in the germline of the founder mouse so is not transmitted to subsequent 
generations.  
 
 
3.4.5 Characterisation of Mice Expressing Arcuate Nucleus Cocaine- and Amphetamine 
-Regulated Transcript Antisense  
Mice expressing ARC CART-AS from line CART-AS 13A were studied for possible 
differences in phenotype relative to wildtype litter mates.  
 
 
3.4.5.1 Tissue Characterisation 
CART peptide was measured in tissue biopsies of specific hypothalamic nuclei namely the 
ARC/VMN and the PVN. The male mouse brains were removed as described in section 3.2.8 
at 8 weeks of age and the concentration of CART peptide measured by RIA. There was no 
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significant difference in the concentration of CART peptide in ARC/VMN tissue biopsies 
between the transgenic and wildtype mice. However, there was a trend for CART peptide 
concentration to be lower in the transgenic mice relative to control mice in biopsies from the 
PVN, but did not reach significance (P = 0.07 as measured by unpaired Students t-test).  
 
A potential explanation for the reduction in CART peptide concentration in the PVN, but not 
in the ARC tissue biopsies, may be due to the spatial difference in the site of synthesis and 
storage of CART neuropeptide within the POMC neurone since limited CART expression has  
been identified in the VMN. The cell body of the POMC neurones is found in the ARC and is 
the site at which the CART peptide is synthesised. However, the CART peptide is stored at 
the synaptic button of the POMC neurones. The synaptic button of POMC neurones are 
found at sites within the CNS that POMC neurones terminate in, this includes the PVN, 
lateral hypothalamus (LH) and dorsal medial nucleus (DMN) (Elmquist et al., 1998; Elmquist 
et al., 1999). Therefore, in mice expressing the CART-AS transgene it is not surprising to 
observe a larger reduction in CART peptide concentration at the site of the synaptic button of 
POMC neurones where the CART peptide is most abundant and this may explain why a 
greater reduction in CART peptide concentration was observed in tissue biopsies from the 
PVN compared with the ARC/VMN. Therefore, it would be interesting to investigate the 
concentration of CART peptide in tissue biopsies from the LH and DMN to establish if 
CART peptide concentration is reduced at these sites.  
 
 
3.4.5.2 Food Intake and Body Weight 
Food intake and body weight were measured in male mice over a 27 week period following 
weaning. The results show a significant increase in the body weight of male mice expressing 
CART-AS. However, the increase in body weight was not due to an increase in food 
consumption as there were no differences in cumulative food intake between control and 
transgenic animals.  
 
Previous studies have suggested that CART acts as an orexigenic agent since study 
paradigms which chronically increase CART peptide in the ARC result in increased food 
intake and body weight (Abbott et al., 2001; Kong et al., 2003). The studies conducted by 
Kong et al and Abbot et al investigated the effect of an increase in ARC CART peptide 
concentration using intra-nuclear injection and polyethylenimine (PEI) gene delivery of a 
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CART expressing plasmid. Both of these techniques cause a local increase in CART peptide 
and consequently will only affect neurones within the ARC. As a result of direct injection of 
CART peptide into the ARC non-CART producing neurones which express the CART 
receptor will be activated. In addition, CART neurones may potentially be affected through 
activation of auto-receptors expressed on the CART expressing neurones. The use of gene 
delivery within the CNS has been found to mainly affect inter-neurones within the nuclei 
targeted (private communication Dr J. Gardiner). This approach will be likely to increase 
CART release specifically in the targeted nucleus. This is in contrast to the transgenic 
approach I have used. A reduction in CART expression in POMC neurones will affect CART 
release from all POMC projections which includes the ARC but also projections to other 
hypothalamic nuclei. For example, I found a reduction in CART peptide concentration in the 
PVN (see section 3.3.5). The different paradigms used between my studies and those by 
Kong et al and Abbot et al may account for the difference in phenotype reported.  
 
Conversely, transgenic studies have been reported which support my findings of CART 
having an anorectic role in energy homeostasis. Two models of mice with a targeted deletion 
of the CART gene have been generated. In the model generated by Wierup et al mice 
deficient in CART peptide exhibited increased body weight with no significant difference in 
food intake (Wierup et al., 2005). The phenotype of mice generated by Wierup at al which 
had a targeted deletion of CART the gene is in agreement with the phenotype demonstrated 
by mice expressing the CART-AS transgene. A second model was generated by Asnicar et al 
in which the CART deficient mice exhibited increased body weight and food intake when 
maintained on a high fat diet (Asnicar et al., 2001). My data suggests a decrease in CART 
peptide in POMC neurones does not alter food intake in transgenic mice maintained on a diet 
of regular chow. However, a difference in food intake may have presented if the mice were 
fed a high fat diet. A potential explanation for the different food intake between the Asnicar 
et al model and my CART-AS model could be due to the extent to which CART peptide 
concentration was reduced. The phenotype of CART-AS transgenic mice is attributed solely 
to the reduction of CART peptide concentration in POMC neurones. The phenotype of the 
CART knockout mouse is a result of loss of CART gene function throughout the whole 
organism which may affect other sites within the CNS to cause an increase in food intake.  
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3.4.5.3 Energy Expenditure 
BAT was dissected and UCP-1 mRNA measured by northern blot analysis in male mice at 32 
weeks of age. UCP-1 is a surrogate marker for thermogenesis (Margareto et al., 2001). UCP-
1 is found in the inner mitochondrial membrane where it allows electrons to flow back across 
the mitochondrial membrane, bypassing ATP synthase, resulting in the dissipation of the 
energy stored in the electrochemical gradient as heat (Nicholls and Locke, 1984). Northern 
blot analysis demonstrated a significant decrease in UCP-1 mRNA expression in transgenic 
male mice. Therefore the resulting reduction in thermogenesis may account for the observed 
increase in body weight in CART-AS expressing mice given that they did not exhibit an 
increase in food intake. The data presented in this chapter suggests that the reduction in UCP-
1 mRNA is a result of reduced CART peptide expression in POMC neurones which project to 
the PVN. This hypothesis is supported by previous studies which have demonstrated that 
CART administration into the PVN leads to an increase in UCP-1 mRNA through stimulation 
of sympathetic outflow (Wang et al., 2000).  
 
A potential mechanism by which the CART peptide in POMC neurones may affect energy 
expenditure could be through modulation of thyrotropin releasing hormone (TRH) release. 
The PVN is the site of TRH expressing neurones and the main role for TRH is to stimulate 
the release of thyroid stimulating hormone (TSH) from the anterior pituitary gland. TSH 
stimulates the synthesis and release of thyroxine (T4) and tri-iodothyronine (T3) from the 
thyroid gland (Mittler et al). Thyroid function has been linked with energy expenditure since 
decreased thyroid function in humans is associated with decreased metabolic rate and 
increased obesity. It would be interesting to investigate whether a reduction in CART peptide 
in POMC neurones at the PVN is involved in modulating TRH release and subsequently 
UCP-1 mRNA expression and thyroid function. Current evidence suggests a role for CART 
in the regulation of TRH. Triple labelling fluorescent in situ hybridisation and 
immunofluorescence studies demonstrate that CART neurones which also stain positive for 
POMC, are in contact with TRH neurones in the PVN, suggesting a physical link between 
CART and TRH neurones (Fekete et al., 2000). Pharmacological evidence suggests a link 
between CART and TRH release since ICV administration of CART suppresses a fasting 
induced decrease in TRH in the PVN which suggests that CART acts to stimulate the release 
of TRH (Fekete et al., 2000). Furthermore, the administration of CART peptide to 
hypothalamic explants has been shown to increase TRH release, confirming a functional role 
for CART in the control of TRH release (Fekete et al., 2000). It would be interesting to 
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investigate proTRH mRNA expression, TSH release and the concentration of thyroid 
hormone in the CART-AS transgenic mice to establish the potential for CART to regulate 
energy expenditure through modulation of TRH release and UCP-1 mRNA expression. In 
addition, it would also be important to study energy expenditure via indirect calorimetry to 
investigate whether a reduction in activity levels in mice expressing the CART-AS transgene 
may account for the observed increase in body weight.   
 
In summary, male mice expressing CART-AS specifically in POMC neurones exhibited 
increased body weight relative to control animals without a significant difference in food 
intake. A reduction in ARC CART peptide was not demonstrated, but a trend towards 
reduced CART peptide in the PVN was observed and may account for the reduction in 
energy expenditure and the resulting increase in weight gain detected in the transgenic mice. 
These data suggest CART peptide in POMC neurones may be a more important regulator of 
energy expenditure than food intake, at least in male mice.  
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Nucleus CART Using rAAV 
Expressing CART Antisense 
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4. Manipulation of Arcuate Nucleus Cocaine- and Amphetamine -Regulated Transcript 
using Recombinant AAV Expressing Cocaine- and Amphetamine -Regulated 
Transcript Antisense 
 
4.1 Introduction 
Studies in the previous chapter demonstrated how gene expression can be altered in mice 
using bacterial artificial chromosome (BAC) transgenesis. The application of BAC 
transgenesis allowed CART-AS expression to be targeted to pro-opiomelanocortin (POMC) 
expressing cells, resulting in a reduction in cocaine- and amphetamine -regulated transcript 
(CART) peptide concentration. However, within the arcuate nucleus (ARC) CART is not 
solely coexpressed in POMC neurones, CART is also colocalised with dynorphin (Elias et al., 
2001). The use of recombinant adeno-associated virus (rAAV) addresses some of the 
questions that are unanswered by BAC transgenesis. rAAV expressing CART antisense 
(CART-AS) will reduce CART peptide expression in all CART expressing neurones rather 
than exclusively in POMC cells. The main advantage of using rAAV is the temporal control 
of transgene expression since it can be administered at different stages in the animal life 
cycle. This avoids the potential for developmental compensation which can mask the true role 
of a gene and is a potential confounding factor for germline modification of the genome. This 
chapter demonstrates how rAAV expressing CART-AS can be used to reduce endogenous 
CART peptide concentration in the rat ARC.  
 
 
4.2 Gene Transfer and Expression Methods 
The transfer of foreign DNA into cells can be achieved by employing the use of a viral 
vector. The choice of vector to use will depend on such factors as the target tissue and the 
length of time transgene expression is required. 
 
 
4.2.1 Viral Gene Delivery Vectors 
Viral gene delivery vectors have been the method of choice for many in vivo gene transfer 
studies as there are established delivery methods and they can produce long term transgene 
expression. 
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4.2.1.1 Herpes Simplex Virus 
Herpes simplex virus (HSV) was the first virus to be used in gene transfer studies. HSV has a 
double stranded (ds) DNA genome which is 150kb long. The virus is rendered replication 
defective by mutation of immediate early (IE) genes which are required for viral packaging 
and replication. The main disadvantages of using HSV in gene transfer are the difficulties in 
maintaining long term gene expression due to cellular toxicity of the virus and the low 
efficiency of transfection relative to other viral vectors (Neve and Geller, 1995). Furthermore 
a major factor for consideration is the containment level required for use in the laboratory 
since it is pathogenic.  
 
 
4.2.1.2 Lentivirus 
Lentivirus belongs to the retrovirus family with the first lentiviral gene transfer vectors being 
derived from human immunodeficiency virus (HIV) (Miller, 1993). Lentiviruses possess the 
gag, pol and env genes that are common to all retroviruses which code for structural proteins, 
viral enzymes such as reverse transcriptase and envelope glycoproteins which are flanked by 
long terminal repeat elements (LTR) (Miller, 1993). For use as a gene transfer agent the 
lentivirus is rendered replication defective by the deletion of the gag, pol and env genes, 
generating a cloning site of approximately 8kb. Once the lentivirus has entered the cell the 
virus faithfully integrates the sequence flanked by the LTR elements into the host genome, 
this is true in both dividing and non dividing cells (Naldini et al., 1996). Integration of the 
transgene into the host cell genome allows for long term gene expression, making it an 
attractive vector for use in gene transfer studies. The main disadvantage associated with using 
lentivirus in gene transfer is one of safety. When manufacturing a replication deficient 
lentiviral vector there is the potential for recombination between the replication defective 
plasmid and the packaging vector resulting in a replication active virus. As a result, use of 
lentivirus in gene transfer requires a higher laboratory containment level than that needed for 
other viral vectors. The ability of a laboratory to meet the necessary containment level is not 
always practical or desirable, especially as alternative viral vectors are available.  
 
 
4.2.1.3 Adenovirus 
Adenovirus (Ad) consists of a linear dsDNA genome of approximately 36kb encased in an 
icosahedral capsid. The Ad genome contains four early genes (E1-E4) that are expressed after 
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infection which are involved in regulating viral and cellular gene expression, viral replication 
and inhibition of cellular apoptosis. For use in gene transfer Ad is rendered replication 
defective by deletion of the E1 and E3 genes which provides a cloning site of approximately 
8kb. The E1 region contains genes that encode proteins necessary for the expression of genes 
E2-E4. Replication defective virions are produced in cell culture using a cell line that 
provides the necessary E1 peptides in trans such as the human embryonic kidney (HEK) 293 
cell line (Graham et al., 1977).  Ad are useful in gene delivery studies as they can infect 
dividing as well as non dividing cells (Wilson, 1996), however, there are disadvantages 
associated with using the Ad viral vector. Ad does not integrate into the host genome and 
provokes an immune response due to Ad viral genes also being transcribed by the host cell. 
This restricts the potential for long term transgene expression in vivo from a period of weeks 
to months (Ehrengruber, 2001; Slack and Miller, 1996; Yang et al., 1996). Ad has also been 
shown to be toxic at high titres and infects glial cells preferentially to neuronal cells which 
limit its use in neuronal studies in the central nervous system (CNS).  Modified Ad with 
deletions in the E2-E4 genes have been manufactured in an attempt to reduce the immune 
effect of Ad (Gao et al., 1996). 
 
 
4.2.1.4 Adeno-associated Virus 
Adeno-associated virus (AAV) is a member of the dependovirus family. A helper virus, 
commonly adenovirus or herpes virus is required to produce lytic infection by AAV. Over 
one hundred AAV serotypes have been identified with AAV serotype 2 (AAV-2) being the 
most studied. AAV-2 has a 4.7 kb single stranded linear DNA genome. It has been shown to 
preferentially infect neuronal cells rather than glial cells making it an attractive vector for use 
in neuronal gene transfer studies in the CNS (Bartlett et al., 1998). The AAV genome consists 
of two open reading frames (ORF) which are flanked by 145bp inverted terminal repeats 
(ITR). The left ORF contains the rep (replication) gene which produces four proteins Rep78, 
68, 52 and 40. These genes are required for DNA replication and regulate gene expression in 
the presence and absence of a helper virus (Pereira et al., 1997). The rep proteins are also 
thought to direct integration of viral DNA at chromosome 19 on the human genome. This is 
thought to be possible due to a short sequence on human chromosome 19 being homologous 
to the rep protein binding sequence on the ITR. The right ORF contains the cap (capsid) gene 
which produces viral capsid proteins VP1, VP2 and VP3.  
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The viral particle enters the cell via binding to a receptor, in the case of AAV-2 this has been 
identified as the heparin sulphate proteoglycan receptor (Summerford & Samulski, 1998). 
Once the virus has entered the cell it translocates to the nucleus, uncoats and releases its viral 
DNA. Upon infection of the host cell by AAV the virus can integrate into the genome in a 
latent state or a productive state. For AAV to enter the productive life cycle a helper virus is 
required. If the helper virus is not present a latent infection occurs (Laughlin et al., 1986).  
 
 
4.2.1.4.1 Recombinant Adeno-associated Virus 
rAAV is adapted from AAV. To generate a virus suitable for use in gene transfer the majority 
of the endogenous viral genome is removed including the rep and cap genes, rendering the 
virus replication defective and creating a cloning site of approximately 4.5kb. The ITRs 
remain in place as they are needed for packaging and integration of the transgene into the 
host genome. Additional elements are also required to produce efficient transgene expression. 
These elements include a strong promoter to drive transgene expression, one example is the 
constitutively active cytomegalovirus (CMV) promoter. The woodchuck hepatitis virus 
posttranscriptional regulatory element (WPRE) and bovine growth hormone (BGH) 
polyadenylation sequence are also required to drive transgene expression as they have been 
shown to enhance transgene expression in vivo (Azzoni et al., 2007; Ribeiro et al., 2004; Xu 
et al., 2003). These elements are flanked by the ITRs. Vectors are available which contain the 
ITRs and the additional elements needed for efficient transgene expression. One such plasmid 
that has been widely used within the Department of Investigative Medicine is the pTRCGW 
plasmid (Figure 4.1). The first stage of rAAV preparation is to modify the pTRCGW plasmid 
by subcloning the transgene of interest into the vector, downstream of the CMV promoter. 
This is achieved using standard molecular biology techniques; PCR, restriction digests, 
ligation and transformation. The modified vector is then transfected into HEK 293 cells. A 
helper plasmid is also transfected. The helper plasmid encodes the adenoviral helper genes, 
E2A and E4, in addition to the genes necessary for viral amplification and packaging; the rep 
and cap genes. The lack of sequence homology between the plasmid containing the 
modification cassette and the helper plasmid means that homologous recombination between 
the two plasmids is not possible. Following viral replication and packaging the HEK cells are 
lysed and the recombinant virus is isolated and purified.  
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4.2.1.4.2 Using Recombinant AAV to Study the Physiological Role of Cocaine- and 
Amphetamine -Regulated Transcript Peptide in the Arcuate Nucleus 
AAV has many advantages over other viruses for gene transfer. It is the safest viral vector in 
terms of pathogenicity in humans thus requiring a lower level of containment for use in the 
laboratory. In addition rAAV does not stimulate an immune response when administered in 
vivo (Ehrengruber, 2001). Further to this different serotypes of AAV have been shown to 
have specificity for certain tissues. The rAAV serotype 2 has been shown to preferentially 
infect neuronal cells making it ideal for use in neuronal studies in the brain (Kaplitt, 1994; 
Peel, 2000). In addition, the use of rAAV is associated with high levels of stable gene 
expression. Injection of β-galactosidase expressing rAAV into muscle resulted in β-
galactosidase positive-staining muscle fibres for up to 2 years (Fisher, 1997). The potential 
for maintenance of long term transgene expression, the lack of immune response associated 
with administration of rAAV and the availability of serotypes which preferentially infect 
neuronal cells make it the vector of choice for studying the physiological effect of CART-AS 
expression in the ARC. 
 
 
4.2.1.4.3 Advantages and Disadvantages of using Recombinant AAV and Bacterial 
Artificial Chromosome Transgenesis 
BAC transgenesis utilises whole expression domains to drive transgene expression. In the 
previous chapter a POMC BAC was modified to drive expression of CART-AS which allows 
for transgene expression to be specifically targeted to cells which express POMC, for 
example the POMC/CART neurones in the ARC. BAC transgenesis can allow for gene 
dosage studies to be conducted in order to investigate the effect of different levels of 
transgene expression. This is possible because the number of modified BACs which integrate 
into the germline may vary between each founder mouse (see section 3.1.2). However, there 
are disadvantages to using BAC transgenesis. Germline manipulation has the potential for 
developmental compensation which can result in a lack of phenotype. In addition, it is a time 
consuming and expensive process to generate the modified BAC and maintain several lines 
of transgenic mice.  
 
There are several advantages to using rAAV to study gene function. rAAV allows for 
temporal control of transgene expression since it can be administered at various stages in the 
life cycle of the animal. This reduces the chance of developmental compensation. Although if 
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rAAV is administered early in the life cycle a degree of developmental compensation can 
occur due to the plastic nature of synaptic connections (Bouret et al., 2004). rAAV is 
normally delivered directly to the target site, especially in studies involving the CNS, which 
offers a degree of spatial control of transgene expression. There are disadvantages to using 
rAAV. Administration of rAAV deep within the hypothalamus requires the use of an injector 
which may damage areas that it passes through. In addition, there is an inherent degree of 
variability associated with administration of rAAV in terms of the exact site of injection in 
each animal and the number and type of neurones that are infected by the virus.  
 
In summary, BAC transgenesis is useful for targeting transgene expression to a specific 
neuronal population throughout development, for example the effect of CART-AS in the 
POMC neurone. Gene dosage studies can also be used to establish the effect of differing 
levels of transgene expression. The use of rAAV allows for the temporal control of transgene 
expression at a specific target site, such as the ARC. Therefore to establish the physiological 
role for CART both approaches can be used as they address different questions which when 
analysed together can offer a physiological overview of the role of the CART peptide in the 
ARC.  
 
 
 
4.3 AIMS: 
1) To test the ability of a CART-AS plasmid to reduce CART peptide levels in a CART 
producing cell line in vitro.  
 
 
2) To use the subsequent plasmid to produce rAAV expressing CART antisense RNA.  
 
3) To use rAAV-CART-AS to investigate the physiological effect of chronic down 
regulation of CART signalling in the ARC on energy homeostasis.  
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4.4 Materials and Methods 
 
4.4.1 Modification of the pTRCGW Plasmid 
The pTRCGW plasmid was selected for modification with the appropriate transgene as it 
contains the CMV promoter, WPRE and the ITRs necessary to produce efficient transgene 
expression by rAAV in vivo. The first stage in modification of the pTRCGW plasmid (a gift 
from Professor J. Verhaagen, The Netherlands Brain Institute, Amsterdam) was to generate 
CART-AS cDNA. Using rat total hypothalami RNA CART-AS cDNA fragments were 
amplified by RT-PCR (see section 2.2.4) using the CART primer set detailed in Table 4.1. 
The primer set was designed to amplify full length CART. Due to alternate splicing of the 
CART mRNA transcript the PCR will produce two fragments of 721bp and 760bp (accession 
number NM_0171101) 
 
   
Primer Name Primer Sequence  Restriction 
Site 
5’CARTAS AGC-TTG-TAC-AAG-CGA-GGA-AGT-CCA-GCA-CCA BsrGI 
3’CARTAS AGC-TGG-ATC-CCG-GGT-TAT-GAT-GTC-ATC-TGC BamHI 
 
Table 4.1. Primers for PCR amplification of CART-AS for use in rAAV. The highlighted 
sequence details the restriction site associated with the particular primer.  The 5’ primer 
corresponds to nucleotides 1-20, and the 3’ primer corresponds to nucleotides 741-760 in the 
rat CART prepropeptide mRNA (accession number NM_0171101). 
 
 
 
The 721bp PCR product was subcloned (see section 2.2.7) in to the pTRCGW plasmid 
(Figure 4.1). The first step in subcloning was to cut the CART-AS PCR product and the 
pTRCGW plasmid using the restriction enzymes BamHI and BsrGI. The use of the restriction 
enzymes BamHI and BsrGI linearises the pTRCGW plasmid and removes the green 
fluorescent protein (GFP) gene. The products from the restriction digest were run on a 1% 
(w/v) agarose gel (see section 2.2.6). The linearised plasmid and the cut CART-AS cDNA 
fragment were excised from the gel and electroeluted (see section 2.2.7.2). The cDNA 
fragment was subcloned (see section 2.2.7) into the linearised plasmid by ligation reaction 
which results in the modified pTRCCART-AS plasmid. The ligated plasmid was then 
transformed into competent bacteria (see section 2.2.8.1) 
 
  
 
 
Figure 4.1 pTRCGW Plasmid
repeats. CMVprom, cytomeglavirus promoter. Gfp, Green fluorescent
woodchuck hepatitis virus posttranscriptional regulatory element. polyA, polyadenylation 
sequence. AmpR, ampicillin resistance
 
 
 
4.4.2 Transformation of Competent Bacteria
Methods for transformation of bacterial cells include incubation in divalent cations (see 
section 2.2.8.1) and electroporation. Electroporation involves exposing cells to an electric 
field, thus increasing the permeability of the cells. Pores are momentari
membrane which allows entry of DNA into the cell. JC8111 bacteria are used in the 
preparation of pTRCCART-AS plasmid since they lack recombination genes which means 
the ITRs are not removed by the bacteria. Since JC8111 cells are resi
by divalent cations, electroporation is used. 
. Map showing the plasmid pTRCGW. ITR, inverted terminal 
 protein gene. WPRE, 
 gene.  
 
ly formed in the cell 
stant to transformation 
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Materials 
Competent JC8111 bacteria (see section 2.2.8.2) 
5mg/ml Glycogen (Ambion, Warrington, UK)  
SOB (appendix I) 
Products from ligation (section 4.4.1) 
LB agar plate with ampicillin (see section 2.2.9) 
0.1cm electrode gap cuvette (BTX, San Diego, CA) 
 
Methods 
Ligated DNA from section 4.4.1 was precipitated at -20oC for one hour with 2.5 volumes 
absolute ethanol, 0.1 volumes 2M sodium acetate (NaAc) pH 5.2 (see section 2.2.2) and 1µl 
glycogen. An aliquot of frozen competent JC8111 bacteria (see section 2.2.8.2) was thawed 
on ice and then transferred into a 0.1cm electrode gap cuvette. Five microlitres of the 
resuspended ligation mix was added to the cuvette and this was electroporated. 
Electroporation conditions were: 1.8kV, 186Ω, 25F in 0.1cm electrode gap cuvette using an 
Electro Cell Manipulator 600 (BTX, CA).  Eight hundred microlitres of warmed SOB was 
added and the entire volume incubated at 37°C for an hour with shaking. An agar plate 
containing ampicillin was warmed and 200µl SOB containing the bacteria was then spread 
evenly across the surface and incubated overnight at 37°C. 
 
Twelve clones were selected and initially grown using small scale culture (see section 2.2.10) 
which allowed for the analysis of several clones simultaneously. The clones were subjected to 
restriction digest analysis using BamHI and BsrGI restriction enzymes (see section 2.2.7.1). 
One clone was selected which had been successfully transformed with the modified plasmid 
(pTRCCART-AS). The selected clone was grown using large scale amplification (see section 
2.2.11). 
 
 
4.4.3 Testing of Cocaine- and Amphetamine -Regulated Transcript Antisense Plasmid 
in vitro 
The pTRCCART-AS plasmid was initially tested in vitro to ensure that the CART-AS 
mRNA reduced CART peptide release.  RIN1056a CART cells were used in cell culture 
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experiments. RIN1056a CART cells are RIN1056a cells that have been transfected with the 
pcDNA3-CART plasmid and express full length CART (Kong et al., 2003).  
 
 
4.4.4 Tissue Culture 
 
Materials 
Dulbecco’s Modified Medium  (DMEM) (Gibco, Paisley, UK) 
2.5% (w/v) Trypsin (Invitrogen)  
Fetal Calf Serum (FCS) (Invitrogen) 
Versene (appendix I)   
 
Methods  
Cells were cultured in 75cm3 flasks (Nunc, Thermo Fisher Scientific, Denmark) with 10ml 
DMEM (Gibco, Paisley, UK) supplemented with 10% (v/v) FCS and 5% (v/v) penicillin and 
streptomycin.  The cells were incubated at 37°C in a 5% CO2 atmosphere.  Medium was 
changed every 2 to 3 days and the cells sub-cultured when 70-80% confluent using 0.25% 
(v/v) trypsin in versene. Briefly, the medium was aspirated from the flask and the cells 
washed with versene containing 0.25% (v/v) trypsin. This was aspirated and the cells 
incubated at room temperature with fresh versene/trypsin until they detached from the flask. 
The trypsin was inactivated by the addition of 10ml fresh medium and the cells recovered by 
centrifugation for 5 minutes at 100g at room temperature (Mistral 1000, MSE, UK). The cells 
were resuspended in fresh medium and transferred to new flasks at a dilution of 1:2.  
   
 
4.4.5 Polyethylenimine Transfection 
Polyethylenimine (PEI) has been used widely in vitro (Lungwitz et al., 2005; Neu, 2005) and 
the low cost associated with this method makes it an attractive method for gene transfer.  
However, the high charge density associated with high molecular weight PEI complexes 
results in toxicity to the cell, a major limitation for use in vivo (Godbey, 1999). 
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4.4.5.1 Polyethylenimine Preparation 
 
Materials 
Water free 25kDa PEI (Sigma-Aldrich) 
GDW 
1M HCl 
 
Methods 
To prepare 0.1M PEI, 450mg of high molecular weight, water free PEI was dissolved in 80ml 
GDW.  The solution was adjusted to pH7 with 1M HCl and the volume made up to 100ml 
using GDW. The PEI solution was then sterilised by passage through a 0.2µm filter.  
Prepared PEI was stored at room temperature for a maximum of 2 weeks. 
 
 
4.4.5.2 Optimisation of Transient Transfection using Polyethylenimine and β-
galactosidase 
To optimise the transfection procedure cells were transfected with the pCMVß plasmid 
(appendix 3). Successfully transfected cells appear blue when incubated in 5-bromo-4-chloro-
3-indolyl-galactopyranoside (X-gal) and can be visualised under a light microscope. The 
main factor which affects the efficiency of transfection using PEI is the ratio between the 
amount of DNA and PEI nitrogen equivalents. 
 
Materials 
1mg/ml pCMVß 
0.1M PEI (prepared as described in section 4.4.5.1) 
10% (w/v) glucose solution  
 
Methods 
Twenty four hours prior to transfection, RIN1056a CART cells were plated at a density of 
1x104 cells/cm onto poly-L-lysine coated six well plates (Nunc, Thermo Fisher Scientific, 
Denmark). Transfections were carried out when the cells were 60% confluent. To optimise 
the transfection process cells were transfected using 2µg of pCMVß plasmid DNA with 0, 3, 
6, 9, 12 or 15 nitrogen equivalents. This was then repeated using 4µg of pCMVß plasmid 
DNA. Plasmid DNA was prepared in 5% (w/v) glucose solution. Three wells were 
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transfected for each treatment. The 0.1M PEI solution at the appropriate ratio equivalents was 
slowly added to the DNA solution, vortexed for 30 seconds and allowed to stand at room 
temperature for 10 minutes before use. The amount of PEI required was calculated according 
to the ratio of PEI amine nitrogen equivalents to DNA phosphate where 1µl of 0.1M PEI = 
100nmol amine nitrogen and 10µg of DNA = 30nmol DNA phosphate. Cells were incubated 
at 37oC in a humid atmosphere containing 5% CO2. After three hours the medium containing 
the transfection mixture was removed and replaced with fresh medium. Forty eight hours post 
transfection the medium was removed and β-galactosidase gene expression analysed.   
 
 
4.4.5.3 β-Galactosidase Staining 
This method was used to visualise the cells transfected with pCMVß using PEI. 
 
Materials 
50 mg/ml X-gal solution (appendix I) 
0.1% (v/v) glutaraldehyde in 0.01M PBS (Sigma-Aldrich) 
0.01M Phosphate Buffered Saline (PBS) (Sigma-Aldrich) (appendix I) 
 
Methods 
Cells were washed twice with 0.01M PBS and then fixed in approximately 2ml 0.1% (v/v) 
glutaraldehyde for 10 minutes at room temperature.  Glutaraldehyde was removed and cells 
were washed twice in 0.01M PBS and incubated in the dark at room temperature in 
approximately 1ml of 0.4mg/ml X-gal in 0.01M PBS solution for 24 hours. Expression of ß-
galactosidase was indicated by the presence of an indigo blue colour on examination by light 
microscopy. 
 
 
4.4.6 Transient Transfection with pTRCCART-AS using Polyethylenimine 
Following optimisation of transient transfection using PEI, RIN1056a CART cells were 
transfected with 4µg pTRCCART-AS or pTRCGW (control cells) at 12 PEI nitrogen 
equivalents as described in section 4.4.5.2 (n= 6 wells). Two days following transfection the 
media was removed and fresh media added, the fresh media was collected and frozen at -
20oC until radioimmunoassay (RIA) (see section 2.2.12) for CART (55-102)-like 
immunoreactivity at 1, 4 and 6 hours was performed. 
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4.4.7 Stable Transfection with pTRCCART-AS using Polyethylenimine 
Stable transfection allows for selection of successfully transfected cells by cotransfecting the 
plasmid of interest with a plasmid which confers antibiotic resistance. Therefore, cells which 
express the transgene will survive in antibiotic containing medium. RIN1056a CART cells 
were transfected with pTRCCART-AS in combination with pcDNA3 (appendix 3) a plasmid 
containing a neomycin (Geneticin) resistance gene. Cells were cotransfected with two 
plasmids as integration usually occurs in tandem. To ensure the CART-AS plasmid was 
incorporated into selected cells pTRCCART-AS was added in excess to the neomycin 
resistance plasmid.  
 
Materials 
RIN1056a CART cells 
1mg/ml  pTRCCART-AS  
1.3 mg/ml pcDNA3   
DMEM (Gibco, Paisley, UK) 
50mg/ml Geneticin (Sigma-Aldrich) 
 
Methods 
RIN1056a CART cells were plated at a density of 1x104  cells/cm onto poly-L-lysine coated 
six well plates (Nunc, Thermo Fischer Scientific, Denmark). Transfections were carried out 
when the cells were 60% confluent. Cells were transfected with 10µg pTRCCART-AS and 
25ng pcDNA3 using PEI at 12 PEI nitrogen equivalents, as described in section 4.4.6. After 2 
days the medium was replaced with DMEM with the addition of 10ml geneticin per 500ml 
DMEM. Cells were maintained in this medium. RIN1056a CART cells that were stably 
transfected with the CART antisense plasmid are referred to as CART antisense CART 
(CAC) cells.  
 
 
4.4.7.1. Confirmation of pTRCCART-AS Plasmid in RIN1056a CART Cells following a 
Stable Transfection by Northern Blot Analysis 
To confirm the presence of pTRCCART-AS in the transfected cells northern blot analysis 
was performed. Two clones were selected (CACA and CACB) and cells from each clone 
were grown to 90% confluence and RNA extracted using tri reagent (see section 2.2.1) and 
the viability of the RNA was confirmed using a 1% denaturing formaldehyde gel (see section 
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2.2.2). A northern blot was then carried out to identify and quantify the RNA (see section 
2.2.3) using a WPRE DNA probe (see Table 4.2). A 310bp WPRE DNA probe (accession 
number J04514) was prepared using the primer set detailed in Table 4.2 (see section 2.2.3).  
 
 
Primer Primer Sequence Restriction 
Site 
WPRE 5’ AGC-TGG-ATC-CGC-TAT-GTG-GAT-ACG-CTG-CTT BamHI 
WPRE 3’ AGC-TGA-ATT-CGG-AAT-TGT-CAG-TGC-CCA-ACA EcoRI 
 
Table 4.2 Table detailing the primer sequence for the WPRE DNA probe. The highlighted 
sequence details the restriction site for the particular primer. The WPRE 5’ primer 
corresponds to nucleotides 1161-1180, and the WPRE 3’ primer corresponds to nucleotides 
1450-1471 in the woodchuck hepatitis B virus genome (accession number J04514). 
 
 
4.4.7.2 Measuring Cocaine- and Amphetamine -Regulated Transcript Expression in 
RIN1056a CART cells that have been transfected with pTRCCART-AS 
CART (55-102) –like immunoreactivity was measured in each clone. The clones CACA and 
CACB were plated onto 24 well plates (Nunc, Thermo Fischer Scientific, Denmark) and 
grown overnight to around 90% confluence. The media was removed and fresh media was 
added. The media was then removed after 1, 2, 4, 6 and 8 hours and stored at -20°C until 
radioimmunoassay for CART (55-102) -like immunoreactivity (see section  2.2.12) (n=6 well 
per time point were analysed).  
 
 
4.4.8  Production of Recombinant AAV 
AAV was produced by Dr. J. Gardiner (Department of Investigative Medicine) using the two 
plasmid system. Briefly, host cells (HEK293) are co-transfected with the rAAV plasmid 
(Figure 4.1) and a helper plasmid pDG (appendix 3) using calcium phosphate. There is no 
homology between the two plasmids so they cannot recombine and form a wild-type virus. 
This results in the production of rAAV particles. To release the particles cells are lysed by 
freeze thawing and the rAAV produced is purified. 
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4.4.8.1 Cell maintenance 
HEK 293 cells were maintained as described in section 4.4.4.  
 
 
4.4.8.2 Calcium Phosphate Transfection 
 
Materials 
HEK 293 cells 
1mg/ml  pTRCCART-AS   
1mg/ml pDG (appendix 3)  
10x HEBS buffer: 
1.36M NaCl 
 0.05M KCl 
 0.007M Na2HPO4.2H20 
 0.2M HEPES (appendix I) 
 0.125g glucose 
2M CaCl2 (appendix I) 
 
Methods 
HEK 293 cells were sub-cultured into a ten chamber cell factory (L x W x H (mm): 335 x 
205 x 190, culture area: 6867cm3) (Nunc, Thermo Fischer Scientific, Denmark) at 2.5x106 
cells per chamber and incubated in 2L of DMEM with 10% (v/v) FCS at 37oC in an 
atmosphere of 5% CO2. Twenty four hours later, when the cells were 50% confluent, the 
culture medium was replaced and the transfection was performed after a two hour incubation 
period at 37oC in an atmosphere of 5% CO2. The transfection mixture was prepared for the 
cell factory, it consisted of 560µg pTRCCART-AS and 1.68mg pDG, in 12 ml of 1xHEBS 
buffer in 52ml GDW. Immediately prior to transfection, 7.2ml 2M CaCl2 was added and 
mixed gently. The transfection mixture was allowed to stand for four minutes at room 
temperature
 
and added drop wise to the cell medium while gently swirling the cell factory. 
Cells were incubated for six hours at 37oC in 5% CO2 atmosphere.  
 
 
 
 
151 
 
4.4.8.3 Recovery and Purification of Recombinant AAV 
 
Materials 
0.01M PBS (appendix I) 
Sepharose Column (GE Healthcare, UK) 
1.32g/ml Iodixanol (Life Sciences Technology, Eggenstein, Germany)  
0.3x PBS/0.1M NaCl 
0.3x PBS/2mM EDTA 
2M MgCl2  
250U/µl  Benzonase (Novagen, Nottingham, UK) 
Lysis buffer (appendix I) 
 
Methods 
After 48 hours incubation, following transfection, cell medium was removed and cells were 
washed using 500ml PBS and then harvested using 500ml PBS/2mM EDTA, the remaining 
cells were removed using a further 500ml PBS/2mM EDTA. Cells were then centrifuged at 
5000g for 10 minutes at 4oC (HB-4 rotor in RC-5B super speed centrifuge, Du Pont) washed 
in a further 150ml PBS and then re-centrifuged at 5000g for 10 minutes at 4oC (HB-4 rotor in 
RC-5B super speed centrifuge, Du Pont ). Cells were then resuspended in a total of 60ml lysis 
buffer in 50ml falcon tubes (15mls in each falcon tube). Cells were exposed to 3 freeze thaw 
cycles which consisted of ten minutes in dry ice/ethanol bath followed by incubation in a 
37ºC waterbath for 10 minutes. 7.3µl 2M MgCl2 and 1.2µl Benzonase were then added to 
each falcon tube and incubated at 37ºC for 30 minutes. The cells were then centrifuged at 
2000g for 10 minutes at 4oC (Mistral 1000 rotor, MSE UK) to pellet cell debris. The 
supernatant was removed and loaded into four 50ml polyallomer tube (Beckmann, CA) and 
under layered with iodixanol gradient (15%, 25%, 40% and 60% iodixanol). The tubes were 
then topped up with lysis buffer, heat sealed and centrifuged at 69,000g for 1 hour at 18ºC 
(Type 70Ti rotor in a Sorvall SE100 centrifuge). To remove the rAAV particles the top of 
each tube was punctured with an 18G needle and rAAV collected by puncturing the tube, and 
collecting a 5ml fraction from the 60/40% interface of the iodixanol gradient. The fractions 
from the 4 tubes were pooled, added to 20ml PBS and loaded onto a Sepharose column (GE 
Healthcare, UK) (pre-washed with 25ml 0.1M NaCl/0.3x PBS and 50ml 0.3x PBS). rAAV 
was then washed with 50ml 0.3x PBS and eluted with 15ml 350mM NaCl/0.3xPBS. The 
elutant was transferred to an Apollo Concentrator (Orbital Biosciences, MA, USA) 
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containing 10ml PBS and centrifuged at 2000g for 5 minutes at room temperature (Mistral 
1000 rotor, MSE UK). The Apollo concentrator is an ultrafiltration device used for the 
concentration or purification of proteins. The flow through was discarded and a further 5ml 
PBS added below and 19.5ml PBS above the filter. The tube was then recentrifuged at 2000g 
for 5 minutes at room temperature (Mistral 1000 rotor, MSE UK) and the 0.5ml rAAV 
remaining in the filter was aliquoted into siliconized eppendorf tubes (Sigma-Aldrich).  The 
viral titre was quantified by dot blot analysis (section 4.4.8.4.) 
 
 
4.4.8.4 Determination of Total Viral Particle Titre by Dot Blot Analysis 
The level of transgene expression is affected by the rAAV titre so total viral particle number 
was determined by dot blot analysis. Dot blot analysis is based in similar principles to 
Southern blots; a specific probe can be used to quantify a specific DNA or RNA species in a 
sample. Rather than being separated by size and transferred to a membrane, the sample being 
analysed is placed directly onto a membrane. The DNA or RNA species present in the sample 
can be detected and quantified using radiolabelled probes.  
 
Materials 
rAAV viral preparation (section 4.4.8.3) 
50ng/µl  pTRCGW (for use as a standard) 
Solution A (appendix I) 
 10mM Tris/HCl pH8.0 
 10mM MgCl2 
 10µg/ml DNaseI  
Solution B (appendix I) 
 10mM Tris/HCl pH8.0 (appendix I) 
 100mM NaCl 
 10mM EDTA (appendix I) 
 0.5% (w/v) SDS 
 1mg/ml proteinase K 
Phenol/chloroform(appendix I) 
3M sodium acetate (appendix I) 
Absolute Ethanol 
5mg/ml  Glycogen (Ambion, Warrington, UK) 
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Denaturing solution (appendix I) 
Neutralising solution (appendix I)  
Hybridisation buffer (appendix I) 
Amasino wash buffer (appendix I) 
Universal wash buffer (appendix I) 
 
Methods 
Forty five microlitres of solution A was added to 5µl rAAV virus stock and incubated for 30 
minutes at 37ºC. Two hundred microlitres of solution B was added and incubated at 55oC for 
30 minutes before the DNA was extracted by adding an equal volume of phenol/chloroform 
(see section 2.2.7.1). Ethanol precipitation of the DNA was performed by adding 1/10 
volume NaAc, 40µg glycogen and 2.5 volumes ice cold ethanol. After 20 minutes at -70ºC 
the solution was centrifuged at 8000g at 4ºC (centrifuge 5417 C/R, Eppendorf, Hamburg, 
Germany), the supernatant removed, the pellet washed in 75% cold ethanol and air-dried. The 
pellet was resuspended in 10µl GDW and 1µl applied to a nylon membrane (Hybond-N). A 
series of dilutions of pTRCGW (50ng, 25ng, 10ng, 5ng, 2.5ng, 1ng, 0.5ng, 0.25ng and 0.1ng) 
were also applied to the membrane to act as a standard curve. The membrane was washed for 
5 minutes in denaturing solution, then washed twice for 5 minutes in neutralising solution. 
The membrane was then baked at 80ºC for 2 hours. The baked membrane was placed in a 
heat sealed polythene bag with 20ml of pre-hybridisation solution and incubated at 60oC for a 
minimum of two hours (see section 2.2.3.2). The WPRE probe (Table 4.2) was then prepared 
as described in section 2.2.3.3, boiled for five minutes and then added to the 20ml pre-
hybridisation buffer. Hybridisation was carried out overnight at 60ºC. The following day the 
membrane was washed as described in section 2.2.3. The membrane was then placed on a 
phosphorimager screen overnight. Radiolabelled areas were visualised and quantified by 
image densitometry using ImageQuant software (Molecular Dynamics). Quantification was 
performed by comparing viral DNA to known amounts of pTRCGW in the standard curve.   
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4.4.9 Recombinant AAV Mediated Transfer of Cocaine- and Amphetamine -Regulated 
Transcript Antisense in the Arcuate Nucleus 
 
4.4.9.1 Animals 
Adult male Wistar rats (Charles River, Bicester, UK) were maintained in individual cages 
under controlled temperature (21-23oC) and light (12 hours light, 12 hours dark) with ad 
libitum access to food and water. All animal procedures were approved under the Animal 
Scientific Procedures Act 1986. For all studies rats were randomised into groups of equal 
mean body-weight (within 2g). Body-weight and food intake were measured at least three 
times per week. Food was weighed on balances accurate to 0.01g (Adam Equipment, Milton 
Keynes, UK). Animals which were considered unwell were excluded from studies 
 
 
4.4.9.2 Intra-nuclear Injection of Recombinant AAV 
Animal were anaesthetised by intraperitoneal (i.p.) injection of xylazine (Rompun 12mg/kg, 
Bayer UK Ltd, Bury St Edmonds, UK) and ketamine (Ketalar 60mg/kg, Parke-Davis, 
Pontypool, UK) in a 2:5 ratio. Prophylactic antibiotics were administered to prevent post-
operative infection, an intraperitoneal injection of amoxicillin sodium (Amoxil, 37.5mg/kg) 
and flucloxacillin (37.5mg/kg) was given prior to surgery. Animals were then placed in a 
Kopf stereotaxic frame (David Kopf instruments, supplied by Clark Electromedical 
Instruments, Kent, UK) with the incisor bar set at 3mm below the interaural line. The head 
was cleaned with 10% (w/v) povidone/iodine solution (Betadine, Seton Scholl Healthcare, 
UK). A 1.5cm incision was made in the scalp and the skull surface exposed by removal of the 
periosteum. A hole was drilled using a stereotactic electric drill (David Kopf Instruments). In 
order for rAAV to be injected bilaterally, two holes were drilled, one each side of the bregma 
according to the co-ordinates of Paxinos and Watson (Paxinos and Watson, 1998) as shown 
in Table 4.3. 
 
 
 
 
 
Table 4.3 Table showing the co-ordinates for intra-nuclear injections into the rat arcuate 
nucleus. 
 Posterior/Anterior 
from bregma 
Lateral 
from bregma 
Cannula length 
Arc 
 
-3.8mm ± 0.5mm 9.5mm 
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A 26-gauge stainless steel cannula (Plastic One inc.) was lowered into the hypothalamus. The 
33-gauge stainless steel injector (Plastic One inc.) was connected by polythene tubing (inner 
diameter 0.5mm, outer diameter 1mm) to a Hamilton syringe (Fisher Scientific, 
Leicestershire, UK) in a Harvard infusion pump (Harvard Apparatus, Massachusetts, USA). 
The tubing was filled with water and an air bubble drawn up to separate the experimental 
compound from the water. Injection of rAAV was carried out while the animals remained 
anaesthetised, at a rate of 12µl per hour, until 1µl rAAV-CART-AS (11.8ng) (n=23) or 
rAAV-eGFP (n=18) had been injected, via a stainless steel injector projecting 1mm beyond 
the tip of the cannula. Following injection of the appropriate volume the injector was left in 
place for 5 minutes before removal. The cannula was removed and used to guide the second 
injection for bilateral injection. The rats were rehydrated by an i.p. injection of 0.9% sodium 
chloride (5ml/rat). Animals received a single subcutaneous injection of buprenophrine 
(45mg/kg, Schering-Plough Corp, Welwyn Garden City, UK) for analgesia post-operatively. 
The incision was closed with Ethilon 5.0 sutures (Johnson and Johnson, Livingston, UK) 
which were removed after 5 to 7 days.   Following injection, animals were returned to their 
home cages with a pre-weighed amount of chow.   
 
 
4.4.9.3 Confirmation of Transgene Expression by In situ Hybridisation 
Transgene expression was investigated in male Wistar rats injected bilaterally into the ARC 
with rAAV-CART-AS (n=3) or rAAV-eGFP (n=2). Brains were removed  and in situ 
hybridisation (see section 2.2.13.2) performed using a 35S labelled 248bp CART riboprobe 
which was generated using the primer set detailed in Table 4.4 (accession number 
NM_017110).  Transgene expression was investigated in animals 26 days post-injection. In 
the remaining animals, food intake and body weight were measured with transgene 
expression being investigated at the end of the study, 130 days post-injection.  
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Primer Primer Sequence Restriction 
site 
CART5’ AGC-TGA-ATT-CCA-TGT-GTG-ACG-CTG-GAG-AGC EcoRI 
CART3’ AGC-TGG-ATC-CTG-AAG-CAG-CAG-GGA-AAG-AGC BamHI 
 
Table 4.4 Table detailing the primer sequence used to generate the CART riboprobe. The 
highlighted sequence details the restriction site for the particular primer. The CART 5’ primer 
corresponds to nucleotides 300-318, and the CART 3’ primer corresponds to nucleotides 529-
548 in the CART mRNA sequence (accession number NM_017110). 
 
 
 
4.4.10 Characterisation of Phenotype Resulting from Intra-arcuate Injection of 
Recombinant AAV- Cocaine- and Amphetamine -Regulated Transcript Antisense  
 
4.4.10.1 Effect on Food Intake and Body Weight 
Male Wistar rats were maintained as described in section 4.4.9.1. Food intake and body-
weight were measured three times per week at 0900h, rAAV-CART-AS (n=10) and rAAV-
eGFP (n=8).  
 
 
4.4.10.2 Effect on Neuropeptide Release from Hypothalamic Slices 
Male Wistar rats that were injected bilaterally into the Arc with rAAV-CART AS (n=10) or 
rAAV-eGFP (n=8) (see section 4.4.9.2) were killed 26 days post injection and the release of 
hypothalamic neuropeptides measured using the static explant system. Male Wistar rats were 
killed and their brains immediately removed. Each brain was mounted with the ventral 
surface uppermost on a precooled block which was then placed in a vibrating microtome 
(Microfield Scientific Ltd. Dartmouth, Devon, U.K.) and placed in artificial cerebrospinal 
fluid (aCSF) (appendix I) which was equilibrated with 95% O2 and 5% CO2. A 1.9mm slice 
was taken from the basal hypothalamus to include the MPOA, SON, PVN, DMN, VMN, LH 
and ARC. The hypothalamic blocks were transferred to Sarstedt tubes (Sarstedt Ltd., 
Leicester, UK) each containing 1ml aCSF.  The tubes were placed on a platform in a water 
bath maintained at 37°C for two hours. After a 2 hour equilibration period, hypothalami were 
incubated for 45 minutes in 600µl aCSF (basal period), followed by exposure to 56mM KCl, 
for 45 minutes, where aCSF was prepared with K+ substituted for Na+.  After each period, 
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aCSF solution was removed and immediately stored at -20°C for analysis. Samples were 
analysed by RIA (see section 2.2.12) for CART (55-102) and α-MSH –like 
immunoreactivity. Mean neuropeptide release was compared between animals injected with 
rAAV-CART-AS and rAAV-eGFP.  
 
 
4.4.10.3 Metabolic Characterisation using the Comprehensive Laboratory Animal 
Monitoring System 
The Comprehensive Laboratory Animal Monitoring System (CLAMS) (Columbus 
Instruments, Columbus, Ohio, USA) is an automated metabolic cage system that allows 
simultaneous and continuous measurement of food intake, locomotor activity and metabolic 
parameters such as CO2 production and O2 consumption. Animals were individually housed 
in plexiglass cages (Columbus instruments) with water and food available ad libitum. Side-
feeders containing powdered RM1 food (SDS Ltd, Witham, UK) rested on balances directly 
linked to a computer measuring food intake every 30 minutes. Cumulative food intake was 
automatically calculated. The locomotor activity of each individually housed animal was 
measured by the number of optical photo-beams (Opto M3, Columbus Instruments) broken in 
a given sampling period. Cumulative activity counts along the x and z axes were recorded 
simultaneously every 30 minutes and were used to determine horizontal X ambulatory 
(XAMB) and Z Total (ZTOT) activity scores. XAMB measures the number of consecutive 
beams broken from horizontal movement of the animal, whereas ZTOT detects rearing 
movements. Sensors measuring O2 and CO2 levels (Columbus Instruments) were calibrated to 
a gas standard (CO2: 0.5%, O2: 20.5%, N2: 79%, BOC Gases, Guildford, Surrey, UK). Room 
concentration of O2 and CO2 were calculated from air passed through a reference cage. The 
range of detection of O2 is 18.9-21.2% and CO2 is 0-0.8% with a variation less than 1% for 
both gases. These background gas levels were used as a reference for sample air sequentially 
obtained from all animal cages, at a flow rate of 0.6L/min. Each cage was sampled for 1 
minute at 30 minute intervals. Background gas levels were re-recorded every 8 cages in order 
to maintain an accurate control for all the indirect calorimetry readings. The O2 consumption 
and CO2 production were corrected for body-weight in each animal. Respiratory exchange 
ratio (RER) was calculated as the change in CO2 production (VCO2) divided by change in 
oxygen consumption (VO2). RER is used as an indicator of fat oxidisation, reduced RER is 
associated with increased fat oxidation and increased RER is associated with increased 
carbohydrate utilisation.  
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Male Wistar rats injected with rAAV-CART-AS (n=10) or rAAV-eGFP (n=8) (described in 
section 4.4.9.2) were analysed in metabolic cages for 3 days. This was carried out 125 days 
post rAAV injection. Animals were allowed ad libitum access to food for the first two study 
days since fasting induces an increase in voluntary locomotor activity (Nishimura et al., 
1996). On the third study day fasting blocks were placed in the feeders to prevent access to 
food. This was because food intake is associated with postprandial thermogenesis (Ricquier, 
2006) which is a process whereby energy is expended digesting and processing food that has 
been consumed. Therefore to avoid the confounding effects of food intake on VCO2 and VO2 
measurements animals were fasted during these measurements. Body-weight was measured 
each morning between 0900 and 1000h, and this was used to normalise O2 consumption and 
CO2 production data. All parameters were measured every 30 minutes.  
 
 
4.4.10.4 Tissue Analysis 
Male Wistar rats injected with rAAV-CART-AS (n=10) or rAAV-eGFP (n=8) were killed by 
CO2 asphyxiation 130 days post-injection. Blood was removed by cardiac puncture into 
lithium heparin tubes containing 0.07µg aprotinin (10,000 KIU/ml, Nordic Pharma, Reading, 
UK), these were centrifuged at 12000g for 15 minutes at 4oC (centrifuge 5417 C/R, 
Eppendorf, Hamburg, Germany), the plasma was removed and stored at -70ºC. Epididymal 
white adipose tissue (WAT) and brown adipose tissue (BAT) from the intra-scapular region 
was dissected out and weighed. BAT was snap frozen in liquid nitrogen and stored at -70ºC 
for further analysis.  
 
 
4.4.10.5 Measurement of Uncoupling Protein-1 mRNA Levels in Brown Adipose Tissue 
BAT was homogenised in 1ml Tri-reagent and total RNA was extracted (see section 2.2.1). 
BAT uncoupling protein-1 (UCP-1) mRNA levels were determined by northern blot analysis 
(see section 2.2.3) using 50µg of total BAT RNA and a 32P labelled 307bp UCP-1 DNA 
probe which was produced using the UCP-1 primer set in Table 4.5 (accession number  
M11814). 
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Primer Primer Sequence Restriction 
site 
UCP-1  5’ ACG-TGG-ATC-CTG-TCT-TAG-GGA-CCA-TCA-CCA BamHI 
UCP-1  3’ ACG-TGA-ATT-CGC-ATT-GTA-GGT-CCC-AGT-GTA EcoRI 
 
Table 4.5 Table detailing the primer sequence for the UCP-1 DNA probe. The highlighted 
sequence details the restriction site of the particular primer. The primer UCP-1 5’ 
corresponds to the nucleotides 350-369 and the primer UCP-1  3’ corresponds to nucleotides 
638-657 of the rat mitochondrial BAT mRNA sequence (accession number M11814). 
 
 
 
4.4.10.6 Measurement of Plasma Leptin Levels 
Plasma leptin levels were measured in animals injected with rAAV-CART-AS (n=10) and 
rAAV-eGFP (n=8) 130 days post-injection. Leptin levels were measured by enzyme linked 
immunosorbent assay (ELISA) (CrystalChem, Ilinois, USA) according to the manufacturer’s 
instructions. Briefly, the antibody coated microplate was washed twice with 300ml wash 
buffer. Forty five microlitres of sample diluent was added to each well along with 50µl 
guinea pig anti-leptin serum. Samples (5µl) and standards (0, 0.2, 0.4, 0.8, 1.6, 3.2, 6.4 and 
12.8ng/ml) were added and the microplate covered and incubated overnight at 4ºC. The 
contents of each well were aspirated and wells washed five times with 300µl wash buffer. 
One hundred microlitres of anti-guinea pig immunoglobin G (IgG) enzyme conjugate was 
added to each well and the microplate covered and incubated for 3 hours at 4ºC. Contents 
were removed and each well was washed seven times in 300µl wash buffer. One hundred 
microlitres of enzyme substrate solution was added to each well and allowed to react for 30 
minutes at room temperature in the dark. Finally, 100µl enzyme reaction stop solution was 
added to each well and the absorbance was measured using a plate reader. Absorbance was 
measured at 450 and 360nm, and the final value calculated by subtracting the A360 value from 
the A450 value. Concentrations of standards were plotted on a semi-log scale and the sample 
concentrations interpolated from this graph.  
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4.5 Results. 
 
4.5.1 Production of the pTRCCART-AS Plasmid 
The CART-AS insert was generated separately before being subcloned into the pTRCGW 
plasmid to produce the modified pTRCCART-AS plasmid vector. Rat hypothalami total 
RNA was used as a template for the production of the CART-AS insert. A RT reaction was 
first performed (see section 2.2.4) followed by a PCR reaction (see section 2.2.5) using the 
CART primer set detailed in Table 4.1. The resulting PCR produced products of 760bp and 
721bp. The 721bp CART PCR product was used in the production of rAAV-CART-AS. The 
CART primer set included the sequence for the BsrGI and BamHI restriction enzyme cut 
sites to facilitate cloning. The resulting product from the PCR reaction is shown in Figure 4.2.  
 
 
 
 
 
Figure 4.2 PCR production of CART-AS. Results from the PCR reaction to generate 
CART-AS using PCR primer set detailed in Table 4.1. Lane 1-1kb ladder; Lane 2- CART-AS 
DNA (721bp and 760bp).  
 
 
 
4.5.2 Optimisation of Transient Transfection using Polyethylenimine 
RIN1056a CART cells were transfected with the pCMVß plasmid. Different PEI nitrogen 
equivalents in combination with different DNA amounts were used. Low transfection 
efficiency (<5%) was observed following transfection with 3, 6 and 15 PEI equivalents in 
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combination with 2µg pCMVß (data not shown). Transfection with 9 or 12 PEI equivalents 
was repeated in combination with 2 and 4µg pCMVß. Results for this are shown in Table 4.6.  
 
 
Table 4.6  Effect of PEI:DNA ratio and DNA  concentration on transfection efficiency in 
RIN1056a CART cells. Values are given as mean percentage of cells transfected ± SEM. 
**P<0.01, ***P<0.001 compared with control cells when analysed using a one way-ANOVA 
followed by a post-hoc Turkeys multiple comparison test. 
 
 
4.5.3 Northern Blot Analysis of RIN1056a CART cells following Stable Transfection 
with the pTRCCART-AS Plasmid 
Northern blot analysis using a WPRE DNA probe (Table 4.2) detected WPRE mRNA 
expression in both CAC cells lines. No WPRE mRNA expression was detected in RIN1056a 
cells. (Figure 4.5). 
 
                                                 
                                                                                
 
 
Figure 4.3 Northern blot analysis of RNA from RIN1056a CART cells following stable 
transfection with pTRCCART-AS. RIN1056a (lane 1), CACA (lane 2), CACB (lane 3), 
RIN1056a CART (lane 4) cells probed with a 32P- dCTP WPRE DNA probe.  
PEI Equivalents  
9 
 
12 
µg pCMVß 0 2 4 0 2 4 
Mean % cells 
transfected (± SEM) 
0 8 ± 0.16** 30±1.35*** 0 7.5±0.34** 35±0.88*** 
Origin 
1       2      3     4  
WPRE probe  
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4.5.4 Transient Transfection with pTRCCART-AS using Polyethylenimine 
Transient transfection of RIN1056a CART cells with 4µg pTRCCART-AS, using PEI at 12 
nitrogen equivalents, did not have a significant effect on CART (55-102)-like 
immunoreactivity when measured by RIA (Figure 4.3) and analysed using an unpaired 
Students t-test (at 1 hour P =  0.86, at 4 hour P = 0.90 and at 6 hour P = 0.93). 
 
 
4.5.5 Stable Transfection with pTRCCART-AS using Polyethylenimine 
Stable transfection of RIN1056a CART cells with pTRCCART-AS and 0.25ng pcDNA3 
significantly reduced production of CART (55-102)-like immunoreactivity for up to 8 hours 
(n=6 wells per time point). Release of CART (55-102)-like immunoreactivity was 
significantly reduced at 1, 2, 4, 6 and 8 hours compared to release from RIN1056a CART 
cells. CART release between 0-8h was 22.21 ± 1.43 fmol/µl [RINA1056a CART], 17.02 ± 
1.00 fmol/µl [CACA], P< 0.05, 16.38 ± 0.10 fmol/µl [CACB], P< 0.05)) (Figure 4.4). 
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Figure 4.4 Release of CART (55-102)-like immunoreactivity from cells transiently 
transfected with pTRCCART-AS. Release of CART (55-102)-like immunoreactivity at 1, 4 
and 6 hours from RIN1056a CART cells and RIN1056a CART cells transfected with 4µg 
pTRCCART-AS using 12 PEI nitrogen equivalents Values represent mean ± SEM (n=6 
wells). 
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Figure 4.5 CART release from RIN1056a CART cells and CAC cells.  Release of CART 
(55-102)-like immunoreactivity at 1, 2, 4, 6 and 8 hours from RIN1056a CART cells and 
CART antisense CART (CAC) cells were studied. The clones CACA and CACB were stably 
transfected with 10µg pTRCCART-AS and 0.25ng pcDNA3 plasmid, using 12 PEI nitrogen 
equivalents. Values represent mean ± SEM, *P<0.05, **P<0.01 (n=6 wells per time point) 
when compared with RIN1056a CART cells using one way ANOVA followed by a post-hoc 
Turkeys multiple comparison test.  
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4.5.6 Determination of Total Viral Particle Titre by Dot Blots Analysis 
Dot blot analysis using linear regression of standard curve values revealed 1µl of rAAV-
CART-AS fraction contained 11.8ng/µl viral DNA (Figure 4.6). This is 2.91 x 1013 virions 
per ml (appendix 4).  
 
 
 
 
 
Figure 4.6 Dot blot analysis of rAAV-CART-AS. Total viral particle titre was detected 
using a 32P labelled WPRE DNA probe. A standard curve of 50ng, 25ng, 10ng, 5ng, 2.5ng, 
1ng, 0.5ng, 0.25ng, 0.1ng pTRCGW were analysed. Duplicate samples, neat, 1:10 and 1:50 
dilutions are also shown. 
 
 
 
4.5.7 Recombinant AAV Mediated Transfer of Cocaine- and Amphetamine -Regulated 
Transcript Antisense in the Arcuate Nucleus 
 
4.5.7.1 Confirmation of Gene Transfer by In situ Hybridisation 
In situ hybridisation was carried out on brain slices from rats that had been injected with 
rAAV-CART-AS using a 35S labelled CART sense probe (Table 4.4). The CART sense probe 
is required to detect any CART antisense that is being expressed as a result of injection of 
rAAV-CART-AS into the ARC. The CART sense probe will bind in a complementary 
fashion to CART-AS mRNA, but will not bind to endogenous CART mRNA. To confirm the 
specificity of detection of CART-AS expression by the CART sense probe an in situ 
hybridisation was performed on rat brain slices that were not injected with rAAV-CART-AS 
(Figure 4.7). 
 
             
 
Samples 
   Neat     Neat     1:10       1:10        1:50       1:50 
Standard curve   
50ng    25ng     10ng       5ng         2.5ng       1ng        0.5ng     0.25ng      0.1ng 
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Figure 4.7 In situ hybridisation demonstrating rAAV-CART-AS expression. In situ 
hybridisation using 35S labelled CART riboprobe showing expression of CART-AS in 13µm 
coronal sections of a male Wistar rat brain approximately -3.8mm from bregma. Brains were 
removed 125 days after bilateral intra-Arc injection. Binding of CART sense riboprobe, 
which is used to detect CART-AS expression, in a rat injected with rAAV-CART-AS is 
shown in (A) and (C), CART sense riboprobe used to detect CART-AS expression is shown 
in an untreated rat (B) highlighting the specificity of the CART sense probe.  Binding of the 
CART sense probe is indicated by a black arrow. The binding area of the CART-AS probe 
shown in (A) is enlarged in (C). The scale bar              is 2mm. 
 
Binding of 
riboprobe 
Binding of 
riboprobe 
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4.5.7.2 Effect of Cocaine- and Amphetamine -Regulated Transcript Antisense on Food 
Intake 
Bilateral intra-ARC injection of rAAV-CART-AS significantly increased cumulative food 
intake over the 124 days measured, compared to animals injected with rAAV-eGFP (P<0.05 
when analysed by the generalised estimation equation (GEE) (Figure 4.8).  
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Figure 4.8 Cumulative food intake. Effect of bilateral intra-ARC injection of rAAV-CART-
AS on cumulative food intake in male Wistar rats. Animals were injected with rAAV- 
CART-AS (n=10) (shown in blue) or rAAV-eGFP (n=8) (shown in green) and cumulative 
food intake measured for 124 days post-injection. Values shown as mean ± SEM. *P<0.05 
compared to animals injected with rAAV-eGFP and analysed using the GEE over whole time 
period.  
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4.5.7.3 Effect of Cocaine- and Amphetamine -Regulated Transcript Antisense on Body 
Weight 
Rats injected bilaterally with rAAV-CART-AS exhibited a significant increase in body 
weight and body weight gain relative to the control group over the 124 days measured when 
analysed using the GEE (P<0.05) (Figure 4.9).  
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Figure 4.9 Body weight and body weight gain. Effect of bilateral intra-ARC injection of 
rAAV-CART-AS on body-weight (A) and body-weight gain (B) in male Wistar rats. Animals 
were injected with rAAV- CART-AS (n=10) (shown in blue) or rAAV-eGFP (n=8) (shown 
in green) and body-weight and body-weight gain recorded for 124 days post-injection. Values 
shown as mean ± SEM. *P<0.05 compared to animals injected with rAAV-eGFP and 
analysed using the GEE over the whole time period.  
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4.5.7.4 Effect on Neuropeptide Release from Hypothalamic Slices 
There was no significant difference in the basal release of CART (P = 0.65 using unpaired 
Students t-test) or α-MSH (P = 0.81 using unpaired Students t-test) -like immunoreactivity in 
rAAV-CART-AS injected rats when compared with animals injected with rAAV-eGFP 
(Figure 4.10). 
 
However, injection of rAAV-CART-AS into the rat ARC resulted in a significant reduction 
in potassium stimulated release of CART (55-102)-like immunoreactivity and a trend towards 
reduced potassium stimulated release of α-MSH-like immunoreactivity when compared to 
control animals (CART, 1.34 ± 0.20fmol/µl [eGFP], 0.95 ± 0.10fmol/µl [CART-AS], P=0.03, 
α-MSH, 0.015 ± 0.001fmol/µl [eGFP], 0.011 ± 0.002fmol/µl  [CART-AS], P=0.1, using an 
unpaired t-test) (Figure 4.10).  
 
 
4.5.7.5 Metabolic Characterisation 
Bilateral intra-ARC injection of rAAV-CART-AS had no significant effect on VO2 (P = 0.51 
fed state, P = 0.84 fasted state when analysed using the GEE), VCO2 (P = 0.51 fed state, P = 
0.72 fasted state when analysed using the GEE) or RER (P = 0.72 fed state, P = 0.92 fasted 
state when analysed using the GEE) in fasted or ad libitum fed animals over the 24 hour 
period recorded by the CLAMS (Figure 4.11).  
 
No significant differences in XAMB movement were detected in fasted or ad libitum fed 
animals (P = 0.69 fed state, P = 0.51 fasted state when analysed using the GEE) (Figure 
4.12). No significant differences in food intake were recorded during the ad libitum fed day, 
although a trend towards increased food intake was observed in rAAV-CART-AS animals (P 
= 0.076 when analysed using the GEE) (Figure 4.12).  
 
 
 
 
171 
 
eGFP CART-AS
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
*
Po
ta
ss
iu
m
 
st
im
u
la
te
d 
CA
RT
 
re
le
a
se
(fm
o
l/µ
l)
eGFP CART-AS
0.0
0.1
0.2
0.3
0.4
0.5
Ba
sa
l r
e
le
a
se
 
o
f C
AR
T 
(fm
o
l/µ
 
l)
eGFP CART-AS
0.000
0.005
0.010
0.015
0.020
Ba
sa
l r
e
le
a
se
 
o
fα
-
M
SH
 
(fm
o
l/µ
 
l)
eGFP CART-AS
0.000
0.002
0.004
0.006
0.008
0.010
0.012
0.014
0.016
0.018
Po
ta
ss
iu
m
 
st
im
u
la
te
d
α
-
M
SH
 
re
le
a
se
(fm
o
l/µ
l)
A B
C D
 
 
 
Figure 4.10 Effect of rAAV-CART-AS on potassium stimulated release of CART and 
αMSH. Effect of bilateral intra-ARC injection of rAAV-CART-AS on basal release of 
CART (55-102) (A) and α-MSH (C) –like immunoreactivity. Potassium stimulated release of 
CART (55-102) (B) and α-MSH (D) –like immunoreactivity was also measured. Animals 
were injected with rAAV-CART-AS or rAAV-eGFP and potassium stimulated release of 
CART (55-102)-like immunoreactivity and α-MSH like immunoreactivity measured from ex-
vivo hypothalamic explants 26 days post-injection. Neuropeptide release was measured by 
RIA and shown as mean ± SEM (n=8-10 per group) *P<0.05 by unpaired Students t-test. 
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 Figure 4.11 Metabolic characterisation. Effect of bilateral intra-ARC injection of rAAV-
CART-AS on metabolic parameters in fasted and fed male Wistar rats. Animals were injected 
with rAAV-CART-AS (shown in blue) or rAAV-eGFP (shown in green) and placed in 
CLAMS cages 125 days post-injection. Oxygen consumption (A and B), carbon dioxide 
production (C and D) and RER (E and F) were measured from 9am for 24 hours, results 
shown as ad libitum fed period on the left and a fasted period on the right. The grey area 
indicates the dark phase. Values shown as mean ± SEM (n = 8-10 per group) 
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Figure 4.12 Effect of rAAV-CART-AS on activity and food intake. Effect of bilateral 
intra-ARC injection of rAAV-CART-AS on activity and food intake.  Animals were injected 
with rAAV-CART-AS (shown in blue) or rAAV-eGFP (shown in green) and placed in 
CLAMS cages 125 days post-injection. XAMB activity was measured in ad libitum fed (A) 
and fasted (B) animals from 9am for 24 hours. Cumulative food intake (C) was also measured 
in ad libitum fed animals. The grey area indicates the dark phase. Values shown as mean ± 
SEM (n = 8-10 per group). 
 
 
 
 
 
 
 
 
 
Dark Phase 
Dark Phase 
Dark Phase 
174 
 
4.5.7.6 Tissue Analysis 
Bilateral intra-ARC injection of rAAV-CART-AS had no significant effect on intrascapular 
BAT weight at 130 days post injection when compared to animals injected with rAAV-eGFP 
(n=8-10). Rats injected with rAAV-CART-AS had a mean BAT weight of 0.78 ± 0.04g and 
control animals exhibited a mean BAT weight of 0.70 ± 0.39g (P = 0.96 using an unpaired 
Students t-test). In addition, there was no significant difference when BAT tissue weight was 
corrected for body weight (P = 0.75 using unpaired Students t-test) 
 
Bilateral intra-ARC injection of rAAV-CART-AS had no significant effect on WAT weight 
at 130 days post injection when compared to animals injected with rAAV-eGFP (n=7-9). 
Mean epididymal WAT weight in rats injected with rAAV-CART-AS was 12.23 ± 1.13g and 
rats injected with rAAV-eGFP exhibited a mean WAT weight of 9.79 ± 0.5g (P = 0.11 using 
an unpaired Students t-test). Furthermore, there was no significant difference when WAT 
weight was corrected for body weight (P = 0.14 using unpaired Students t-test) (Figure 4.13). 
 
 
4.5.7.7 Measurement of Uncoupling Protein-1 mRNA levels in Brown Adipose Tissue  
Northern blot was used to measure UCP-1 mRNA expression in rats injected with either 
rAAV-CART-AS or rAAV-eGFP 130 days post injection. There was no significant 
difference in BAT UCP-1 mRNA expression between animals injected with rAAV-CART-
AS, which exhibited a mean expression level of 0.65 ± 0.047 AU, and the rAAV-eGFP 
control group, which displayed mean UCP-1 mRNA expression levels of 0.5 ± 0.079 AU (P 
= 0.22 unpaired Students t-test) (n=8-10). UCP-1 expression was normalised using oligodT 
and calculated using imageQuant software (Figure 4.14).  
 
 
4.5.7.8 Plasma Leptin Levels 
Bilateral intra-ARC injection of rAAV-CART-AS had no significant effect on plasma leptin 
levels (P = 0.64 using unpaired Students t-test) as measured by ELISA at 130 days post 
injection compared to animals injected with rAAV-eGFP (n=8-10). Rats injected with rAAV-
CART-AS displayed a mean plasma leptin concentration of 7.21 ± 0.71ng/ml and rats in the 
control group had a mean plasma leptin concentration of 6.30 ± 0.66ng/ml (Figure 4.15).   
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Figure 4.13 Tissue weight analysis. Effect of bilateral intra-ARC injection of rAAV-CART-
AS on WAT (A) and BAT (B) weight. WAT (C) and BAT (D) weight corrected for body-
weight are also shown. Animals were injected with rAAV-CART-AS or rAAV-eGFP and 
epididymal WAT pads and intrascapular BAT removed and weighed 130 days post-injection. 
Values shown as mean ± SEM (n = 8-10 per group). 
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Figure 4.14 UCP-1 mRNA expression. Effect of bilateral intra-ARC injection of rAAV-
CART-AS on UCP-1 mRNA levels in BAT (n = 8-10 per group). UCP-1 mRNA levels were 
measured by northern blot and quantified using ImageQuant software. Values shown as mean 
± SEM.  
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Figure 4.15 Plasma leptin. Effect of bilateral intra-ARC injection of rAAV-CART-AS on 
plasma leptin levels. Animals were injected with rAAV-CART-AS or rAAV-eGFP and 
plasma leptin measured 130 days post-injection by ELISA. Values shown as mean ± SEM (n 
= 8-10 per group). 
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4.6 Discussion 
 
4.6.1 Productions of Recombinant AAV Construct  
The pTRCGW plasmid was chosen for modification with CART-AS because it has been 
successfully used within the Department of Investigative Medicine in previous neuronal gene 
transfer studies (Gardiner et al., 2005) and contains the necessary sequence elements required 
for in vivo rAAV transgene expression, including the ITRs which are required for transgene 
integration into the host genome. The pTRCGW vector contains the CMV promoter which is 
used to drive expression of the CART-AS transgene. The CMV promoter is a strong 
constitutively active promoter and has been shown to drive transgene expression for up to a 
year following rAAV gene delivery (Guy et al., 1999). Additional elements in the pTRCGW 
plasmid are the WPRE which has been shown to enhance in vivo transcription of mRNA (Xu 
et al., 2003) and the BGH polyadenylation sequence which stabilises the mRNA transcript, 
protecting it from degradation (Ribeiro et al., 2004). An antibiotic resistance gene is also 
present in the pTRCGW plasmid to allow for selection of successfully modified clones, but is 
positioned outside the region flanked by the ITR elements to ensure that it is not transferred 
into the host genome with the transgene. The first stage in preparation of the rAAV plasmid 
was to generate the CART-AS transgene by RT-PCR. Due to alternate splicing in the CART 
transcript two CART fragments (760bp and 721bp) were produced in the resulting PCR. The 
721bp CART fragment produced by a PCR reaction was subcloned downstream of the CMV 
promoter to produce the modified pTRCCART-AS plasmid. This fragment was chosen 
because this is the more abundant form of CART. 
 
 
4.6.2 In vitro Testing pTRCCART-AS in RIN1056a CART cells 
RIN1056a CART cells are rat pancreatic insulinoma cells that have been transfected with a 
CART transgene and consequently express CART peptide. Successful transfection of 
pTRCCART-AS plasmid was confirmed by northern blot analysis. RNA was analysed from 
RIN1056a, RIN1056a CART and CAC cells. A northern blot was carried out using a WPRE 
probe since WPRE is a component of the pTRCCART-AS plasmid, but is not endogenous to 
RIN1056a CART cells. This confirmed the presence of the pTRCCART-AS plasmid in the 
transfected cell lines.  
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Initially a transient transfection was performed so the cells would express the transgene for a 
limited time. The transient transfection was optimised using β-galactosidase expressing 
plasmid pCMVβ (appendix 3). This allowed for successfully transfected cells to be visualised 
as they stain blue when treated with X-gal as a result of the β-galactosidase enzyme cleaving 
the galactoside from the indole ring of X-gal. The highest transfection efficiency was 
obtained using 4µg pCMVβ with 12 PEI equivalents which resulted in approximately 35% of 
cells being successfully transfected. 
 
When the transient transfection was carried out using pTRCCART-AS plasmid no difference 
in the release of CART (55-102) -like immunoreactivity compared with control cells was 
observed. The lack of a reduction in CART (55-102) -like immunoreactivity may be a 
consequence of the nature of transient transfection. As can be seen from the optimisation 
studies involving β-galactosidase only a proportion of cells are successfully transfected and 
there is no method of selection for these cells. As a result, any subtle knock down in CART 
peptide caused by cells expressing the CART-AS transgene may be masked by the high 
portion of cells which have not been transfected and consequently exhibit normal CART 
peptide expression.   
 
To overcome these difficulties a stable transfection procedure was used to ensure the majority 
of cells contained the CART-AS expressing plasmid. Cotransfection was carried out using 
the pTRCCART-AS plasmid and a plasmid expressing the neomycin resistance gene to allow 
for selection of successfully transfected cells. Due to the use of cotransfection there is a 
possibility some of the cells which were transfected with the neomycin resistance plasmid 
were not successfully transfected with the pTRCCART-AS plasmid. These cells would 
remain when exposed to geneticin but would not express the CART-AS transgene. However, 
as pTRCCART-AS was transfected in 200 fold excess of the neomycin resistance plasmid 
this is unlikely to occur frequently. The amount of CART (55-102) -like immunoreactivity 
released from cells following a stable transfection with the pTRCCART-AS plasmid, of 
which there were two clones, CACA and CACB, was significantly lower than release from 
the RIN1056a CART cells. In the first 2 hours, CAC cells produced around 50% less CART 
(55-102)-like immunoreactivity than RIN1056a CART cells. The difference in CART (55-
102) release between the cell lines did diminish over time, with a 30% reduction in CART 
(55-102) -like immunoreactivity seen in CAC cells at 8 hours. This was potentially due to a 
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reduction in the rate of CART (55-102) release from all the cell lines, which may reflect a 
negative feedback response to the high levels of CART (55-102) in the bathing media.   
 
 
4.6.3 Recombinant AAV Injection in the Arcuate Nucleus 
Following on from confirmation of CART-AS action in vitro, the pTRCCART-AS plasmid 
was used to produce rAAV particles for use in vivo. Dot blot analysis was used to quantify 
the total viral particle for in vivo injection. Animals were injected with rAAV-CART-AS or 
rAAV-eGFP into the arcuate nucleus to elucidate the physiological effect of a reduction in 
ARC CART peptide concentration. Recombinant AAV serotype 2 was used in this study 
since it preferentially infects neuronal cells rather than glial cells (Bartlett et al., 1998). In 
addition rAAV has been widely used in gene transfer studies within the brain with no reports 
of toxicity and a low immune reaction (Tenenbaum et al., 2004).  
 
The coordinates chosen for rAAV injection into the ARC were based upon those used by 
Paxinos and Watson and were confirmed by pilot studies which involved injecting ink into 
the hypothalamus to confirm the accuracy of the co-ordinates that would be used (see 
appendix 2)  
 
 
4.6.4 Recombinant AAV Injection and Detection in vivo 
In order to confirm expression of the transgene in the ARC in situ hybridisation was carried 
out to detect transgene derived mRNA species using a radiolabelled CART probe. Expression 
of CART-AS mRNA was demonstrated 125 days post injection in the ARC confirming 
expression of the CART-AS transgene. Expression of rAAV transgenes have been shown to 
increase gradually following injection and reach a detectable peak approximately 2 weeks 
post injection (Flannery et al., 1997). The slow increase in transgene expression is thought to 
be due to inefficient second strand synthesis by rAAV since in the absence of the helper virus 
rAAV relies on the host DNA repair mechanism to generate the second strand for integration 
(Ferrari et al., 1996). 
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4.6.5 Characterisation of Animals Injected with Recombinant AAV- Cocaine- and 
Amphetamine -Regulated Transcript Antisense in the Arcuate Nucleus 
 
4.6.5.1 Food Intake and Body weight 
Food intake and body weight of rats injected with rAAV-CART-AS and rAAV-eGFP were 
measured over a 4 month period. The results show that there was a significant increase in 
cumulative food intake, body weight and body weight gain in the rAAV-CART-AS treated 
group relative to the rAAV-eGFP group. This suggests heavier animals had increased food 
intake compared to those with a lower body weight which is consistent with studies by Chen 
et al which demonstrated that intracerebroventricular (ICV) injection of rAAV expressing 
CART resulted in a decrease in food intake and body weight in rats (Qing and Chen, 2007).  
 
Previous studies have demonstrated arcuate nucleus CART to have an orexigenic role. Kong 
et al and Abbot et al showed that intra-ARC injections of CART peptide resulted in increased 
food intake (Kong et al., 2003; Abbott et al., 2001). In addition, Kong et al demonstrated that 
PEI transfer of a CART expressing plasmid, pcDNA3-CART, into the ARC chronically 
overexpressed CART peptide and resulted in an increase in food intake and body weight. I 
used rAAV expressing CART-AS to down regulate physiological CART peptide expression 
and the results suggest that CART has an anorectic role. The different results obtained 
between the studies may support the hypothesis of CART existing in two circuits within the 
ARC, one of which is orexigenic in nature and a second ARC circuit which causes anorectic 
actions. Alternatively, results reported by Kong et al and Abbot et al following administration 
of CART peptide to the ARC may be the result of activation of pre-synaptic auto-receptors 
expressed on CART containing neurones. The activation of the auto-receptors may follow as 
a result of the ARC CART peptide concentration being raised beyond physiological 
concentrations. This may cause a decrease in release of either CART or α-MSH from 
synaptic terminals of POMC neurones. This may explain why an increase food intake was 
observed in both studies conducted by Kong et al and Abbot et al and in my study. Whilst a 
receptor for CART has not yet been identified there is precedent for hypothalamic 
neuropeptides self-regulating their release through actions on presynaptic auto-receptors. The 
Y2 receptor has been shown to act as an auto-inhibitory receptor for neuropeptide Y (NPY) 
release. Localisation studies have identified Y2 receptors in NPY neurones in the ARC 
(Broberger et al., 1997) and  administration of the Y2 receptor antagonist BIIE0246 to rat 
hypothalamic slices shows results in a reduction in the release of NPY (King et al., 2000).  
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Additional factors need to be considered when comparing the results from my studies using 
rAAV-CART-AS and those reported by Kong et al which used PEI to transfect neurones with 
a CART expressing plasmid. The use of PEI will lead to the infection of neuronal cells as 
well as glial cells, which have a role in synapse development and plasticity (Pfrieger, 2002). 
Therefore the observed increase in cumulative food intake and body weight gain reported by 
Kong et al may be in part due to CART expression in glial cells. Although glial cells are 
unlikely to release the CART neuropeptide, the expression of CART may disrupt the normal 
function of the glial cells. Furthermore, utilising a vector to overexpress the CART peptide 
will result in CART peptide expression and release from the synaptic terminals of all 
transfected neurones even if they do not normally express endogenous CART. Given that the 
interactions between CART and specific receptors are yet to be identified there is the 
potential that CART peptide release from normally non CART producing neurones will act 
on receptor which CART would not normally interact with, for example CART may act as an 
antagonist at the postsynaptic neurone. In my studies I have used rAAV serotype 2 which 
results in the preferential infection of neuronal cells. In addition, whilst rAAV expressing 
CART-AS will not discriminate in the type of neurone it infects, the antisense will only have 
an effect on neuropeptide release in CART producing neurones.  
 
 
4.6.5.2 Potassium Stimulated Release 
Exposure of neurones to high concentrations of potassium ions induces depolarisation of 
neuronal membranes and the release of intracellular contents. Hypothalamic explants from 
rats injected with rAAV-CART-AS and rAAV-eGFP were exposed to high levels of 
potassium ions and the resulting peptides that were released were measured by RIA (see 
section 2.2.12). Potassium stimulated release of CART (55-102)-like immunoreactivity from 
hypothalamic explants was significantly reduced in animals injected with rAAV-CART-AS 
in the ARC compared to rAAV-eGFP controls, which is consistent with CART-AS 
expression in the ARC. There was a trend towards reduced α-MSH although this was not 
significant. There was no significant difference in the basal release of α-MSH or CART (55-
102) –like immunoreactivity suggesting that results from potassium stimulated release are not 
due to a decrease basal leakage of the neuropeptides in rats injected with rAAV-CART-AS. 
Recent electrophysiological evidence suggests that CART may in fact stimulate the release of 
α-MSH (private communication with Dr K Murphy). Therefore a reduction in potassium 
stimulated release of CART (55-102) –like immunoreactivity may account for a non 
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significant reduction in α-MSH release. Alternatively, CART may exert a direct effect on 
food intake.  
 
 
4.6.5.3 Energy Expenditure 
Analysis of rAAV-CART-AS and rAAV-eGFP injected animals when in the CLAMS 
showed no difference in activity levels, RER, oxygen consumption or carbon dioxide 
production. This suggests that reduced activity or energy expenditure did not contribute to the 
increase in body weight that was observed. Indirect calorimetry measurements in mice with 
targeted deletion of the CART gene (Asnicar et al., 2001) and in diet induced obese rats 
injected with rAAV overexpressing CART (Qing and Chen, 2007), support the observations 
that neither an increase in or decrease in CART peptide alter activity levels.  
 
WAT from the epididymal fat pad and BAT from the intrascapular region was removed from 
the animals that were injected with rAAV-CART-AS and rAAV-eGFP to act as markers of 
whole body adiposity and energy expenditure. There was no significant difference in WAT 
weight from the rAAV-CART-AS treated group which was consistent with there being no 
significant difference in plasma leptin levels between the rAAV-CART-AS group and the 
control animals. This is in keeping with previous studies by Chen et al using rAAV to 
overexpress CART since there was no significant difference in fat mass between treated and 
control animals, although a decrease in lean mass was reported (Qing and Chen, 2007). 
 
There was no significant difference in UCP-1 mRNA expression or BAT weight in the 
rAAV-CART-AS treated rats relative to the levels observed in the rAAV-eGFP control 
animals. However, in contrast to my observations, Kong et al did report that chronic 
upregulation of CART peptide expression resulted in an increase in BAT UCP-1 mRNA 
expression. As has been discussed, rAAV-CART-AS will affect neuropeptide release only in 
those neurones that express CART mRNA. In contrast using a vector to overexpress CART 
may result in the release of CART peptide from the synaptic terminals of non CART 
expressing neurones. Since CART and non CART producing neurones are affected this may 
account for why Kong et al observed an increase in UCP-1 mRNA expression, which is 
consistent with anorectic factor, and an increase in food intake which is consistent with 
CART being an orexigen, although Kong et al attributes the effect to a role for CART in cold 
adaptation (Kong et al., 2003). 
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As has been discussed there is a hypothesis that CART may be differentially regulated within 
the hypothalamus (Abbott et al., 2001) and for this reason it is important to study the effect of 
CART in specific nuclei to fully dissect the role of CART. By using rAAV-CART-AS it is 
possible to observe the effect of chronic down regulation of ARC CART peptide expression 
which has several advantages over other approaches. Kong et al utilised PEI to transfect cell 
in the ARC with a vector to overexpress CART (Kong et al., 2003). However, PEI infects 
neurones and glial cells. In studies conducted as part of this these neurones have been 
specifically targeted using rAAV serotype 2 which negates the possible involvement of glial 
cells in any phenotype analysis. In my thesis I have chosen to study the effect of a reduction 
in CART peptide expression in the ARC which is more physiologically relevant since this 
does not lead to supra-physiological concentrations of CART peptide in the ARC that may 
activate CART auto-receptors involved in mediating negative feedback. In addition, rAAV-
CART-AS, due to the use of the constitutive CMV promoter, will result in the expression of 
CART-AS in all infected neurones. However, CART-AS expression will only affect 
neuropeptide release from neurones which express CART. This is not necessarily the case 
when using  vectors to overexpress CART peptide since the CART peptide will be expressed 
and released from all neurones that are transfected with the vector whether they normally 
express endogenous CART or not. Due to there being no identified CART receptor it is not 
possible to conclude whether CART release from neurones which do not normally express 
CART will have an effect on phenotype.  
 
In summary, rAAV expressing CART-AS was injected into the rat arcuate nucleus to 
establish a physiological role for ARC CART in energy homeostasis. Expression of CART-
AS resulted in a reduction in CART peptide levels in the ARC which resulted in increased 
cumulative food intake, body weight and body weight gain over a four month period. 
Potassium stimulation of hypothalamic explants demonstrated a significant reduction in 
release of CART (55-102) –like immunoreactivity which may account for a non significant 
reduction in α-MSH in rats injected with rAAV-CART-AS. It appears that the effect of 
CART-AS on body weight is through increased food intake since there was no significant 
difference in energy expenditure between the rAAV-CART-AS and rAAV-eGFP injected 
animals. 
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5. General Discussion and Future Work 
 
5.1 Discussion 
The hypothalamus is an important area of the central nervous system (CNS) involved in the 
control of energy homeostasis. The arcuate nucleus (ARC) is one of several nuclei that 
constitute the hypothalamus, and it has been shown to be essential in the integration of 
peripheral signals of energy store status (Hakansson et al., 1996; Obici et al., 2002; Parton et 
al., 2007).  It is by further understanding the role of hypothalamic neuropeptides that a better 
understanding of the physiological processes that underlie obesity can be attained and this 
may offer the potential for the development of anti-obesity therapies. The aim of this thesis 
was to elucidate the physiological role of arcuate nucleus derived cocaine- and amphetamine 
–regulated transcript (CART) in energy homeostasis. 
 
CART was originally identified in the rat striatum as a mRNA transcript that was upregulated 
in response to peripheral administration of cocaine and amphetamine (Douglass et al., 1995) 
which is also associated with a decrease in food intake (Balopole, 1979; Hsieh et al., 2005). 
CART is widely expressed within the CNS (Hunter et al., 2005; Vrang et al., 1999) including 
the hypothalamic paraventricular nucleus (PVN), ARC and lateral hypothalamic nucleus 
(LH) (Vrang et al., 1999). Early studies linked CART with a role in regulating food intake 
since CART mRNA expression was shown to be upregulated by leptin (Kristensen, 1998) 
and intracerebroventricular (ICV) administration of recombinant CART peptide resulted in an 
inhibition of feeding in rats (Kristensen, 1998). Since these early studies, attempts have been 
made to elucidate the true physiological role of CART in energy homeostasis. However, 
attempts to define CART as an anorectic or an orexigen have proved inconclusive. 
Administration of anti-CART antibody, which blocks endogenous CART, resulted in 
stimulation of overnight feeding (Lambert, 1998). In addition, CART peptide has been shown 
to reduce feeding upon ICV administration in satiated and fasted rats (Kristensen, 1998). 
These data are consistent with CART acting as an anorectic peptide. However, ICV 
administration of CART peptide was associated with movement tremors which were a result 
of diffusion of CART peptide to the fourth ventricle (Aja et al., 2002) which suggested that 
the observed reduction in food intake was secondary to the effects of CART on motor 
behaviour. The effect of CART on motor behaviour is unlikely to fully account for the 
reduction in feeding since a reduction in food intake was still observed when diffusion of 
CART peptide to the fourth ventricle was blocked (Aja et al., 2002). Interestingly, CART has 
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also been implicated in an orexigenic role since intra-nuclear administration of CART peptide 
in rats resulted in increased feeding (Abbott et al., 2001).  Administration of 0.2nmol of 
CART peptide into the rat ARC, PVN, LH and dorsal medial nucleus (DMN) resulted in an 
increase in feeding (Abbott et al., 2001). Due to the conflicting data which has implicated 
CART as both an anorectic and orexigenic factor the true role of CART remains unclear. 
Instead the data gathered so far may serve to highlight the complexity in the physiological 
function of CART. This has given rise to the hypothesis that CART may be differentially 
regulated within the hypothalamus with CART being expressed in two circuits, one 
orexigenic and one anorectic (Abbott et al., 2001). 
 
The aim of my thesis was to investigate the physiological role of ARC CART peptide in 
energy homeostasis. In order to achieve this I sought to study the phenotype resulting from a 
reduction in CART peptide concentration in the rodent arcuate nucleus. I chose to target the 
CART peptide since no receptor for CART has been identified.  
 
To date, studies investigating the role of CART have mainly focussed on studying the 
phenotype that results from an increase in CART peptide which may have the result in 
producing a non physiological phenotype  (Kong et al., 2003; Kristensen, 1998). Although 
there have been studies which have investigated the effect of loss of CART gene function 
these studies utilised transgenic methods to achieve a whole body deletion of the CART gene 
(Asnicar et al., 2001; Wierup et al., 2005). Therefore given that CART is expressed in the 
periphery and CNS and may potentially be differentially regulated within the brain, the loss 
of CART peptide throughout the organism does not provide evidence for a conclusive role for 
hypothalamic CART. For these reasons I have chosen to downregulate endogenous CART 
peptide expression specifically in the ARC. To produce a reduction in ARC CART peptide 
concentration I utilised two methods of genetic manipulation to target CART-AS expression. 
Initially I generated a CART-AS expressing transgenic mouse line by bacterial artificial 
chromosome (BAC) transgenesis to reduce CART peptide concentrations specifically in pro-
opiomelanocortin (POMC) expressing cells.  In the second part of my thesis I reduced ARC 
CART peptide concentration using recombinant adeno-associated virus (rAAV) expressing 
CART-AS. 
 
In the first part of my thesis I set out to selectively express the CART-AS transgene in POMC 
neurones.  In order to achieve this, a BAC was identified which contained the POMC gene at 
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the centre of its insert as this increases the likelihood that all the necessary regulatory 
elements required for driving accurate POMC like expression are present. Barsh et al 
demonstrated accurate POMC like expression of eGFP using a BAC containing 60kb 5’ 
flanking sequence and 30kb of 3’ flanking sequence (Xu et al., 2005). I chose to use the 
RP24_340C3  BAC and since the amount of flanking sequence present in the RP24_340C3  
BAC (84kb 5’ flanking sequence and 70kb 3’ flanking sequence) was greater than that used 
by Barsh et al it is likely that it will drive accurate POMC like expression pattern. Following 
the selection of the BAC, homologous recombination, driven by the pGETrec plasmid, was 
used to modify the POMC BAC so that it contained the CART-AS transgene. The 
successfully modified BAC was then injected into the pronuclei of fertilised mouse eggs from 
which founder mice were identified and used to set up separate transgenic lines. Expression 
of the CART-AS transgene in POMC neurones appeared to reduce CART peptide release at 
the synaptic terminals of POMC neurones which includes projections within the ARC and to 
other areas within the hypothalamus  (Elmquist et al., 1998; Elmquist et al., 1999).  For 
example I found a reduction in CART peptide concentration in PVN tissue biopsies.  
 
Expression of the CART-AS transgene in POMC neurones significantly increased body 
weight in male mice maintained on regular chow when compared with wildtype litter mates.  
The increased body weight appeared to be due to decreased thermogenesis since brown 
adipose tissue (BAT) uncoupling protein-1 (UCP-1) mRNA expression was reduced with no 
significant difference in food intake. A reduction in CART peptide release at the PVN, and 
UCP-1 mRNA expression, is consistent with previous studies which have demonstrated that 
injection of CART peptide into the PVN results in increased UCP-1 mRNA expression 
through stimulation of sympathetic outflow (Wang et al., 2000). These data suggest that 
CART peptide in POMC neurones has a catabolic role in energy homeostasis, and that this 
role may be more important in the control of thermogenesis than food intake.  
 
In the second part of my thesis I set out to reduce CART peptide expression in the ARC using 
rAAV (serotype 2) expressing CART-AS. The use of rAAV allows temporal control of 
transgene expression as the viral vector can be administered at any stage in the life cycle of 
the rodent. This allows delivery of the transgene to the adult circumventing the problem of 
developmental compensation which can occur in BAC transgenesis and is a confounding 
factor in determining any potential phenotype. In addition, rAAV serotype 2 preferentially 
infects neuronal cells (Bartlett et al., 1998) and this coupled with the use of the constitutive 
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cytomegalovirus (CMV) promoter to drive CART-AS expression caused the transgene to be 
expressed in all neuronal cells that the virus infected. Therefore the reduction in CART 
peptide release is not confined to POMC expressing neurones as is the case in the CART-AS 
transgenic mice. It is important to note that although rAAV does not discriminate in the 
neurones it infects, CART-AS expression will only affect neurones which express the CART 
peptide.  
 
Injection of rAAV-CART-AS into the rat ARC resulted in increased body weight in rats 
which is consistent with the findings from the transgenic CART-AS mouse model. However, 
the increase in body weight resulting from rAAV-CART-AS injection appeared to be due to 
increased food intake. Analysis of parameters governing energy expenditure did not reveal 
any significant difference in activity levels, oxygen consumption or BAT UCP-1 mRNA 
expression which is consistent with the findings reported by Chen et al following ICV 
injection of rAAV expressing CART (Qing and Chen, 2007). Chen et al also reported a 
decrease in food intake and body weight (Qing and Chen, 2007). These data support the 
findings from the CART-AS expressing mice which suggest that CART acts as an anorectic 
factor. Furthermore, results from hypothalamic explants raise the possibility that CART may 
influence release and/or storage of α-melanocortin stimulating hormones (MSH). Previous 
studies using hypothalamic explants have demonstrated interaction between ARC 
neuropeptides since administration of 1, 10 and 100nmol neuropeptide Y (NPY) to the 
explant system resulted in an increase in release of agouti related peptide (AgRP) (Dhillo et 
al., 2002). It would therefore be interesting to confirm whether interaction between CART 
and POMC was of physiological significance.  
 
The experiments performed as part of my thesis provide additional information regarding the 
role of the CART peptide within the ARC. Collectively, these data suggests that a reduction 
in CART peptide, specifically in POMC neurones and in the ARC, supports the hypothesis of  
CART having a catabolic role in energy homeostasis. However, results from CART-AS 
expressing mice suggests that the role of CART in the POMC neurone is one that is important 
in the regulation of energy expenditure whereas the effect of rAAV-CART-AS expression on 
body weight appears to be due to increased food intake.  
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The different causes behind the observed increase in body weight in the two rodent models 
used in this thesis may be explained by the different sites at which CART peptide expression 
was reduced. CART-AS expressing mice displayed a reduction in CART peptide release 
from POMC neurone projections in the ARC and other hypothalamic nuclei. Therefore the 
data suggests that CART peptide in POMC neurones is involved in regulating energy 
expenditure.  In contrast, given that 90% of CART neurones in the ARC express α-MSH, 
there are 10% of CART neurones where peptide release is not reduced in the transgenic mice, 
but are reduced in the rAAV-CART-AS model (Elias et al., 1998). It is possible that POMC 
derived CART neurones are important in energy expenditure, and additional ARC CART 
neurones are important in the control of food intake. An alternative explanation is that rAAV 
is more effective at reducing CART peptide concentration in the ARC and therefore in 
rAAV-CART-AS injected animals CART peptide is reduced below a threshold which is not 
achieved using BAC transgenesis and results in the increase in food intake.  
 
The studies conducted as part of my thesis implicate CART with a catabolic role, and several 
studies have been conducted which support these findings, such as the study by Chen et al in 
which rAAV expressing CART was injected ICV in rats and was shown to reduce food 
intake and body weight with no effect on activity levels (Qing and Chen, 2007). In addition, 
Wierup et al developed a line of transgenic mice with a targeted deletion of the CART gene 
which exhibited an increase in body weight but with no significant difference in food intake. 
The authors suggest that this may be due to a decrease in energy expenditure (Wierup et al., 
2005) and is consistent with my findings from the CART-AS expressing mice described in 
this thesis.  
 
A second model generated by Asnicar et al showed that mice with a targeted deletion of the 
CART gene resulted in an increase in food intake and body weight when fed a high fat diet 
(Asnicar et al., 2001). The reported increase in food intake in mice deficient in the CART 
peptide is in keeping with results from studies I have conducted involving injection of rAAV-
CART-AS. However, mice expressing the CART-AS transgene did not exhibit an increase in 
food intake. This may be explained by CART-AS mice exhibiting reduced CART peptide 
expression in the 90% of CART neurones that are colocalised with α-MSH (Elias et al., 
1998). In contrast rAAV-CART-AS injected animals, like the mice with targeted deletion of 
CART, have reduced CART peptide concentration in all CART expressing neurones within 
the ARC. The reduction in CART peptide in the 10% of ARC CART neurones which are not 
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colocalised with α-MSH may account for why the increase in food intake was not observed in 
mice expressing the CART-AS transgene. An alternative explanation may be that rAAV-
CART-AS, and mice with a targeted deletion of the CART gene, reduce CART peptide 
concentration below the threshold needed to affect food intake whereas CART-AS expressing 
mice generated by BAC transgenesis are not as efficient at reducing CART peptide 
concentration. Although Asnicar et al did not find any difference in energy expenditure when 
compared with wildtype mice, humans which have a mutation at leu34phe in the CART gene 
display a reduced metabolic rate  which suggests a role for CART in energy expenditure (del 
Giudice et al., 2001).  
 
However, studies have also implicated CART as an orexigenic agent since experimental 
paradigms which chronically increase CART peptide in the ARC result in increased food 
intake and body weight (Abbott et al., 2001; Kong et al., 2003). This is in contrast to the 
results I have obtained which suggest that a reduction in CART peptide in the ARC results in 
an increase in body weight, and in the case of rAAV-CART-AS also an increase in food 
intake. These conflicting data may be explained by the way in which CART is targeted to the 
ARC. Administration of CART peptide will result in activation of non CART producing 
neurones which express the CART receptor. In addition, an increase in CART peptide may 
activate pre-synaptic auto-receptors expressed on CART neurones which would cause a 
reduction in CART peptide release from the synaptic terminal as a result of negative 
feedback. The same is true when using a vector which chronically overexpresses CART 
peptide. Kong et al utilised polyethylenimine (PEI) to transfect cells in the ARC with a 
plasmid to cause an increase in CART peptide expression. The consequence of using peptide 
overexpression to investigate peptide function is that non CART expressing neurones will 
synthesise and release the CART peptide. This may result in the activation of neurones which 
would not normally be activated by CART.  Hence the increase in food intake and body 
weight reported in studies investigating an increase ARC CART peptide concentration may 
be, in part, a product of reduced CART either through activation of auto-receptors, or through 
activation of neurones which do not express endogenous CART. In choosing to use the 
POMC expression domain to drive CART-AS expression in mice and rAAV serotype 2 to 
ensure neurones are preferentially infected, a greater specificity is achieved compared with 
other studies discussed here. In addition, the methods that I have employed ensure that 
neuropeptide release will only be affected in cells which express CART since the antisense 
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mRNA will only bind to sense CART mRNA therefore neuropeptide release will not be 
affected in cells which do not express CART.   
CART is still the least understood neuropeptide in the ARC and further studies need to be 
conducted once a CART receptor has been identified. Studies involving the CART receptor 
may provide a further insight into the theory that suggests CART acts both as an orexigenic 
and an anorectic factor since different CART receptor subtypes may exist to mediate the two 
CART appetite circuits.  
 
 
5.2 Future Work 
 
5.2.1 Bacterial Artificial Chromosome transgenesis Cocaine- and Amphetamine -
Regulated Transcript Antisense Model 
Further work is needed to fully characterise the CART-AS mouse model. Initially it will be 
important to confirm the site of CART-AS transgene expression by in situ hybridisation. 
CART has been shown to colocalise with POMC in the ARC, retrochiasmatic nucleus and 
pituitary and in situ hybridisation will highlight any expression in these areas which will need 
to be taken into account when analysing the phenotype (Elias et al., 1998; Stanley et al., 
2004). Following this, the level of transgene expression can be determined using quantitative 
in situ hybridisation.  
 
Given that analysis of tissue biopsies from the PVN demonstrated a reduction in CART 
peptide it would be interesting to investigate whether CART peptide concentration was 
reduced in other hypothalamic nuclei to which POMC/CART neurones project, such as the 
LH and DMN. In addition it would also be interesting to investigate whether CART-AS 
expression altered the release of other neuropeptides in these nuclei. The content and release 
of the neuropeptides CART, POMC, AgRP and NPY from whole hypothalami and tissue 
biopsies from specific hypothalamic nuclei will be investigated by a static hypothalamic 
explant incubation system.  The explants will be incubated in artificial cerebrospinal fluid 
(aCSF) to determine basal release prior to stimulation with potassium. Upon stimulation 
CART, α-MSH, POMC and NPY immunoreactivity will be measured by radioimmunoassay 
(RIA). 
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Previous studies have demonstrated that CART neurones that coexpress POMC synapse with 
thyrotropin releasing hormone (TRH) neurones in the PVN (Fekete et al., 2000). In addition, 
injection of CART peptide into the PVN has been shown to result in an increase in BAT 
UCP-1 mRNA expression (Wang et al., 2000). In light of this evidence, coupled with my 
findings that CART-AS expressing mice displayed reduced CART peptide concentration in 
the PVN tissue biopsies and reduced BAT UCP-1 mRNA expression, the effect of reduced 
CART peptide concentration in POMC neurones on energy expenditure needs to be 
investigated further. It will be interesting to study proTRH mRNA expression by quantitative 
PCR to establish if reduced TRH expression may account for decreased BAT UCP-1 mRNA 
expression. Further to this, TRH release stimulates the release of thyroid stimulating hormone 
(TSH) from the pituitary which causes an increase in circulating thyroid hormones. 
Therefore, TSH release and the plasma concentration of T3 and T4 thyroid hormone from 
CART-AS expressing mice should be measured by RIA. It would also be important to study 
energy expenditure via indirect calorimetry to establish any differences in activity levels or 
oxygen consumption between transgenic and wildtype mice. This can be studied using the 
CLAMS which are detailed in section 4.4. 
 
Due to the ARC being a site at which peripheral hormones can signal on the status of energy 
stores circulating plasma leptin should be measured using a standard leptin enzyme linked 
immunosorbent assay (ELSIA) to investigate the possibility of a feedback mechanism 
between CART and leptin. Nutrients have also been shown to act at the hypothalamus as 
peripheral signals of immediate fuel availability, for example, glucose sensing neurones have 
been identified in the ARC (Parton et al., 2007). Glucose sensing is thought to occur through 
the kir6.2 protein channel subunit and the kir6.2 protein subunit has been identified on the 
POMC neurone (Parton et al., 2007). Therefore it would be interesting to investigate whether 
a reduction in CART peptide in the POMC neurones affected the ability of mice expressing 
the CART-AS transgene to sense and respond to glucose. This could be investigated using 
standard glucose tolerance tests (GTT) and insulin tolerance tests (ITT). 
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5.2.2 Recombinant AAV- Cocaine- and Amphetamine -Regulated Transcript Antisense  
Model 
There is scope for further investigation of the effect of intra-ARC injection of rAAV-CART-
AS. Considering the result from the hypothalamic explant study which suggests a potential 
for CART to affect α-MSH release it would be interesting to investigate whether this was 
physiological and whether CART also affects NPY or AgRP release. This could be addressed 
by studying the effect of CART-AS expression on the release of α-MSH, NPY and AgRP 
from ARC tissue biopsies using a static explant system. The tissue will be incubated in aCSF 
to determine basal release before measuring potassium stimulated release of neuropeptides. In 
addition, it would be useful to carry out electrophysiological studies on ARC neurones to 
establish if animals expressing CART-AS exhibit increased action potential frequency on the 
NPY/AgRP neurones relative to control animals which could potentially explain the increase 
in food intake in rAAV-CART-AS injected animals. To put this into context, NPY/GABA 
neurones within the ARC have been shown to inhibit the POMC/CART neurone population 
(Cowley et al., 2001) so it is possible that CART interneurones may exert inhibitory tones on 
the orexigenic neurone population, either directly or through stimulation of α-MSH.   
 
 
5.3 Conclusion 
Collectively the data presented in this thesis supports the hypothesis of ARC CART having a 
catabolic role in energy homeostasis. Although further work is needed in the characterisation 
of the CART-AS mouse model the data gathered regarding the effect of CART on 
thermogenesis is consistent with previous studies involving CART administration into the 
PVN. This suggests that the CART-AS expressing mouse is a promising model to study the 
role of CART peptide.  However, given the wide distribution of CART within the brain, the 
fact that CART has been implicated in mediating stress and the effect of psychostimulants, 
coupled with the conflicting data showing CART to act as an anorectic and orexigenic 
peptide, it raises questions about the suitability of targeting CART as a possible anti-obesity 
therapy. Drugs which affect peptides that are involved in multiple systems can have adverse 
side effects, one example is rimonobant. The drug rimonobant was found to reduce food 
intake but approval was withdrawn following reports of a link between psychiatric disorders. 
However, it may be more practical to target CART as an anti-obesity therapy once a CART 
receptor and its subtypes have been identified since it may then be possible to target an 
antagonist to a specific receptor subtype that mediates the orexigenic effect of CART peptide. 
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Although even this may be problematic, CART has been shown to cause movement disorders 
upon diffusion to the fourth ventricle following ICV administration of CART in rodents.  
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Appendix 1 - Solutions 
 
ABC buffer 
Combine solution A, B and C in the following proportions - 100:250:150, and store at -20ºC. 
Solution A 
Add 1ml of 125mM MgCl2 and 1.25M Tris (pH8.0) to 18µl Mercaptoethanol, 5µl 100mM 
dATP, 5µl 100mM dTTP and 5µl dGTP. 
 
Solution B 
2M HEPES pH6.6 (titrated with 4M NaOH) 
 
Solution C 
Random oligonucleotides at 112µg/ml 
 
Artificial CSF (aCSF) stock solutions 
NaHCO3 (0.1M) 4.62g dissolved in 500ml GDW 
NaCl (0.63M) 18.43g dissolved in 550ml GDW 
Na2HPO4.2H2O (0.09M) 1.56g dissolved in 100ml GDW 
MgSO4.7H20 (0.09M) 2.2g dissolved in 100ml GDW 
CaCl2 (0.07M) 0.792g dissolved in 100ml GDW 
All stock solutions were stored at 4ºC 
 
aCSF 
20ml NaHCO3 (0.1M), 20ml NaCl (0.63M), 1ml Na2HPO4.2H2O (0.09M), 10ml KCl 
(0.56M), 1ml MgSO4.7H20 (0.09M), 90mg glucose, 1ml aprotinin, 17.6mg ascorbic acid 
were made up to 100ml with GDW. The solution was gassed with O2 and kept on ice.  
 
Alkaline SDS (0.2M NaOH/1%SDS): 
Mix 2ml 10M sodium hydroxide, 5ml 20% SDS and 93ml autoclaved distilled 
water. 
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Amasino wash buffer  
Mix 250ml 1M Na phosphate buffer pH 7.2, 2ml 500mM EDTA and 100ml 
20% SDS with 650ml of distilled water. 
 
5M ammonium acetate: 
Dissolve 385g CH3.COONH4 in 600ml autoclaved distilled water, then make 
up to 1l. 
 
100mg/ml ampicillin: 
Dissolve 1g in 10ml autoclaved distilled water, sterilise by passage through a 
0.2µm filter and distribute into 1ml aliquots. 
 
10% l-arabinose: 
Dissolve 1g of L-arabinose in 10ml autoclaved distilled water. Sterilise by 
passage through a 0.2µm filter. 
2.5mM ATA: 
  Dissolve 0.1183g ATA in 100ml autoclaved distilled water. 
 
Caesium chloride-saturated isopropanol: 
Vigorously mix 100g CsCl2, 100ml autoclaved distilled water, and 100ml 
propan-2-ol and leave to settle. 
 
2M calcium chloride: 
Dissolve 5.88g of CaCl2.2H2O in 20ml distilled water and sterilise by passage 
through a 0.2µm filter.  Store in 1ml aliquots at -20oC. 
 
25mg/ml chloramphenicol 
 Dissolve 250mg of chloramphenicol in 10ml of molecular biology grade 
ethanol.   
 
Denaturing solution (DNA): 
  Dissolve 43.5g of NaCl in GDW, add 25ml of 10MNaOH and make up to  
 500ml with GDW. 
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DENAT (RNA denaturing solution): 
  Mix 1ml of formamide, 300µl formaldehyde and 100µl 20x MOPS. 
 
Dextran coated charcoal: 
Add 2.4g of charcoal and 0.24g of dextran to 100ml of phosphate buffer with 
gelatine, and mix for twenty minutes at 20°C. 
 
Dialysis tubing: 
Dialysis tubing is cut into ~10cm lengths, immersed in 2% (w/v) 
NaHCO3/1mM EDTA and boiled for ten minutes. Tubing is then rinsed in 
distilled water then boiled for five minutes in 1mM C10H14H2O8Na2.2H2O. 
After cooling, tubing is stored in solution at 4oC. 
 
Gel loading buffer: 
Mix 3.125ml 80% glycerol, 50µl 0.5M EDTA, and 10mg orange G in 6.075ml 
of autoclaved distilled water. 
 
dNTP mix for PCR and reverse transcription: 
Mix 10µl each of the 100mM dGTP, dCTP, dATP, and dTTP in 60µl of 
autoclaved distilled water and aliquot into 20µl batches. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA): 
Dissolve 186.1g C10H14H2O8Na2.2H2O in 800ml autoclaved distilled water 
and adjust to pH 8.0 with 1M NaOH.  Make up to 1l with water. 
 
Formamide (de-ionised): 
Add 2.7g Duolite MB 6113 (Merck) to 100ml formamide and mix until 
duolite turns brown (~1 hour).  Remove Duolite by passage through Whatman 
GF/C filters, aliquot and store at -20oC. 
 
10% glycerol in water: 
 Add 10ml glycerol to 90ml of distilled water. 
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80% glycerol in water: 
 Add 80ml glycerol to 20ml of distilled water. 
 
GTE: 
Mix 2.5ml 1M Tris-HCl pH 8.0, 2ml 0.5M EDTA, and 5ml 18% glucose and 
make up to 100ml.  Sterilise by passing through a 0.2µm filter. 
 
2x HEPES-buffered saline (HBS): 
dissolve 1.6g NaCl, 75mg KCl, 21mg, Na2HPO4, 0.22g dextrose and 1g 
HEPES in a total volume of 90 mls of water.  Adjust to pH 7.05 with 0.5M 
sodium hydroxide and volume to 100 mls with water.  Sterilise by passing 
through a 0.22 micron filter and store in 5 ml aliquots at -20oC. 
 
 
Hybridisation buffer for Northern and dot blot  
Dissolve 0.5g dried milk powder and 0.5ml EDTA (500mM stock) in 48ml GDW, leave at 
37ºC to dissolve. Allow to cool then add 25ml of Na Phosphate buffer (1M stock), 25ml SDS 
(20% stock), and 1ml ATA (2.5mM stock) 
 
 
25mg/ml IPTG: 
Dissolve 100mg of IPTG in 4ml autoclaved distilled water. Sterilise by 
passage through a 0.2µm filter. 
 
LB culture media: 
Dissolve 5g sodium chloride, 10g tryptone and 5g yeast extract to 1l of 
distilled water. Adjust to pH 7.5 with 10M sodium hydroxide and sterilise by 
autoclaving. 
 
Lysis buffer 
Add 8.765g NaCl, 6.055g Tris, make up to 1l with GDW and adjust to pH8.5 
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20x MOPS: 
 Dissolve 83.6g 3-(N-Morpholino)propanesulphonic acid (MOPS), 8.1g 
 sodium acetate, 7.4g C10H14H2O8Na2.2H2O and 2.5ml formaldehyde in 
 800ml water.  Adjust to pH 7.0 with 10M sodium hydroxide and make  up 
to 1l. 
 
Neutralising solution 
Dissolve 43.5g sodium chloride and 60.2g Trizma base in 430ml GDW. Adjust pH to 7.5 by 
addition of 70ml hydrochloric acid. 
 
 
0.01M phosphate buffered saline (PBS): 
Dissolve 8.7g NaCl, 0.272g KH2PO4, and 1.41g Na2HPO42H20 in 800ml of 
distilled water. Adjust to pH 7.5 and make up to 1l.  
 
 
0.01M PBS/0.1% Na Azide/ 0.1% BSA: 
 Dissolve 1g Na azide  and 1g of BSA in 100ml of 0.01M PBS, then make up 
to 1l. 
 
PBS/Tween: 
 Add 0.25ml Tween 20 to 500ml 0.01M PBS. 
 
Phenol/chloroform/IAA: 
Mix equilibrated phenol, chloroform and iso-amyl alcohol in the ratio 25:24:1 
and store under 0.1M Tris-HCl, pH 8.0. 
 
Phosphate buffer (RIA buffer): 
48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g C10H14H2O8Na2.2H2O, 2.5g 
NaN3 were dissolved in 5l of distilled water that had been boiled and allowed 
to cool, the pH was measured to confirm it was 7.6 ± 0.1 and the buffer was 
stored at 4oC. 
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Phosphate buffer with gelatin: 
The buffer was produced as above with 12.5g of gelatin dissolved in the 
boiling water then cooled before the addition of the other reagents 
 
3M potassium acetate: 
Dissolve 294.4g CH3COOK in 500ml distilled water, add 115ml glacial acetic 
acid and make up to 1l with water. 
 
20mg/ml proteinase K: 
Dissolve 20mg for every 1ml of autoclaved distilled water and store at -20oC. 
 
10mg/ml RNase A: 
Dissolve 100mg RNase A in 10ml 10mM Tris-HCl, pH 7.5/15mM NaCl and 
boil for fifteen minutes.  Allow to cool and distribute in to 1ml aliquots. 
 
Sephadex G50: 
Add 8g fine grade Sephadex G-50 beads (diameter: 20-80µm) (Sigma), 2ml 
100x TE and 0.1ml 20% SDS to 200ml distilled water and autoclave to expand 
the beads. 
 
SOB 
Dissolve 20g bactotryptone, 5g yeast extract, 0.5g NaCl in 1l GDW. pH to 7.4 and autoclave. 
Before use add 20ml 1M MgSO4. 
 
2M sodium acetate, pH 5.2: 
Dissolve 164.1g CH3COONa in 800ml autoclaved distilled water, adjust to pH 
5.2 with glacial acetic acid and make up to 1l with water. 
 
5M sodium chloride: 
Dissolve 292.2g NaCl in 1l of distilled water. 
 
0.75M sodium citrate: 
Dissolve 220.5g Na3C6H5O7.2H2O in 1l autoclaved distilled water and adjust 
to pH 7.0. 
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20% sodium dodecyl sulphate (SDS): 
Add 200g SDS to 800ml autoclaved distilled water, heat to 60oC while 
stirring.  Allow to cool and make up to 1l with water. 
 
10M sodium hydroxide: 
Dissolve 400g of NaOH in 500ml autoclaved distilled water.  Once dissolved 
make up to 1l with water. 
 
0.2% sodium hydroxide 1% SDS 
Add 3ml 10M NaOH to 140ml GDW, mix and add 7.5ml 20% SDS.   
 
 
0.5M sodium phosphate, pH 6.8: 
Dissolve 71g Na2HPO4.2H2O in 1l distilled water and 41.4g NaH2PO4.H2O in 
600ml distilled water.  Then mix. 
 
 
 
50mg/ml spectinomycin: 
Dissolve 0.5g of spectinomycin in 10ml of autoclaved distilled water. Sterilise 
by passage through a 0.2µm filter and distribute into 1ml aliquots. 
 
 
20x SSC: 
Dissolve 1,753g NaCl and 882g Na3C6H5O7.2H2O in 8l distilled water, adjust 
to pH 7.0 and make up to 10l. 
 
20x SSPE: 
Dissolve 210.4g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in 
700ml of distilled water, adjust to pH 7.7 with 10M NaOH and make up to 1l 
with water. 
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50x TAE: 
Dissolve 242g Trizma base in 843ml distilled water. Add 57ml glacial acetic 
acid and 100ml 0.5M C10H14H2O8Na2.2H2O and mix. 
 
100x TE: Dissolve 121.1g Trizma base and 3.7g C10H14H2O8Na2.2H2O in 800ml 
autoclaved distilled water. Adjust to pH 7.5 with hydrochloric acid and make 
up to 1l. 
 
0.1M TEA Buffer: 
Dissolve 18.6g C6H15NO3.HCl (triethanolamine-hydrochloride) in 800ml of 
distilled water, pH adjusted to 8.0 with hydrochloric acid and the volume 
adjusted to 1l with water. 
 
TES Buffer: 
Mix 25ml 1M Tris-HCl pH 8.0, 5ml 5M NaCl, and 5ml 
C10H14H2O8Na2.2H2O. Make up to a final volume of 500ml with autoclaved 
distilled water. 
 
100mg/ml tetracyclin: 
Dissolve 50mg in 10ml ethanol and distribute in 1ml aliquots. 
 
Transformation buffer II (TFBII): 
Dissolve 418mg MOPS, 3.28g CaCl2.2H2O and 242mg RbCl in autoclaved 
distilled water.  Add 37.5ml 80% glycerol and adjust the volume to 200ml 
with water.  The solution is sterilised by passing through a 0.2µm filter. 
 
Transformation buffer I (TFBI): 
Dissolve 589mg CH3.COOK, 2.418g RbCl, 1.979g CaCl2.2H2O and 438mg 
MnCl2.4H2O in autoclaved distilled water.  Add 37.5 ml 80% glycerol and 
adjust the volume to 200ml with water.  Sterilise by passing through a 0.2µm 
filter. 
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0.1MTris/HCl pH 8.2: 
 Dissolve 12.1g of Trizma base in 1l of distilled water, adjust pH to 8.2 with 
HCl. 
 
1M Tris-HCl pH 7.5: 
Dissolve 121.1g Trizma base in 800ml of distilled water. Adjust to pH 7.5 
with HCl and make up to 1l. 
 
2M Tris-HCl, pH 8.0: 
Dissolve 121.1g Trizma base in 450ml of distilled water. Adjust to pH 8.0 
with HCl and make up to 500ml. 
 
Universal wash buffer: 
  Mix 10ml 20% SDS and 10ml 20x SSPE with 980ml of distilled water. 
 
Versene: 
dissolve 16g NaCl, 0.4g KCl, 2.88g Na2HPO4.2H2O, 1.2g 
C10H14H2O8Na2.2H2O and 0.4g KH2PO4 to 1L water, add 3 mls phenol red 
(Sigma) and make up to 2L with water.  Sterilise by autoclaving 
 
 
 
X-Gal solution 
Add 1.5ml 0.1M K3FE(CN)6  , 1.5ml 0.1M K4Fe(CN)6.3H2O, 60µl 1M MgCl2  and 240µl X-
Gal 50mg/ml (Promega) and make up to 30ml with 0.01M PBS (Sigma-Aldrich) 
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Appendix 2 – Ink Injections in the Rat Arcuate Nucleus 
 
 
                 
  
 
 
   
 
 
 
Ink injection in the rat arcuate nucleus using coordinates of Paxinos and Watson 
(Posterior/anterior from bregma -3.8mm, lateral from bregma ± 0.5mm). Magnification 4X 
using Nikon eclipse 50i. The scale bar represents 100µm. 
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Appendix 3 - Plasmids 
 
 
pcDNA3 (neomycin resistance plasmid) 
 
http://www.pkclab.org/PKC/vector/pcDNA3.gif 
 
 
 
 
pDG 
 
(Grimm, 2003)  
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pCMVβ 
 
 
http://www.clontech.com/images/products/1184_fig1.gif 
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Appendix 4 – Calculation of Virion Concentration 
 
Calculation of virion concentration for rAAV-CART-AS: 
 
Dot blot analysis revealed 1µl rAAV-CART-AS fraction contained 11.8ng/µl viral DNA.  
 
The molecular weight of rAAV is 975000. 
Therefore the number of moles of rAAV in 11.8ng of viral DNA is 1.21x10-14 
 
Avagadro’s number is 6.022x1023 
Therefore the number of rAAV single stranded DNA particles is 7288164103 
rAAV is double stranded, so this number  is multiplied by 2, hence the number of DNA 
paticles per 11.8ng of rAAV-CART-AS is 1.457x1010 
 
Taking into account of dilution factors the number of rAAV particles per µl is 2.9x1010 
Therefore the number of rAAV particles in 11.8ng is 2.91x1013  particles/ml 
 
 
